<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2305210745
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Abrilada
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ADALIMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2955.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ABRILADA contains the active substance adalimumab, a medicine that acts on your body&rsquo;s immune (defence) system.</p><p>&nbsp;</p><p>ABRILADA is intended for the treatment of the following inflammatory diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatoid arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polyarticular juvenile idiopathic arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paediatric enthesitis‑related arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankylosing spondylitis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; axial spondyloarthritis without radiographic evidence of ankylosing spondylitis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psoriatic arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psoriasis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hidradenitis suppurativa,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&rsquo;s disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcerative colitis and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non‑infectious uveitis.</p><p>&nbsp;</p><p>The active ingredient in ABRILADA, adalimumab, is a monoclonal antibody. Monoclonal antibodies are proteins that attach to a specific target in the body.</p><p>&nbsp;</p><p>The target of adalimumab is another protein called tumour necrosis factor (TNF&alpha;), which is involved in the immune (defence) system and is present at increased levels in the inflammatory diseases listed above. By attaching to TNF&alpha;, ABRILADA blocks its action and reduces the inflammation in these diseases.</p><p>&nbsp;</p><p><u>Rheumatoid arthritis </u></p><p>&nbsp;</p><p>Rheumatoid arthritis is an inflammatory disease of the joints.</p><p>&nbsp;</p><p>ABRILADA is used to treat rheumatoid arthritis in adults. If you have moderate to severe active rheumatoid arthritis, you may first be given other disease‑modifying medicines, such as methotrexate. If these medicines do not work well enough, you will be given ABRILADA to treat your rheumatoid arthritis.</p><p>&nbsp;</p><p>ABRILADA can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.</p><p>&nbsp;</p><p>ABRILADA can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function.</p><p>&nbsp;</p><p>Usually, ABRILADA is used with methotrexate. If your doctor considers that methotrexate is inappropriate, ABRILADA can be given alone.</p><p>&nbsp;</p><p><u>Polyarticular juvenile idiopathic arthritis</u></p><p>&nbsp;</p><p>Polyarticular juvenile idiopathic arthritis is an inflammatory disease of the joints that usually first appears in childhood.</p><p>&nbsp;</p><p>ABRILADA is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2&nbsp;to 17&nbsp;years. Patients may first be given other disease‑modifying medicines, such as methotrexate. If these medicines do not work well enough, patients will be given ABRILADA to treat their polyarticular juvenile idiopathic arthritis.</p><p>&nbsp;</p><p><u>Paediatric enthesitis-related arthritis</u></p><p>&nbsp;</p><p>Paediatric enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the bone.</p><p>&nbsp;</p><p>ABRILADA is used to treat enthesitis‑related arthritis in children and adolescents aged 6&nbsp;to 17&nbsp;years. Patients may first be given other disease‑modifying medicines, such as methotrexate. If these medicines do not work well enough, patients will be given ABRILADA to treat their enthesitis‑related arthritis.</p><p>&nbsp;</p><p><u>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis </u></p><p>&nbsp;</p><p>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, are inflammatory diseases of the spine.</p><p>&nbsp;</p><p>ABRILADA is used in adults to treat these conditions. If you have ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, you will first be given other medicines. If these medicines do not work well enough, you will be given ABRILADA to reduce the signs and symptoms of your disease.</p><p>&nbsp;</p><p><u>Psoriatic arthritis </u></p><p>&nbsp;</p><p>Psoriatic arthritis is an inflammation of the joints associated with psoriasis.</p><p>&nbsp;</p><p>ABRILADA is used to treat psoriatic arthritis in adults. ABRILADA can slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.</p><p>&nbsp;</p><p><u>Plaque psoriasis in adults and children </u></p><p>&nbsp;</p><p>Plaque psoriasis is an inflammatory skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away from the nail bed which can be painful. Psoriasis is believed to be caused by a problem with the body&rsquo;s immune system that leads to an increased production of skin cells.</p><p>&nbsp;</p><p>ABRILADA is used to treat moderate to severe plaque psoriasis in adults. ABRILADA is also used to treat severe plaque psoriasis in children and adolescents aged 4&nbsp;to 17&nbsp;years for whom medicines applied to the skin and treatment with UV light have either not worked very well or are not suitable.</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa in adults and adolescents </u></p><p>&nbsp;</p><p>Hidradenitis suppurativa (sometimes called acne inversa) is a long‑term and often painful inflammatory skin disease. Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most commonly affects specific areas of the skin, such as under the breasts, the armpits, inner thighs, groin and buttocks. Scarring may also occur in affected areas.</p><p>&nbsp;</p><p>ABRILADA is used to treat hidradenitis suppurativa in adults and adolescents from 12&nbsp;years of age. ABRILADA can reduce the number of nodules and abscesses you have and the pain that is often associated with the disease. You may first be given other medicines. If these medicines do not work well enough, you will be given ABRILADA.</p><p><u>&nbsp;</u></p><p><u>Crohn&rsquo;s disease in adults and children </u></p><p>&nbsp;</p><p>Crohn&rsquo;s disease is an inflammatory disease of the gut.</p><p>&nbsp;</p><p>ABRILADA is used to treat Crohn&rsquo;s disease in adults and children aged 6&nbsp;to 17&nbsp;years.</p><p>&nbsp;</p><p>If you have Crohn&rsquo;s disease you will first be given other medicines. If you do not respond well enough to these medicines, you will be given ABRILADA to reduce the signs and symptoms of your Crohn&rsquo;s disease.</p><p>&nbsp;</p><p><u>Ulcerative colitis in adults and children</u></p><p>&nbsp;</p><p>Ulcerative colitis is an inflammatory disease of the large intestine.</p><p>&nbsp;</p><p>ABRILADA is used to treat moderate to severe ulcerative colitis in adults and children aged 6&nbsp;to 17&nbsp;years. If you have ulcerative colitis you may first be given other medicines. If these medicines do not work well enough, you will be given ABRILADA to reduce the signs and symptoms of your disease.</p><p>&nbsp;</p><p><u>Non‑infectious uveitis in adults and children</u></p><p>&nbsp;</p><p>Non‑infectious uveitis is an inflammatory disease affecting certain parts of the eye. This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or wispy lines that move across the field of vision). ABRILADA works by reducing this inflammation.</p><p>&nbsp;</p><p>ABRILADA is used to treat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults with non‑infectious uveitis with inflammation affecting the back of the eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children from 2&nbsp;years of age with chronic non‑infectious uveitis with inflammation affecting the front of the eye.</p><p>&nbsp;</p><p>You may first be given other medicines. If these medicines do not work well enough, you will be given ABRILADA to reduce the signs and symptoms of your disease.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use ABRILADA </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection, including active tuberculosis, sepsis (blood poisoning) or opportunistic infections (unusual infections associated with a weakened immune system). It is important that you tell your doctor if you have symptoms of infections, for example, fever, wounds, feeling tired, dental problems (see &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have moderate or severe heart failure. It is important to tell your doctor if you have had or have a serious heart condition (see &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using ABRILADA.</p><p>&nbsp;</p><p>It is important that you and your doctor record the brand name and batch number of your medication.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash, do not inject more ABRILADA and contact your doctor immediately, since in rare cases, these reactions can be life‑threatening.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infection, including long‑term infection or an infection in one part of the body (for example, leg ulcer), consult your doctor before starting ABRILADA. If you are unsure, contact your doctor.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You might get infections more easily while you are receiving ABRILADA treatment. This risk may increase if you have problems with your lungs. These infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other opportunistic infections (unusual infectious organisms) and sepsis (blood poisoning). In rare cases, these infections may be life‑threatening. It is important to tell your doctor if you get symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may recommend temporarily stopping ABRILADA.</p><p>&nbsp;</p><p><u>Tuberculosis (TB)</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting ABRILADA. This will include a thorough medical evaluation including your medical history and screening tests (for example chest X‑ray and a tuberculin test). The conduct and results of these tests should be recorded on your patient reminder card.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tuberculosis can develop during therapy even if you have had preventative treatment for tuberculosis.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack of energy, mild fever), or any other infection appear during or after therapy tell your doctor immediately.</p><p>&nbsp;</p><p><u>Travel / recurrent infection</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have lived or travelled in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic (found).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have infections which keep coming back or other conditions that increase the risk of infections.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should pay special attention to signs of infection while you are being treated with ABRILADA. It is important to tell your doctor if you get symptoms of infections, such as fever, wounds, feeling tired or dental problems.</p><p>&nbsp;</p><p><u>Hepatitis B virus</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV infection or if you think you might be at risk of getting HBV. Your doctor should test you for HBV. Adalimumab can reactivate HBV infection in people who carry this virus. In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV infection can be life‑threatening.</p><p>&nbsp;</p><p><u>Age over 65&nbsp;years</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are over 65&nbsp;years you may be more susceptible to infections while taking ABRILADA. You and your doctor should pay special attention to signs of infection while you are being treated with ABRILADA. It is important to tell your doctor if you get symptoms of infections, such as fever, wounds, feeling tired or dental problems.</p><p>&nbsp;</p><p><u>Surgery or dental procedures</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are about to have surgery or dental procedures, tell your doctor that you are taking ABRILADA. Your doctor may recommend temporarily stopping ABRILADA.</p><p>&nbsp;</p><p><u>Demyelinating disease</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or develop demyelinating disease (a disease that affects the insulating layer around the nerves, such as multiple sclerosis), your doctor will decide if you should receive or continue to receive ABRILADA. Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body.</p><p>&nbsp;</p><p><u>Vaccination</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain vaccines contain living but weakened forms of disease‑causing bacteria or viruses that may cause infections and should not be given during treatment with ABRILADA. Check with your doctor before you receive any vaccines. It is recommended that, if possible, children be given all the scheduled vaccinations for their age before they start treatment with ABRILADA. If you receive ABRILADA while you are pregnant, your baby may be at higher risk for getting an infection for up to about five months after the last dose you received during pregnancy. It is important that you tell your baby&rsquo;s doctors and other health care professionals about your ABRILADA use during your pregnancy so they can decide when your baby should receive any vaccine.</p><p>&nbsp;</p><p><u>Heart failure</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important to tell your doctor if you have had or have a serious heart condition. If you have mild heart failure and you are being treated with ABRILADA, your heart failure status must be closely monitored by your doctor. If you develop new or worsening symptoms of heart failure (e.g. shortness of breath, or swelling of your feet), you must contact your doctor immediately.</p><p>&nbsp;</p><p><u>Fever, bruising, bleeding or looking pale</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In some patients the body may fail to produce enough of the blood cells that fight off infections or help you to stop bleeding. If you develop a fever that does not go away, or you bruise or bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop treatment.</p><p>&nbsp;</p><p><u>Cancer</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been very rare cases of certain kinds of cancer in children and adults taking adalimumab or other TNF&alpha; blockers. People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting lymphoma and leukaemia (cancers that affect blood cells and bone marrow). If you take ABRILADA the risk of getting lymphoma, leukaemia, or other cancers may increase. On rare occasions, an uncommon and severe type of lymphoma has been seen in patients taking adalimumab. Some of those patients were also treated with the medicines azathioprine or mercaptopurine. Tell your doctor if you are taking azathioprine or mercaptopurine with ABRILADA.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, cases of non‑melanoma skin cancer have been observed in patients taking adalimumab. If new areas of damaged skin appear during or after treatment or if existing marks or areas of damage change appearance, tell your doctor.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been cases of cancers, other than lymphoma in patients with a specific type of lung disease called chronic obstructive pulmonary disease (COPD) treated with another TNF&alpha; blocker. If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF&alpha; blocker is appropriate for you.</p><p>&nbsp;</p><p><u>Autoimmune disease</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On rare occasions, treatment with ABRILADA could result in lupus‑like syndrome. Contact your doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness occur.</p><p>&nbsp;</p><p><strong>Other medicines and ABRILADA </strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>ABRILADA can be taken together with methotrexate or certain disease‑modifying anti‑rheumatic agents (for example, sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non‑steroidal anti‑inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p>You should not take ABRILADA with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection. The combination of adalimumab as well as other TNF‑antagonists and anakinra or abatacept is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. If you have questions, please ask your doctor.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding </strong></p><p>&nbsp;</p><p>You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last ABRILADA treatment.</p><p>&nbsp;</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice about taking this medicine.</p><p>&nbsp;</p><p>ABRILADA should only be used during a pregnancy if needed.</p><p>&nbsp;</p><p>According to a pregnancy study, there was no higher risk of birth defects when the mother had received adalimumab during pregnancy compared with mothers with the same disease who did not receive adalimumab.</p><p>&nbsp;</p><p>ABRILADA can be used during breast‑feeding.</p><p>&nbsp;</p><p>If you receive ABRILADA during your pregnancy, your baby may have a higher risk for getting an infection. It is important that you tell your baby&rsquo;s doctors and other health care professionals about your ABRILADA use during your pregnancy before the baby receives any vaccine. For more information on vaccines see the &ldquo;Warnings and precautions&rdquo; section.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>&nbsp;</p><p>ABRILADA may have a small effect on your ability to drive, cycle or use machines. Room spinning sensation (vertigo) and vision disturbances may occur after taking ABRILADA.</p><p>&nbsp;</p><p><strong>ABRILADA contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol of sodium (23&nbsp;mg) per 0.8&nbsp;ml dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor may prescribe another strength of ABRILADA if you need a different dose.</p><p>&nbsp;</p><p>ABRILADA is injected under the skin (subcutaneous use).</p><p>&nbsp;</p><p><u>Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</u></p><p>&nbsp;</p><p>The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, and for patients with psoriatic arthritis is 40&nbsp;mg adalimumab given every other week as a single dose.</p><p>&nbsp;</p><p>In rheumatoid arthritis, methotrexate is continued while using ABRILADA. If your doctor determines that methotrexate is inappropriate, ABRILADA can be given alone.</p><p>&nbsp;</p><p>If you have rheumatoid arthritis and you do not receive methotrexate with your ABRILADA therapy, your doctor may decide to give 40&nbsp;mg adalimumab every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children, adolescents and adults with polyarticular juvenile idiopathic arthritis </u></p><p>&nbsp;</p><p><em>Children and adolescents from 2&nbsp;years of age weighing 10&nbsp;kg to less than 30&nbsp;kg</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is 20&nbsp;mg every other week.</p><p><em>&nbsp;</em></p><p><em>Children, adolescents and adults from 2&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children, adolescents and adults with enthesitis‑related arthritis </u></p><p>&nbsp;</p><p><em>Children and adolescents from 6&nbsp;years of age weighing 15&nbsp;kg to less than 30&nbsp;kg</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is 20&nbsp;mg every other week.</p><p>&nbsp;</p><p><em>Children, adolescents and adults from 6&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with psoriasis</u></p><p>&nbsp;</p><p>The usual dose for adults with psoriasis is an initial dose of 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one&nbsp;day), followed by 40&nbsp;mg given every other week starting one week after the initial dose. You should continue to inject ABRILADA for as long as your doctor has told you. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children and adolescents with plaque psoriasis </u></p><p>&nbsp;</p><p><em>Children and adolescents from 4 to 17&nbsp;years of age weighing 15&nbsp;kg to less than 30&nbsp;kg</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is an initial dose of 20&nbsp;mg, followed by 20&nbsp;mg one&nbsp;week later. Thereafter, the usual dose is 20&nbsp;mg every other week.</p><p>&nbsp;</p><p><em>Children and adolescents from 4 to 17&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is an initial dose of 40&nbsp;mg, followed by 40&nbsp;mg one&nbsp;week later. Thereafter, the usual dose is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with hidradenitis suppurativa </u></p><p>&nbsp;</p><p>The usual dose regimen for hidradenitis suppurativa is an initial dose of 160&nbsp;mg (as four&nbsp;40&nbsp;mg injections in one day or as two&nbsp;40&nbsp;mg injections per day for two consecutive days), followed by an 80&nbsp;mg dose (as two&nbsp;40&nbsp;mg injections in one&nbsp;day) two weeks later. After two further weeks, continue with a dosage of 40&nbsp;mg every week or 80&nbsp;mg every other week, as prescribed by your doctor. It is recommended that you use an antiseptic wash daily on the affected areas.</p><p>&nbsp;</p><p><u>Adolescents with hidradenitis suppurativa from 12 to 17&nbsp;years of age weighing 30&nbsp;kg or more </u></p><p>&nbsp;</p><p>The recommended dose of ABRILADA is an initial dose of 80&nbsp;mg (as two 40&nbsp;mg injections in one day), followed by 40&nbsp;mg every other week starting one week later. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>It is recommended that you use an antiseptic wash daily on the affected areas.</p><p>&nbsp;</p><p><u>Adults with Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>The usual dose regimen for Crohn&rsquo;s disease is 80&nbsp;mg (as two 40&nbsp;mg&nbsp;injections in one&nbsp;day) initially followed by 40&nbsp;mg every other week starting two weeks later. If a faster response is required your doctor may prescribe an initial dose of 160&nbsp;mg (as four&nbsp;40&nbsp;mg injections in one day or as two&nbsp;40&nbsp;mg injections per day for two consecutive days), followed by 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one&nbsp;day) two weeks later, and thereafter as 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children and adolescents with Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p><em>Children and adolescents from 6 to17&nbsp;years of age weighing less than 40&nbsp;kg </em></p><p>&nbsp;</p><p>The usual dose regimen is 40&nbsp;mg initially followed by 20&nbsp;mg two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one&nbsp;day) followed by 40&nbsp;mg starting two weeks later.</p><p>&nbsp;</p><p>Thereafter, the usual dose is 20&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dose frequency to 20&nbsp;mg every week.</p><p>&nbsp;</p><p><em>Children and adolescents from 6 to 17&nbsp;years of age weighing 40&nbsp;kg or more</em></p><p>&nbsp;</p><p>The usual dose regimen is 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one day) initially followed by 40&nbsp;mg&nbsp;two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 160&nbsp;mg (as four&nbsp;40&nbsp;mg injections in one&nbsp;day or as two 40&nbsp;mg&nbsp;injections per day for two&nbsp;consecutive days) followed by 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one day) two weeks later.</p><p>&nbsp;</p><p>Thereafter, the usual dose is 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with ulcerative colitis</u></p><p>&nbsp;</p><p>The usual ABRILADA dose for adults with ulcerative colitis is 160&nbsp;mg initially (as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days), then 80&nbsp;mg (as two 40&nbsp;mg injections in one&nbsp;day) two weeks later, and then 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children and adolescents with ulcerative colitis</u></p><p><em>&nbsp;</em></p><p><em>Children and adolescents from 6</em>&nbsp;<em>years of age weighing less than 40</em>&nbsp;<em>kg</em></p><p>&nbsp;</p><p>The usual ABRILADA dose is 80&nbsp;mg (as two 40&nbsp;mg injections in one day) initially followed by 40&nbsp;mg (as one 40&nbsp;mg injection) two weeks later. Thereafter, the usual dose is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p>Patients who turn 18&nbsp;years of age while on 40&nbsp;mg every other week, should continue their prescribed dose.</p><p>&nbsp;</p><p><em>Children and adolescents from 6</em>&nbsp;<em>years of age weighing 40</em>&nbsp;<em>kg or more</em></p><p>&nbsp;</p><p>The usual ABRILADA dose is 160&nbsp;mg (as four 40&nbsp;mg injections in one day or two 40&nbsp;mg injections per day for two consecutive days) initially, followed by 80&nbsp;mg (as two 40&nbsp;mg injections in one day) two weeks later. Thereafter the usual dose is 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Patients who turn 18&nbsp;years of age while on 80&nbsp;mg every other week, should continue their prescribed dose.</p><p>&nbsp;</p><p><u>Adults with non‑infectious uveitis</u></p><p>&nbsp;</p><p>The usual dose for adults with non‑infectious uveitis is an initial dose of 80&nbsp;mg (as two&nbsp;40&nbsp;mg injections in one&nbsp;day), followed by 40&nbsp;mg given every other week starting one week after the initial dose. You should continue to inject ABRILADA for as long as your doctor has told you.</p><p>&nbsp;</p><p>In non‑infectious uveitis, corticosteroids or other medicines that influence the immune system may be continued while using ABRILADA. ABRILADA can also be given alone.</p><p>&nbsp;</p><p><u>Children and adolescents with chronic non‑infectious uveitis from 2&nbsp;years of age</u></p><p><u>&nbsp;</u></p><p><em>Children and adolescents from 2&nbsp;years of age weighing less than 30&nbsp;kg</em></p><p>&nbsp;</p><p>The usual dose of ABRILADA is 20&nbsp;mg every other week with methotrexate.</p><p>&nbsp;</p><p>Your doctor may also prescribe an initial dose of 40&nbsp;mg which may be administered one week prior to the start of the usual dose.</p><p><u>&nbsp;</u></p><p><em>Children and adolescents from 2&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The usual dose of ABRILADA is 40&nbsp;mg every other week with methotrexate.</p><p>&nbsp;</p><p>Your doctor may also prescribe an initial dose of 80&nbsp;mg which may be administered one week prior to the start of the usual dose.</p><p>&nbsp;</p><p><strong>Method and route of administration </strong></p><p>&nbsp;</p><p>ABRILADA is administered by injection under the skin (by subcutaneous injection).</p><p>&nbsp;</p><p>Detailed instructions on how to inject ABRILADA.</p>&nbsp;<p><strong>&nbsp;</strong></p><p><strong>INSTRUCTIONS FOR USE</strong></p><p>ABRILADA (adalimumab) 40 mg</p><p>Single-dose Pre-filled Syringe, for subcutaneous injection</p><p>&nbsp;</p><p><strong>Keep this leaflet. These instructions show step-by-step how to prepare and give an injection. </strong></p><p><strong>Store your ABRILADA pre-filled syringe in the refrigerator between 2&deg;C to 8&deg;C. </strong></p><p><strong>Store ABRILADA pre-filled syringe in the original carton until use to protect from direct sunlight.</strong></p><p><strong>If needed, for example when you are traveling, you may store </strong><strong>ABRILADA </strong><strong>pre-filled syringe</strong><strong> </strong><strong>at room temperature up to 30&deg;C for up to 30 days.</strong></p><p><strong>Keep ABRILADA, injection supplies, and all other medicines out of the reach of children.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>ABRILADA<strong> </strong>for injection comes in a disposable single use pre-filled syringe that contains a single dose of medicine.</p><p><strong>Do not</strong> try to inject ABRILADA yourself until you have read and understood the Instructions for Use. If your doctor, nurse or pharmacist decides that you or a caregiver may be able to give your injections of ABRILADA at home, you should receive training on the correct way to prepare and inject ABRILADA.</p><p>It is also important to talk to your doctor, nurse or pharmacist to be sure you understand your ABRILADA dosing instructions. To help you remember when to inject ABRILADA, you can mark your calendar ahead of time. Talk to your doctor, nurse or pharmacist if you or your caregiver have any questions about the correct way to inject ABRILADA.</p><p>After proper training, ABRILADA for injection can be self-administered or given by a caregiver.</p><p><strong>&nbsp;</strong></p><p><strong>1. Supplies you need</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will need the following supplies for each injection of ABRILADA. Find a clean, flat surface to place the supplies on.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 ABRILADA pre-filled syringe in a tray, inside the carton</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 alcohol swab, inside the carton</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 cotton ball or gauze pad (not included in your ABRILADA carton)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A suitable sharps container (not included in your ABRILADA carton).</p><p><strong>Important: </strong>If you have any questions about your ABRILADA pre-filled syringe or medicine, talk to your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1044" type="#_x0000_t75"
 style='width:314.5pt;height:180.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="419" height="241" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>2. Getting ready</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove ABRILADA carton from the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the carton and take out the tray containing your pre-filled syringe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check your carton and tray; <strong>do not</strong> use if:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the expiration date has passed</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has been frozen or thawed</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has been dropped, even if it looks undamaged</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has been out of the refrigerator for more than 30 days</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it appears to be damaged</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the seals on a new carton are broken.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above apply, dispose of your pre-filled syringe in the same way as a used syringe. You will need a new pre-filled syringe to give your injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands with soap and water, and dry completely.</p><p>If you have any questions about your medicine, please talk to your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_34"
 o:spid="_x0000_i1043" type="#_x0000_t75" style='width:315pt;height:166pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="420" height="221" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel back the paper seal on the tray.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove 1 pre-filled syringe from the tray and put the original carton with any unused pre-filled syringes back in the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> use your syringe if it appears to be damaged.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your pre-filled syringe may be used straight from the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may find that using your pre-filled syringe at room temperature reduces stinging or discomfort. Leave your pre-filled syringe at room temperature away from direct sunlight for 15 to 30&nbsp;minutes before your injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>remove the needle cover from your pre-filled syringe until you are ready to inject.</p><p><strong>Always hold the pre‑filled syringe by the syringe barrel to prevent damage.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_35"
 o:spid="_x0000_i1042" type="#_x0000_t75" style='width:302pt;height:196pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="403" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look carefully at your medicine in the window.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently tilt your pre-filled syringe back and forth to check the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> shake your pre-filled syringe. Shaking can damage your medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure the medicine in the pre-filled syringe is clear and colourless to very light brown and free from flakes or particles. It is normal to see one or more air bubbles in the window.<strong> Do not </strong>attempt to remove air bubbles.</p><p>If you have any questions about your medicine, please talk to your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_i1041"
 type="#_x0000_t75" style='width:314.5pt;height:165.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
</v:shape><![endif]--><img width="419" height="221" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose a different site each time you give yourself an injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>inject into bony areas or areas on your skin that are bruised, red, sore (tender) or hard. Avoid injecting into areas with scars or stretch marks.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have psoriasis, <strong>do not</strong> inject directly into any raised, thick, red, or scaly skin patches or lesions on your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>inject through your clothes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the injection site with the alcohol swab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the injection site to dry.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_28"
 o:spid="_x0000_i1040" type="#_x0000_t75" style='width:300.5pt;height:198pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png"
  o:title=""/>
</v:shape><![endif]--><img width="401" height="264" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the pre-filled syringe by the syringe barrel. Carefully pull the needle cover straight off and away from your body when you are ready to inject.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is normal to see a few drops of medicine at the needle tip when you remove the needle cover.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throw the needle cover away into a sharps disposal container.</p><p><strong>Note:</strong> Be careful when you handle your pre-filled syringe to avoid an accidental needle stick injury.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_29"
 o:spid="_x0000_i1039" type="#_x0000_t75" style='width:300.5pt;height:196.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="401" height="262" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently pinch up a fold of skin in the cleaned injection site area.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the needle to its full depth into the skin, at a 45 degree angle, as shown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the needle is inserted, release the pinched skin.</p><p><strong>Important: Do not </strong>re-insert the needle into your skin. If the needle has already been inserted into the skin and you change your mind about where to inject, you will need a replacement pre‑filled syringe.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_36"
 o:spid="_x0000_i1038" type="#_x0000_t75" style='width:300pt;height:195pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.png"
  o:title=""/>
</v:shape><![endif]--><img width="400" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using slow and constant pressure, push the plunger rod all the way down until the barrel is empty. It usually takes 2 to 5 seconds to deliver the dose.</p><p><strong>Note:</strong> It is recommended to hold your pre-filled syringe in the skin<strong> </strong>for an additional 5 seconds after the plunger has been pressed down completely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull the needle out of the skin at the same angle at which it entered.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_31"
 o:spid="_x0000_i1037" type="#_x0000_t75" style='width:300.5pt;height:197pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.png"
  o:title=""/>
</v:shape><![endif]--><img width="401" height="263" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check that your medicine has completely emptied from your pre-filled syringe.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Never re-insert the needle.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Never re-cap the needle.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Note: </strong>If the grey stopper is not in the position shown, you may not <strong>have </strong>injected all of your medicine. Talk to your doctor, nurse or pharmacist right away.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_38"
 o:spid="_x0000_i1036" type="#_x0000_t75" style='width:300pt;height:196.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.png"
  o:title=""/>
</v:shape><![endif]--><img width="400" height="262" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dispose of the syringe straight away as instructed by your doctor, nurse or pharmacist and in accordance with local health and safety laws.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_i1035"
 type="#_x0000_t75" style='width:306pt;height:196pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png"
  o:title=""/>
</v:shape><![endif]--><img width="408" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look closely at your injection site. If there is blood, use a clean cotton ball or gauze pad to press lightly on the injection area for a few seconds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> rub the site.</p><p><strong>Note: </strong>Store any unused syringes in the refrigerator in the original carton.</p><p>&nbsp;</p><p>&nbsp;</p><p>See over for</p><p>Package leaflet: Information for the patient</p>&nbsp;<p><strong>&nbsp;</strong></p><p><strong>INSTRUCTIONS FOR USE</strong></p><p>ABRILADA (adalimumab)</p><p>40 mg</p><p>Single-dose Pre-filled Pen, for subcutaneous injection<strong> </strong></p><p>&nbsp;</p><p><strong>Keep this leaflet. These instructions show step-by-step how to prepare and give an injection. </strong></p><p><strong>Store your ABRILADA pen in the refrigerator between 2&deg;C to 8&deg;C. </strong></p><p><strong>Store ABRILADA pen in the original carton until use to protect from direct sunlight.</strong></p><p><strong>If needed, for example when you are traveling, you may store </strong><strong>ABRILADA pen </strong><strong>at room temperature up to 30&deg;C for up to 30 days.</strong></p><p><strong>Keep ABRILADA, injection supplies, and all other medicines out of the reach of children.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>ABRILADA<strong> </strong>for injection comes in a disposable single use pen that contains a single dose of medicine.</p><p><strong>Do not</strong> try to inject ABRILADA yourself until you have read and understood the Instructions for Use. If your doctor, nurse or pharmacist decides that you or a caregiver may be able to give your injections of ABRILADA at home, you should receive training on the correct way to prepare and inject ABRILADA.</p><p>It is also important to talk to your doctor, nurse or pharmacist to be sure you understand your ABRILADA dosing instructions. To help you remember when to inject ABRILADA, you can mark your calendar ahead of time. Talk to your doctor, nurse or pharmacist if you or your caregiver have any questions about the correct way to inject ABRILADA.</p><p>After proper training, ABRILADA for injection can be self-administered or given by a caregiver.</p><p><strong>&nbsp;</strong></p><p><strong>1. Supplies you need</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will need the following supplies for each injection of ABRILADA. Find a clean, flat surface to place the supplies on.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 ABRILADA pen, inside the carton</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 alcohol swab, inside the carton</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 cotton ball or gauze pad (not included in your ABRILADA carton)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A suitable sharps container (not included in your ABRILADA carton).</p><p><strong>Important: </strong>If you have any questions about your ABRILADA pen or medicine, talk to your doctor, nurse or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>2. Getting ready</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the ABRILADA carton from the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take out 1 ABRILADA pen and the alcohol swab. Keep your pen out of direct sunlight. Put the original carton with any unused pens back in the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> use your pen if:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your pen or the carton containing the pen has been dropped, even if it looks undamaged</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has been frozen or thawed</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it appears to be damaged</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the seals on a new carton are broken</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has been out of the refrigerator for more than 30 days</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the expiration date has passed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above apply, dispose of your pen in the same way as a used pen. You will need a new pen to give your injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your pen may be used straight from the refrigerator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may find that using your pen at room temperature reduces stinging or discomfort. Leave your pen at room temperature away from direct sunlight for 15 to 30&nbsp;minutes before your injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands with soap and water, and dry completely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>remove the cap until you are ready to inject.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_17" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:267.5pt;
 height:85.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image014.png"
  o:title=""/>
</v:shape><![endif]--><img width="357" height="114" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_18"
 o:spid="_x0000_i1033" type="#_x0000_t75" style='width:315.5pt;height:132.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image016.png"
  o:title=""/>
</v:shape><![endif]--><img width="421" height="177" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image017.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look carefully at your medicine in the window.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently tilt your pen back and forth to check the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> shake your pen. Shaking can damage your medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure the medicine in the pen is clear and colourless to very light brown and free from flakes or particles. It is normal to see one or more air bubbles in the window.<strong> Do not </strong>attempt to remove air bubbles.</p><p>If you have any questions about your medicine, please talk to your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_19"
 o:spid="_x0000_i1032" type="#_x0000_t75" style='width:314.5pt;height:129.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image018.png"
  o:title=""/>
</v:shape><![endif]--><img width="419" height="173" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image019.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose a different site each time you give yourself an injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>inject into bony areas or areas on your skin that are bruised, red, sore (tender) or hard. Avoid injecting into areas with scars or stretch marks.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have psoriasis, <strong>do not</strong> inject directly into any raised, thick, red, or scaly skin patches or lesions on your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>inject through your clothes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the injection site with the alcohol swab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the injection site to dry.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_20"
 o:spid="_x0000_i1031" type="#_x0000_t75" style='width:235pt;height:196pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.png"
  o:title=""/>
</v:shape><![endif]--><img width="313" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist and pull off the cap.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throw the cap away into a sharps disposal container; it is not needed again.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is normal to see a few drops of medicine at the needle tip when you remove the cap.</p><p><strong>Caution:</strong> Handle your pen with care to avoid an accidental needle stick injury.</p><p><strong>Note:</strong> The needle cover stays inside the cap after removal.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_21"
 o:spid="_x0000_i1030" type="#_x0000_t75" style='width:235.5pt;height:193pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image021.png"
  o:title=""/>
</v:shape><![endif]--><img width="314" height="257" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image021.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Push</strong> your pen firmly against the skin at 90 degrees, as shown.</p><p><strong>Note:</strong> The needle goes into the skin as you push your pen down. The injection button will unlock when you are pushing the pen down firmly enough.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep your pen pushed against the skin until Step 8.</strong></p><p><strong>Note: Do not </strong>re-insert the needle into your skin if you change your mind about where to inject. You will need a replacement pen if the needle has already been inserted into the skin.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_25" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:375pt;
 height:159.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image022.png"
  o:title=""/>
</v:shape><![endif]--><img width="500" height="213" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image023.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Press </strong>the injection button all the way down and you will hear a click. You may take your finger off the injection button when the injection has started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep holding </strong>your pen firmly against the skin while the orange bar moves across the window. This usually takes 3 to 10 seconds to deliver the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Wait </strong>for at least 5 more seconds after the 2<sup>nd</sup> click to allow the medicine to be absorbed.</p><p><strong>Note: </strong>If you cannot press down the injection button, it is because you are not pushing the pen down firmly enough. Take your finger off the injection button and push your pen down more firmly against the skin. Then try pushing the button again. If this does not work, stretching or pinching the skin may make the injection site firmer, making pressing the injection button easier.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_23"
 o:spid="_x0000_i1028" type="#_x0000_t75" style='width:234pt;height:195pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.png"
  o:title=""/>
</v:shape><![endif]--><img width="312" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not remove your pen until you have waited at least 5 seconds after the 2<sup>nd</sup> click. </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove your pen from the skin.</p><p><strong>Note: </strong>After you remove your pen from the skin, the needle will be automatically covered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you see more than a small drop of medicine on the skin after your injection, next time you inject wait a little longer to remove the pen from the skin.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_27"
 o:spid="_x0000_i1027" type="#_x0000_t75" style='width:235pt;height:195pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image025.png"
  o:title=""/>
</v:shape><![endif]--><img width="313" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should see an orange bar in the window.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the window has not turned orange, or if it looks like the medicine is still injecting, this means you have not received a full dose. Talk to your doctor, nurse or pharmacist right away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not inject another dose.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_32"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:235pt;height:194pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.png"
  o:title=""/>
</v:shape><![endif]--><img width="313" height="259" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dispose of the pen straight away as instructed by your doctor, nurse or pharmacist and in accordance with local health and safety laws.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_33"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:236.5pt;height:194pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image027.png"
  o:title=""/>
</v:shape><![endif]--><img width="315" height="259" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image027.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look closely at your injection site. If there is blood, use a clean cotton ball or gauze pad to press lightly on the injection area for a few seconds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> rub the injection site.</p><p><strong>Note: </strong>Store any unused pens in the refrigerator in the original carton.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more ABRILADA than you should</strong></p><p>&nbsp;</p><p>If you accidentally inject ABRILADA more frequently than you should, call your doctor or pharmacist and explain that you have taken more than required. Always take the outer carton of the medicine with you, even if it is empty.</p><p>&nbsp;</p><p><strong>If you forget to use ABRILADA</strong></p><p>&nbsp;</p><p>If you forget to give yourself an injection, you should inject the next dose of ABRILADA as soon as you remember. Then take your next dose as you would have on your originally scheduled day, had you not forgotten a dose.</p><p>&nbsp;</p><p><strong>If you stop using ABRILADA</strong></p><p>&nbsp;</p><p>The decision to stop using ABRILADA should be discussed with your doctor. Your symptoms may return upon stopping treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur at least up to 4&nbsp;months after the last ABRILADA injection.</p><p>&nbsp;</p><p><strong>Seek medical attention urgently,</strong> if you notice any of the following signs:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rash, hives or other signs of allergic reaction;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, hands, feet;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing, swallowing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath with exertion or upon lying down or swelling of the feet.</p><p>&nbsp;</p><p><strong>Tell your doctor as soon as possible,</strong> if you notice any of the following:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs and symptoms of infection such as fever, feeling sick, wounds, dental problems, burning on urination, feeling weak or tired or coughing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of nerve problems such as tingling, numbness, double vision, or arm or leg weakness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of skin cancer such as a bump or open sore that does not heal;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding, paleness</p><p>&nbsp;</p><p>The signs and symptoms described above can represent the side effects listed below, which have been observed with adalimumab:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1&nbsp;in 10&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions (including pain, swelling, redness or itching);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal (belly) pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the muscles or joints.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1&nbsp;in 10 people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious infections (including blood poisoning and influenza);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal infections (including gastroenteritis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infections (including cellulitis and shingles);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth infections (including tooth infections and cold sores);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reproductive tract infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benign tumours;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cancer;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (including seasonal allergy);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood swings (including depression);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation disorders such as tingling, prickling or numbness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of nerve root compression (including low back pain and leg pain);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision disturbances;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye inflammation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eye lid and eye swelling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo (sensation of room spinning);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of heart beating rapidly;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haematoma (a solid swelling with clotted blood);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal bleeding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyspepsia (indigestion, bloating, heart burn);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acid reflux disease;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sicca syndrome (including dry eyes and dry mouth);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin (such as eczema);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breaking of finger nails and toe nails;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new onset or worsening of psoriasis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in urine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (a build‑up of fluid in the body which causes the affected tissue to swell);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood platelets which increases risk of bleeding or bruising;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired healing.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1&nbsp;in 100&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; opportunistic (unusual) infections (which include tuberculosis and other infections) that occur when resistance to disease is lowered;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neurological infections (including viral meningitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diverticulitis (inflammation and infection of the large intestine);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer, including cancer that affects the lymph system (lymphoma) and melanoma (a type of skin cancer);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune disorders that could affect the lungs, skin and lymph nodes (most commonly as a condition called sarcoidosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vasculitis (inflammation of blood vessels);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor (shaking);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neuropathy (nerve damage);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing loss, buzzing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of heart beating irregularly such as skipped beats;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems that can cause shortness of breath or ankle swelling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sac in the wall of a major artery, inflammation and clot of a vein; blockage of a blood vessel;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung diseases causing shortness of breath (including inflammation);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary embolism (blockage in an artery of the lung);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pleural effusion (abnormal collection of fluid in the pleural space);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas which causes severe pain in the abdomen and back;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial oedema (swelling of the face);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallbladder inflammation, gallbladder stones;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatty liver (build up of fat in liver cells);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scar;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal muscle breakdown;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic lupus erythematosus (an immune disorder including inflammation of skin, heart, lung, joints and other organ systems);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep interruptions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammations.</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1&nbsp;in 1,000&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leukaemia (cancer affecting the blood and bone marrow);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction with shock;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple sclerosis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve disorders (such as inflammation of the optic nerve to the eye, and Guillain‑Barr&eacute; syndrome, a condition that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart stops pumping;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary fibrosis (scarring of the lung);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal perforation (hole in the wall of the gut);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitis (liver inflammation);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactivation of hepatitis B infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autoimmune hepatitis (inflammation of the liver caused by the body&rsquo;s own immune system);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cutaneous vasculitis (inflammation of blood vessels in the skin);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens‑Johnson syndrome (life‑threatening reaction with flu‑like symptoms and blistering rash);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial oedema (swelling of the face) associated with allergic reactions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme (inflammatory skin rash);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus‑like syndrome;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angioedema (localised swelling of the skin);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lichenoid skin reaction (itchy reddish‑purple skin rash).</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from available data)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatosplenic T‑cell lymphoma (a rare blood cancer that is often fatal);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaposi&rsquo;s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi&rsquo;s sarcoma most commonly appears as purple lesions on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain (for most patients, the weight gain was small).</p><p>&nbsp;</p><p>Some side effects observed with adalimumab may not have symptoms and may only be discovered through blood tests. These include:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1&nbsp;in 10&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for white blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for red blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased lipids in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised liver enzymes.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1&nbsp;in 10&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood measurements for white blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for platelets;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased uric acid in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood measurements for sodium;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for calcium;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for phosphate;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood measurements for lactate dehydrogenase;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autoantibodies present in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood potassium.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised bilirubin measurement (liver blood test).</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1&nbsp;in 1,000&nbsp;people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for white blood cells, red blood cells and platelet count.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Shelf-life: 3&nbsp;years</p><p>Do not use this medicine after the expiry date which is stated on the label / blister / carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash;8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Keep the pre‑filled syringe or pre‑filled pen in the outer carton in order to protect from light.</p><p>&nbsp;</p><p><u>Alternative Storage:</u></p><p>&nbsp;</p><p>When needed (for example, when you are travelling), a single ABRILADA pre‑filled syringe or pre‑filled pen may be stored at room temperature (up to 30&deg;C) for a maximum period of 30&nbsp;days &ndash; be sure to protect it from light. Once removed from the refrigerator for room temperature storage, the syringe or pen <strong>must be used within 30&nbsp;days or discarded</strong>, even if it is returned to the refrigerator.</p><p>&nbsp;</p><p>You should record the date when the syringe or pen is first removed from refrigerator and the date after which it should be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is adalimumab.</p><p>&nbsp;</p><p>The other ingredients are L‑histidine, L‑histidine hydrochloride monohydrate, sucrose, edetate disodium dihydrate, L‑methionine, polysorbate 80, and water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ABRILADA pre filled syringe
ABRILADA 40 mg solution for injection in pre filled syringe is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution. 

The ABRILADA pre filled syringe is a glass syringe containing a clear, colourless to very light brown solution of adalimumab. 

Each pack contains 2 pre filled syringes for patient use with 2 alcohol pads.

ABRILADA pre-filled pen
ABRILADA 40 mg solution for injection in pre filled pen is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution. 

The ABRILADA pre-filled pen contains a clear, colourless to very light brown solution of adalimumab.

Each pack contains 2 pre filled pens for patient use with 2 alcohol pads.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer AG, Switzerland</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>Catalent Indiana, LLC</p><p>United States</p><p>&nbsp;</p><p>and</p><p>&nbsp;</p><p>SHL Pharma LLC</p><p>United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;يحتوي أبريلادا على المادة الفعالة أداليموماب، وهو دواء يعمل على الجهاز المناعي (الدفاعي) في جسمك.</p><p>&nbsp;</p><p dir="RTL">أبريلادا مخصص لعلاج الأمراض الالتهابية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الروماتويدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل المتعدد اليفعي مجهول السبب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل المرتبط بالتهاب الارتكاز لدى الأطفال،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفقار المقسط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصدفي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصدفية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدد العرقية القيحي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كرون،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; والتهاب العنبية غير المُعدي.</p><p>&nbsp;</p><p dir="RTL">المكون الفعال في أبريلادا، أداليموماب، هو جسم مضاد وحيد النسيلة. الأجسام المضادة وحيدة النسيلة هي بروتينات ترتبط بهدف محدد في الجسم.</p><p>&nbsp;</p><p dir="RTL">يستهدف أداليموماب بروتينًا آخر يسمى عامل نخر الورم ألفا (TNF&alpha;) الذي يشارك في عمل الجهاز المناعي (الدفاعي) ويوجد بمستويات مرتفعة في الأمراض الالتهابية المذكورة أعلاه. من خلال الارتباط بعامل نخر الورم ألفا، يقوم أبريلادا بإحصار عمله وتقليل الالتهاب في هذه الأمراض.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الروماتويدي</u></p><p>&nbsp;</p><p dir="RTL">التهاب المفاصل الروماتويدي هو مرض التهابي يصيب المفاصل.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب المفاصل الروماتويدي لدى البالغين. إذا كنت مصابًا بحالة متوسطة إلى شديدة من التهاب المفاصل الروماتويدي النشط، فقد تُعطى أولًا أدوية أخرى معدلة لسير المرض، مثل ميثوتريكسات. إذا لم تكن هذه الأدوية فعالة بما يكفي، فستُعطى أبريلادا لعلاج التهاب المفاصل الروماتويدي الذي تعاني منه.</p><p>&nbsp;</p><p dir="RTL">يمكن استخدام أبريلادا أيضًا لعلاج التهاب المفاصل الروماتويدي الشديد، والنشط، والتقدمي دون علاج سابق بميثوتريكسات.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يبطئ أبريلادا الضرر الملحق بغضاريف وعظام المفاصل الذي يسببه المرض، ويحسّن الوظائف الجسدية.</p><p>&nbsp;</p><p dir="RTL">عادة ما يُستخدم أبريلادا مع ميثوتريكسات. إذا رأى طبيبك أن ميثوتريكسات غير مناسب، يمكن إعطاء أبريلادا بمفرده.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب المفاصل المتعدد اليفعي مجهول السبب</u></p><p>&nbsp;</p><p dir="RTL">التهاب المفاصل المتعدد اليفعي مجهول السبب هو مرض التهابي يصيب المفاصل ويظهر عادةً لأول مرة في مرحلة الطفولة.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب المفاصل المتعدد اليفعي مجهول السبب لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين عامين و۱۷ عامًا. يمكن إعطاء المرضى أدوية أخرى معدلة لسير المرض أولًا، مثل ميثوتريكسات. إذا لم تكن هذه الأدوية فعالة بما يكفي، فسيُعطى المرضى أبريلادا لعلاج التهاب المفاصل المتعدد اليفعي مجهول السبب الذي يعانون منه.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب المفاصل المرتبط بالتهاب الارتكاز لدى الأطفال</u></p><p>&nbsp;</p><p dir="RTL">التهاب المفاصل المرتبط بالتهاب الارتكاز لدى الأطفال هو مرض التهابي يصيب المفاصل والمواضع التي تلتقي عندها الأوتار بالعظام.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب المفاصل المرتبط بالتهاب الارتكاز لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين ٦ أعوام و۱۷ عامًا. يمكن إعطاء المرضى أدوية أخرى معدلة لسير المرض أولًا، مثل ميثوتريكسات. إذا لم تكن هذه الأدوية فعالة بما يكفي، فسيُعطى المرضى أبريلادا لعلاج التهاب المفاصل المرتبط بالتهاب الارتكاز الذي يعانون منه.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب الفقار المقسط والتهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي</u></p><p>&nbsp;</p><p dir="RTL">التهاب الفقار المقسط والتهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي هما مرضان من الأمراض الالتهابية التي تصيب العمود الفقري.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا مع البالغين لعلاج هاتين الحالتين. إذا كنت مصابًا بالتهاب الفقار المقسط أو التهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي، فستُعطى أدوية أخرى أولًا. إذا لم تكن هذه الأدوية فعالة بما يكفي، فستُعطى أبريلادا لتقليل علامات وأعراض مرضك.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الصدفي</u></p><p>&nbsp;</p><p dir="RTL">التهاب المفاصل الصدفي هو التهاب المفاصل الذي يصاحب الصدفية.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب المفاصل الصدفي لدى البالغين. يمكن أن يبطئ أبريلادا الضرر الملحق بغضاريف وعظام المفاصل الذي يسببه المرض، ويحسّن الوظائف الجسدية.</p><p>&nbsp;</p><p dir="RTL"><u>الصدفية اللويحية لدى البالغين والأطفال</u></p><p>&nbsp;</p><p dir="RTL">الصدفية اللويحية حالة جلدية التهابية تسبب بقعًا حمراء قشرية جافة على الجلد مغطاة بقشور فضية. يمكن أن تصيب الصدفية اللويحية الأظافر أيضًا مما يؤدي إلى تكسرها وزيادة سمكها ورفعها عن بطانة الظفر، وهو ما قد يكون مؤلمًا. يُعتقد أن سبب الإصابة بالصدفية هو مشكلة في الجهاز المناعي للجسم تؤدي إلى زيادة إنتاج خلايا الجلد.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج الصدفية اللويحية المتوسطة إلى الشديدة لدى البالغين. يُستخدم أبريلادا أيضًا لعلاج الصدفية اللويحية الشديدة لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين ٤ أعوام و۱۷ عامًا وكانت الأدوية الموضوعة على الجلد والعلاج بالأشعة فوق البنفسجية (UV) غير فعّالة بما يكفي أو غير مناسبة لحالتهم.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب الغدد العرقية القيحي لدى البالغين والمراهقين</u></p><p>&nbsp;</p><p dir="RTL">التهاب الغدد العرقية القيحي (يسمى أحيانًا حب الشباب العكسي) هو مرض جلدي التهابي طويل الأمد وغالبًا ما يكون مؤلمًا. قد تتضمن الأعراض عقيدات (كتلًا) مؤلمة وخراجات (دمامل) قد تفرز صديدًا. ويصيب في أغلب الأحيان مناطق معينة من الجلد مثل تحت الثديين، والإبطين، وباطن الفخذين، والأربية، والردفين. قد يحدث تندب أيضًا في المناطق المصابة.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب الغدد العرقية القيحي لدى البالغين والمراهقين من عمر ۱۲ عامًا. يمكن أن يقلل أبريلادا عدد العقيدات والخراجات التي تعاني منها والألم المرتبط غالبًا بالمرض. يمكن إعطاؤك أدوية أخرى أولًا. إذا لم تكن هذه الأدوية فعالة بما يكفي، فستُعطى أبريلادا.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>مرض كرون لدى البالغين والأطفال</u></p><p>&nbsp;</p><p dir="RTL">مرض كرون هو مرض التهابي يصيب الأمعاء.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج مرض كرون لدى البالغين والأطفال الذين تتراوح أعمارهم بين ٦ أعوام و۱۷ عامًا.</p><p>&nbsp;</p><p dir="RTL">إذا كنت مصابًا بمرض كرون، فستعطى أدوية أخرى أولًا. إذا لم تستجب جيدًا بما يكفي لهذه الأدوية، فستُعطى أبريلادا لتقليل علامات وأعراض مرض كرون الذي تعاني منه.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب القولون التقرحي لدى البالغين والأطفال</u></p><p>&nbsp;</p><p dir="RTL">التهاب القولون التقرحي هو مرض التهابي يصيب الأمعاء الغليظة.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج التهاب القولون التقرحي المتوسط إلى الشديد لدى البالغين والأطفال في عمر ٦ أعوام إلى ۱۷ عامًا. إذا كنت مصابًا بالتهاب القولون التقرحي، يمكن إعطاؤك أدوية أخرى أولًا. إذا لم تكن هذه الأدوية فعالة بما يكفي، فستُعطى أبريلادا لتقليل علامات وأعراض مرضك.</p><p>&nbsp;</p><p dir="RTL"><u>التهاب العنبية غير المُعدي لدى البالغين والأطفال</u></p><p>&nbsp;</p><p dir="RTL">التهاب العنبية غير المُعدي هو مرض التهابي يصيب أجزاءً معينة من العين. يمكن أن يؤدي هذا الالتهاب إلى انخفاض الرؤية و/أو وجود أشياء عائمة في العين (نقاط سوداء أو خطوط رفيعة تتحرك عبر مجال الرؤية). يعمل أبريلادا عن طريق تقليل هذا الالتهاب.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أبريلادا لعلاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين المصابين بالتهاب العنبية غير المُعدي إذا كان الالتهاب يصيب مؤخرة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال من سن عامين المصابين بالتهاب العنبية غير المُعدي المزمن إذا كان الالتهاب يصيب مقدمة العين.</p><p>&nbsp;</p><p dir="RTL">يمكن إعطاؤك أدوية أخرى أولًا. إذا لم تكن هذه الأدوية فعالة بما يكفي، فستُعطى أبريلادا لتقليل علامات وأعراض مرضك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أبريلادا</strong></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أداليموماب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى شديدة، بما في ذلك مرض السل النشط، أو الإنتان (تسمم الدم)، أو حالات العدوى الانتهازية (عدوى غير معتادة مرتبطة بضعف الجهاز المناعي). من المهم أن تخبر طبيبك إذا أصبت بأعراض العدوى، مثل الحمى، الجروح، الشعور بالتعب، مشكلات الأسنان (انظر قسم &quot;الاحتياطات عند استعمال أبريلادا&quot;).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفشل القلب المتوسط أو الشديد. من المهم أن تخبر طبيبك إذا كنت قد عانيت أو تعاني حاليًا من حالة قلبية خطيرة (انظر قسم &quot;الاحتياطات عند استعمال أبريلادا&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال أبريلادا</strong></p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام أبريلادا.</p><p>&nbsp;</p><p dir="RTL">من المهم أن تسجّل أنت وطبيبك الاسم التجاري ورقم الدفعة لدوائك.</p><p>&nbsp;</p><p dir="RTL"><u>تفاعلات الحساسية</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتفاعلات حساسية مصحوبة بأعراض مثل ضيق الصدر، أو الأزيز، أو الدوار، أو التورم، أو الطفح الجلدي، فلا تحقن كمية أخرى من أبريلادا وتواصل مع طبيبك فورًا، لأنه في حالات نادرة، يمكن أن تكون هذه التفاعلات مهددة للحياة.</p><p>&nbsp;</p><p dir="RTL"><u>حالات العدوى</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى، بما في ذلك عدوى طويلة الأمد أو عدوى في جزء واحد من الجسم (مثل، قرحة الساق)، فاستشر طبيبك قبل بدء استخدام أبريلادا. إذا كنت غير متأكد مما يتعين عليك فعله، فتواصل مع طبيبك.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بالعدوى بسهولة أكبر أثناء تلقيك العلاج بأبريلادا. يمكن أن يزيد هذا الخطر إذا كنت تعاني من مشكلات في رئتيك. قد تكون هذه العدوى خطيرة وتتضمن مرض السل، والعدوى التي تسببها الفيروسات أو الفطريات أو الطفيليات أو البكتيريا أو غيرها من حالات العدوى الانتهازية (كائنات حية مُعدية غير معتادة)، والإنتان (تسمم الدم). في حالات نادرة، قد تكون هذه العدوى مهددة للحياة. من المهم أن تخبر طبيبك إذا أصبت بأعراض مثل الحمى، أو الجروح، أو الشعور بالتعب، أو مشكلات الأسنان. قد يوصي طبيبك بإيقاف أبريلادا مؤقتًا.</p><p>&nbsp;</p><p dir="RTL"><u>مرض السل (</u><u>TB</u><u>)</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لقد تم الإبلاغ عن حدوث حالات من مرض السل لدى المرضى الذين عولجوا بأداليموماب، لذا سيفحصك طبيبك للكشف عن علامات وأعراض مرض السل قبل بدء استخدام أبريلادا. سيتضمن هذا تقييمًا طبيًا شاملًا، بما في ذلك تاريخك الطبي واختبارات الفحص (مثل، تصوير الصدر بالأشعة السينية واختبار توبيركولين). ينبغي تسجيل إجراء هذه الاختبارات ونتائجها في بطاقة المريض التذكيرية الخاصة بك.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدًا أن تخبر طبيبك إذا أصبت من قبل بمرض السل، أو إذا خالطت عن قرب شخصًا كان يعاني من مرض السل.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تصاب بمرض السل أثناء العلاج حتى إذا تلقيت من قبل علاجًا وقائيًا لمرض السل.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت أعراض مرض السل (مثل سعال لا يزول، فقدان الوزن، نقص الطاقة، الحمى الخفيفة) أو أي عدوى أخرى تظهر أثناء العلاج أو بعده، فأخبر طبيبك فورًا.</p><p>&nbsp;</p><p dir="RTL"><u>السفر / العدوى المتكررة</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت قد عشت أو سافرت إلى مناطق تتوطن (توجد) فيها العدوى الفطرية مثل داء النوسجات، أو الفطار الكرواني، أو الفطار البرعمي.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت مصابًا بعدوى تعاود الظهور أو حالات أخرى تزيد خطر الإصابة بالعدوى.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي أن تولي اهتمامًا خاصًا بعلامات العدوى أثناء علاجك بأبريلادا. من المهم أن تخبر طبيبك إذا ظهرت عليك أعراض العدوى مثل الحمى، أو الجروح، أو الشعور بالتعب، أو مشكلات الأسنان.</p><p>&nbsp;</p><p dir="RTL"><u>فيروس التهاب الكبد الوبائي </u><u>B</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت حاملًا لفيروس التهاب الكبد الوبائي B&rlm; (HBV)، أو إذا كنت مصابًا بعدوى نشطة من فيروس التهاب الكبد الوبائي B، أو إذا اعتقدت أنك قد تكون معرضًا لخطر الإصابة بفيروس التهاب الكبد الوبائي B. ينبغي أن يُجري لك طبيبك اختبارًا للكشف عن فيروس التهاب الكبد الوبائي B. يمكن لأداليموماب إعادة تنشيط عدوى فيروس التهاب الكبد الوبائي B لدى الأشخاص الذين يحملون هذا الفيروس. في بعض الحالات النادرة، خاصةً إذا كنت تتناول أدوية أخرى تثبط الجهاز المناعي، يمكن أن تكون إعادة تنشيط عدوى فيروس التهاب الكبد الوبائي B مهددة للحياة.</p><p>&nbsp;</p><p dir="RTL"><u>العمر الأكبر من ٦٥ عامًا</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك أكبر من ٦٥ عامًا، فقد تكون أكثر عرضة للإصابة بالعدوى أثناء تناول أبريلادا. ينبغي أن تولي أنت وطبيبك اهتمامًا خاصًا بعلامات العدوى أثناء علاجك بأبريلادا. من المهم أن تخبر طبيبك إذا ظهرت عليك أعراض العدوى مثل الحمى، أو الجروح، أو الشعور بالتعب، أو مشكلات الأسنان.</p><p>&nbsp;</p><p dir="RTL"><u>الجراحة أو إجراءات الأسنان</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك الخضوع لجراحة أو إجراءات تتعلق بالأسنان، فأخبر طبيبك أنك تتناول أبريلادا. قد يوصي طبيبك بإيقاف أبريلادا مؤقتًا.</p><p>&nbsp;</p><p dir="RTL"><u>مرض إزالة الميالين</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو أصبت بمرض إزالة الميالين (مرض يصيب الطبقة العازلة المحيطة بالأعصاب، مثل التصلب المتعدد)، فسيقرر طبيبك ما إذا كان ينبغي أن تتلقى أو تواصل تلقي أبريلادا. أخبر طبيبك فورًا إذا أصبت بأعراض مثل تغيرات في رؤيتك، أو ضعف في ذراعيك أو ساقيك، أو خدر أو وخز في أي جزء من جسمك.</p><p>&nbsp;</p><p dir="RTL"><u>اللقاحات</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي بعض اللقاحات على أشكال حية لكنها ضعيفة من البكتيريا أو الفيروسات المسببة للمرض، وقد تسبب العدوى وينبغي عدم إعطائها أثناء العلاج بأبريلادا. راجع طبيبك قبل أن تتلقى أي لقاحات. يوصى، إن أمكن، بإعطاء الأطفال جميع اللقاحات المقررة لأعمارهم قبل البدء في علاجهم بأبريلادا. إذا تلقيتِ أبريلادا أثناء الحمل، فقد يكون طفلكِ أكثر عرضة للإصابة بعدوى لمدة تصل إلى خمسة أشهر تقريبًا بعد آخر جرعة تلقيتِها أثناء الحمل. من المهم أن تخبري أطباء طفلكِ ومتخصصي الرعاية الصحية الآخرين بشأن استخدامكِ لأبريلادا أثناء الحمل حتى يتمكنوا من تحديد متى ينبغي أن يتلقى طفلكِ أي لقاح.</p><p>&nbsp;</p><p dir="RTL"><u>فشل القلب</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن تخبر طبيبك إذا كنت قد عانيت أو تعاني حاليًا من حالة قلبية خطيرة. إذا كنت مصابًا بفشل القلب الخفيف وتخضع للعلاج بأبريلادا، يجب أن يراقب طبيبك حالة فشل القلب لديك عن كثب. إذا ظهرت عليك أعراض جديدة أو متفاقمة لفشل القلب (مثل، ضيق التنفس أو تورم قدميك)، يجب أن تتواصل مع طبيبك فورًا.</p><p>&nbsp;</p><p dir="RTL"><u>الحمى أو التكدم أو النزيف أو شحوب المظهر</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة بعض المرضى، قد يفشل الجسم في إنتاج ما يكفي من خلايا الدم التي تحارب العدوى أو تساعدك على إيقاف النزيف. إذا أصبت بحمى لا تزول، أو كنت تتعرض للتكدم أو النزيف بسهولة شديدة، أو كنت تبدو شاحبًا جدًا، فاتصل بطبيبك على الفور. قد يقرر طبيبك إيقاف العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>السرطان</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت هناك حالات نادرة جدًا لأنواع معينة من السرطان لدى الأطفال والبالغين الذين يتناولون أداليموماب أو غيره من حاصرات عامل نخر الورم ألفا. إن الأشخاص المصابين بحالة أخطر من التهاب المفاصل الروماتويدي وعانوا من المرض لفترة طويلة قد يكونون عرضة لخطر أعلى من المتوسط للإصابة بسرطان الغدد الليمفاوية وابيضاض الدم (سرطانان يصيبان خلايا الدم ونخاع العظم). إذا تناولت أبريلادا، فقد يزيد خطر الإصابة بسرطان الغدد الليمفاوية أو ابيضاض الدم أو سرطانات أخرى. في حالات نادرة، لوحظ نوع غير شائع وشديد من سرطان الغدد الليمفاوية لدى المرضى الذين تناولوا أداليموماب. وتم أيضًا علاج بعض هؤلاء المرضى بأدوية آزاثيوبرين أو ميركابتوبيورين. أخبر طبيبك إذا كنت تتناول آزاثيوبرين أو ميركابتوبيورين مع أبريلادا.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالإضافة إلى ذلك، لوحظت حالات من سرطان الجلد غير الميلانيني في المرضى الذين تناولوا أداليموماب. أخبر طبيبك إذا ظهرت مناطق جديدة من الجلد التالف أثناء العلاج أو بعده، أو إذا تغير مظهر علامات أو مناطق التلف الموجودة.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت هناك حالات من السرطانات، بخلاف سرطان الغدد الليمفاوية، لدى المرضى المصابين بنوع معين من مرض الرئة يسمى مرض الانسداد الرئوي المزمن (COPD) الذين عولجوا بعقار آخر من حاصرات عامل نخر الورم ألفا. إذا كنت مصابًا بمرض الانسداد الرئوي المزمن، أو كنت مدخنًا شرهًا، ينبغي أن تتناقش مع طبيبك فيما إذا كان العلاج بأحد حاصرات عامل نخر الورم ألفا مناسبًا لك أم لا.</p><p>&nbsp;</p><p dir="RTL"><u>المرض المناعي الذاتي</u></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة، يمكن أن يؤدي العلاج بأبريلادا إلى متلازمة شبيهة بالذئبة. تواصل مع طبيبك إذا حدثت أعراض مثل الطفح الجلدي المستمر غير المبرر، أو الحمى، أو ألم المفاصل، أو التعب.</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">يمكن تناول أبريلادا بالاقتران مع ميثوتريكسات أو بعض العوامل المضادة للروماتيزم المعدلة لسير المرض (مثل سلفاسالازين، وهيدروكسي كلوروكوين، وليفلونوميد، ومستحضرات الذهب القابلة للحقن)، أو الستيرويدات القشرية أو أدوية تخفيف الألم بما في ذلك مضادات الالتهاب غير الستيرويدية (NSAID).</p><p>&nbsp;</p><p dir="RTL">ينبغي ألا تتناول أبريلادا مع الأدوية التي تحتوي على المادتين الفعالتين أناكينرا أو أباتاسيبت بسبب زيادة خطر الإصابة بعدوى خطيرة. لا يوصى بالجمع بين أداليموماب، وكذلك مضادات عامل نخر الورم الأخرى، وأناكينرا أو أباتاسيبت بناءً على احتمال زيادة خطر الإصابة بالعدوى، بما في ذلك العدوى الخطيرة وغيرها من التفاعلات الدوائية المحتملة. إذا كانت لديك أسئلة، يرجى طرحها على طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p>&nbsp;</p><p dir="RTL">يجب أن تأخذي في اعتباركِ استخدام وسيلة مناسبة لمنع الحمل ومواصلة استخدامها لمدة ٥ أشهر على الأقل بعد تلقي آخر علاج بأبريلادا.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ بشأن تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">ينبغي عدم استخدام أبريلادا أثناء الحمل إلا إذا كان ضروريًا.</p><p>&nbsp;</p><p dir="RTL">وفقًا لإحدى دراسات الحمل، لم يكن هناك خطر أعلى لحدوث العيوب الولادية عندما تلقت الأم أداليموماب أثناء الحمل مقارنة بالأمهات المصابات بنفس المرض اللاتي لم يتلقين أداليموماب.</p><p>&nbsp;</p><p dir="RTL">يمكن استخدام أبريلادا أثناء الرضاعة الطبيعية.</p><p>&nbsp;</p><p dir="RTL">إذا تلقيتِ أبريلادا أثناء الحمل، فقد يكون طفلكِ أكثر عرضة للإصابة بعدوى. من المهم أن تخبري أطباء طفلكِ ومتخصصي الرعاية الصحية الآخرين بشأن استخدامكِ لأبريلادا أثناء الحمل قبل أن يتلقى الطفل أي لقاح. لمزيد من المعلومات حول اللقاحات انظر قسم &quot;الاحتياطات عند استعمال أبريلادا&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير أبريلادا على القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL">قد يؤثر أبريلادا تأثيرًا طفيفًا على قدرتك على القيادة أو ركوب الدراجات أو استخدام الآلات. قد يحدث إحساس بدوران الغرفة (دوخة) واضطرابات في الرؤية بعد تناول أبريلادا.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات أبريلادا </strong></p><p dir="RTL"><strong>يحتوي أبريلادا على الصوديوم</strong></p><p>&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة قدرها ٠.٨ مل، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL"><table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>۳.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طريقة استخدام أبريلادا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله. يمكن أن يصف طبيبك تركيزًا آخر من أبريلادا إذا احتجت إلى جرعة مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحقن أبريلادا تحت الجلد (الاستخدام تحت الجلد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بالتهاب المفاصل الروماتويدي، أو التهاب المفاصل الصدفي، أو التهاب الفقار المقسط، أو التهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين المصابين بالتهاب المفاصل الروماتويدي، والتهاب الفقار المقسط، والتهاب المفاصل الفقارية المحوري دون وجود دليل على الإصابة بالتهاب الفقار المقسط بالتصوير الإشعاعي، وللمرضى بالتهاب المفاصل الصدفي هي ٤٠ ملجم من أداليموماب تُعطى كل أسبوعين كجرعة فردية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة التهاب المفاصل الروماتويدي، يستمر استخدام ميثوتريكسات أثناء استخدام أبريلادا. إذا قرر طبيبك أن ميثوتريكسات غير مناسب، يمكن إعطاء أبريلادا بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مصابًا بالتهاب المفاصل الروماتويدي ولا تتلقى ميثوتريكسات مع علاجك بأبريلادا، يمكن أن يقرر طبيبك إعطاء ٤٠ ملجم من أداليموماب كل أسبوع أو ٨٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون والبالغون المصابون بالتهاب المفاصل المتعدد اليفعي مجهول السبب</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر عامين الذين يزنون ١٠ كلجم إلى أقل من ٣٠ كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي ۲٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون والبالغون من عمر عامين الذين يزنون ٣٠ كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي ٤٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون والبالغون المصابون بالتهاب المفاصل المرتبط بالتهاب الارتكاز</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٦ أعوام الذين يزنون ١٥ كلجم إلى أقل من ٣٠ كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي ۲٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون والبالغون من عمر ٦ أعوام الذين يزنون ٣٠ كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي ٤٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بالصدفية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين المصابين بالصدفية هي جرعة مبدئية قدرها ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد)، تليها جرعة قدرها ٤٠ ملجم كل أسبوعين وتبدأ بعد الجرعة المبدئية بأسبوع واحد. ينبغي أن تواصل حقن أبريلادا طوال المدة التي أخبرك بها طبيبك. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك الجرعة إلى ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون المصابون بالصدفية اللويحية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٤ أعوام إلى ١٧ عامًا الذين يزنون ١٥ كلجم إلى أقل من ٣٠ كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي جرعة مبدئية قدرها ۲٠ ملجم، تليها جرعة قدرها ۲٠ ملجم بعد أسبوع واحد. بعد ذلك، تصبح الجرعة المعتادة ۲٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٤ أعوام إلى ١٧ عامًا الذين يزنون ٣٠ كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي جرعة مبدئية قدرها ٤٠ ملجم، تليها جرعة قدرها ٤٠ ملجم بعد أسبوع واحد. بعد ذلك، تصبح الجرعة المعتادة ٤٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بالتهاب الغدد العرقية القيحي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظام الجرعة المعتادة لعلاج التهاب الغدد العرقية القيحي هو جرعة مبدئية قدرها ١٦٠ ملجم (في صورة أربع حقن بتركيز ٤٠ ملجم في يوم واحد، أو في صورة حقنتين بتركيز ٤٠ ملجم يوميًا لمدة يومين متتاليين)، تليها جرعة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) بعد أسبوعين. بعد أسبوعين إضافيين، استمر على جرعة قدرها ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين، حسبما يصف طبيبك. يوصى بأن تستخدم غسولًا مطهرًا يوميًا على المناطق المصابة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المراهقون المصابون بالتهاب الغدد العرقية القيحي الذين تتراوح أعمارهم بين ١٢ و١٧ عامًا ويزنون ٣٠ كلجم أو أكثر</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من أبريلادا هي جرعة مبدئية قدرها ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد)، تليها جرعة ٤٠ ملجم كل أسبوعين وتبدأ بعد أسبوع واحد. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك الجرعة إلى ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى بأن تستخدم غسولًا مطهرًا يوميًا على المناطق المصابة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بمرض كرون</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظام الجرعة المعتادة لعلاج مرض كرون هو ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) مبدئيًا تتبعها جرعة ٤٠ ملجم كل أسبوعين وتبدأ بعد أسبوعين. إذا كان يلزم حدوث استجابة أسرع، فقد يصف طبيبك جرعة مبدئية قدرها ١٦٠ ملجم (في صورة أربع حقن بتركيز ٤٠ ملجم في يوم واحد، أو في صورة حقنتين بتركيز ٤٠ ملجم يوميًا لمدة يومين متتاليين)، تليها جرعة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) بعد أسبوعين، ثم كجرعة قدرها ٤٠ ملجم كل أسبوعين. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك الجرعة إلى ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون المصابون بمرض كرون</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٦ أعوام إلى ١٧ عامًا الذين يزنون أقل من ٤٠ كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظام الجرعة المعتادة هو ٤٠ ملجم مبدئيًا تتبعها ۲٠ ملجم بعد أسبوعين. إذا كان يلزم حدوث استجابة أسرع، فقد يصف طبيبك جرعة مبدئية قدرها ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) تليها جرعة ٤٠ ملجم تبدأ بعد أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد ذلك، تصبح الجرعة المعتادة ۲٠ ملجم كل أسبوعين. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك معدل تكرار الجرعة إلى ۲٠ ملجم كل أسبوع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٦ أعوام إلى ١٧ عامًا الذين يزنون ٤٠ كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظام الجرعة المعتادة هو ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) مبدئيًا تتبعها جرعة ٤٠ ملجم بعد أسبوعين. إذا كان يلزم حدوث استجابة أسرع، فقد يصف طبيبك جرعة مبدئية قدرها ١٦٠ ملجم (في صورة أربع حقن بتركيز ٤٠ ملجم في يوم واحد، أو في صورة حقنتين بتركيز ٤٠ ملجم يوميًا لمدة يومين متتاليين)، تليها جرعة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) بعد أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد ذلك، تصبح الجرعة المعتادة ٤٠ ملجم كل أسبوعين. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك الجرعة إلى ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بالتهاب القولون التقرحي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة أبريلادا المعتادة للبالغين المصابين بالتهاب القولون التقرحي هي ١٦٠ ملجم مبدئيًا (في صورة أربع حقن بتركيز ٤٠ ملجم في يوم واحد، أو في صورة حقنتين بتركيز ٤٠ ملجم يوميًا لمدة يومين متتاليين)، ثم جرعة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) بعد أسبوعين، ثم جرعة ٤٠ ملجم كل أسبوعين. إذا لم تكن هذه الجرعة فعالة بما يكفي، فقد يزيد طبيبك الجرعة إلى ٤٠ ملجم كل أسبوع أو ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون المصابون بالتهاب القولون التقرحي</u></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٦&nbsp;أعوام الذين يزنون أقل من ٤٠&nbsp;كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة أبريلادا المعتادة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) مبدئيًا تليها جرعة ٤٠ ملجم (في صورة حقنة واحدة ٤٠ ملجم) بعد أسبوعين. بعد ذلك، تصبح الجرعة المعتادة ٤٠ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي للمرضى الذين يبلغون ۱۸ عامًا أثناء تلقي جرعة ٤٠ ملجم كل أسبوعين أن يواصلوا الجرعة الموصوفة لهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال والمراهقون من عمر ٦&nbsp;أعوام الذين يزنون ٤٠&nbsp;كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة أبريلادا المعتادة ١٦٠ ملجم (في صورة أربع حقن بتركيز ٤٠ ملجم في يوم واحد أو حقنتين بتركيز ٤٠ ملجم يوميًا لمدة يومين متتاليين) مبدئيًا، تليها جرعة ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد) بعد أسبوعين. بعد ذلك، تصبح الجرعة المعتادة ۸۰ ملجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي للمرضى الذين يبلغون ۱۸ عامًا أثناء تلقي جرعة ۸۰ ملجم كل أسبوعين أن يواصلوا الجرعة الموصوفة لهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون المصابون بالتهاب العنبية غير المُعدي</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين المصابين بالتهاب العنبية غير المُعدي هي جرعة مبدئية قدرها ۸۰ ملجم (في صورة حقنتين بتركيز ٤٠ ملجم في يوم واحد)، تليها جرعة ٤٠ ملجم كل أسبوعين وتبدأ بعد الجرعة المبدئية بأسبوع واحد. ينبغي أن تواصل حقن أبريلادا طوال المدة التي أخبرك بها طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في التهاب العنبية غير المُعدي، يمكن مواصلة إعطاء الستيرويدات القشرية أو الأدوية الأخرى التي تؤثر على الجهاز المناعي أثناء استخدام أبريلادا. يمكن أيضًا إعطاء أبريلادا بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقون من عمر عامين المصابون بالتهاب العنبية غير المُعدي المزمن</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><em>الأطفال والمراهقون من عمر عامين الذين يزنون أقل من ٣٠ كلجم</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة من أبريلادا هي ۲٠ ملجم كل أسبوعين مع ميثوتريكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف طبيبك أيضًا جرعة مبدئية قدرها ٤٠ ملجم يمكن إعطاؤها قبل بدء الجرعة المعتادة بأسبوع واحد.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><em>الأطفال والمراهقون من عمر عامين الذين يزنون ٣٠ كلجم أو أكثر</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة من أبريلادا هي ٤٠ ملجم كل أسبوعين مع ميثوتريكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف طبيبك أيضًا جرعة مبدئية قدرها ۸۰ ملجم يمكن إعطاؤها قبل بدء الجرعة المعتادة بأسبوع واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال ومسار التعاطي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء أبريلادا بالحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p>تتوفر تعليمات مفصلة حول كيفية حقن أبريلادا.</p>&nbsp;<p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL">أبريلادا (أداليموماب) ٤۰ ملجم</p><p dir="RTL">محقنة مسبقة التعبئة بجرعة فردية للحقن تحت الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتفظ بهذه النشرة. توضح هذه التعليمات كيفية تحضير وإعطاء الحقنة خطوة بخطوة.</strong></p><p dir="RTL"><strong>&nbsp;خزن محقنة أبريلادا مسبقة التعبئة الخاصة بك في الثلاجة في درجة حرارة تتراوح بين درجتين مئويتين و۸ درجات مئوية.</strong></p><p dir="RTL"><strong>&nbsp;خزن محقنة أبريلادا مسبقة التعبئة في العبوة الكرتونية الأصلية حتى استخدامها لحمايتها من ضوء الشمس المباشر.</strong></p><p dir="RTL"><strong>إذا لزم الأمر، على سبيل المثال، إذا كنت مسافرًا، يمكنك تخزين محقنة أبريلادا مسبقة التعبئة في درجة حرارة الغرفة حتى ۳۰ درجة مئوية لمدة تصل إلى ۳۰ يومًا.</strong></p><p dir="RTL"><strong>احتفظ بأبريلادا، ومستلزمات الحقن، وجميع الأدوية الأخرى بعيدًا عن متناول الأطفال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر أبريلادا المخصص للحقن في محقنة مسبقة التعبئة للاستخدام لمرة واحدة فقط ثم يتم التخلص منها، وتحتوي على جرعة فردية من الدواء.</p><p dir="RTL"><strong>لا</strong> تحاول حقن أبريلادا بنفسك إلا بعد أن تقرأ تعليمات الاستخدام وتفهمها. إذا قرر طبيبك أو الممرضة أو الصيدلي أنه يمكنك، أنت أو القائم على الرعاية، إعطاء حقن أبريلادا في المنزل، ينبغي أن تتلقيا تدريبًا على الطريقة الصحيحة لتحضير وحقن أبريلادا.</p><p dir="RTL">من المهم أيضًا أن تتحدث مع طبيبك أو الممرضة أو الصيدلي للتأكد من فهم تعليمات جرعاتك من أبريلادا. لمساعدتك على تذكر موعد حقن أبريلادا، يمكنك وضع علامة في التقويم الذي تستخدمه قبل موعد الحقن. تحدث إلى طبيبك أو الممرضة أو الصيدلي إذا كان لديك أو لدى القائم على رعايتك أي أسئلة حول الطريقة الصحيحة لحقن أبريلادا.</p><p dir="RTL">بعد التدريب المناسب، يمكن أن يقوم المريض بإعطاء أبريلادا المخصص للحقن بنفسه، أو أن يقوم القائم على الرعاية بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>۱. المستلزمات التي تحتاج إليها</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحتاج إلى المستلزمات التالية في كل من حقن أبريلادا. ابحث عن سطح نظيف ومستوٍ لتضع عليه المستلزمات.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محقنة واحدة من محاقن أبريلادا مسبقة التعبئة في حاوية داخل العبوة الكرتونية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحة كحولية واحدة داخل العبوة الكرتونية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرة قطن أو ضمادة شاش واحدة (غير متضمنة في عبوة أبريلادا الكرتونية الخاصة بك)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاوية مناسبة للأدوات الحادة (غير متضمنة في عبوة أبريلادا الكرتونية الخاصة بك).</p><p dir="RTL"><strong>مهم</strong>: إذا كانت لديك أي أسئلة بشأن محقنة أبريلادا مسبقة التعبئة أو دوائك، فتحدث إلى طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
   id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_1286094393" o:spid="_x0000_s1084"
   type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
   margin-left:-2.9pt;margin-top:139.6pt;width:64.05pt;height:14.15pt;
   z-index:251662336;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:9.0pt'>مقبض المكبس</span><span
      dir=LTR style='font-size:9.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="88" height="22" alt="Text Box: مقبض المكبس" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_543923784" o:spid="_x0000_s1083" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:131.05pt;
   margin-top:154.35pt;width:54.85pt;height:28.3pt;z-index:251663360;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:9.0pt'>الجسم الأسطواني</span><span dir=LTR
      style='font-size:9.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="76" height="40" alt="Text Box: الجسم الأسطواني" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1329167669" o:spid="_x0000_s1082" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:247.8pt;
   margin-top:163.25pt;width:64.05pt;height:14.15pt;z-index:251664384;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:9.0pt'>غطاء الإبرة</span><span
      dir=LTR style='font-size:9.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="88" height="21" alt="Text Box: غطاء الإبرة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1305724121" o:spid="_x0000_s1081" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:215.55pt;
   margin-top:86.45pt;width:40.25pt;height:14.15pt;z-index:251661312;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:9.0pt'>النافذة</span><span dir=LTR style='font-size:
      9.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="57" height="21" alt="Text Box: النافذة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1364321759" o:spid="_x0000_s1080" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:210.25pt;
   margin-top:59.1pt;width:68.2pt;height:28.3pt;z-index:251660288;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:9.0pt'>تاريخ انتهاء الصلاحية</span><span dir=LTR
      style='font-size:9.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="94" height="41" alt="Text Box: تاريخ انتهاء الصلاحية" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1876928789" o:spid="_x0000_s1079" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:181.35pt;
   margin-top:27.65pt;width:61.25pt;height:15.85pt;z-index:251659264;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:8.0pt'>عام شهر يوم</span><span dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="84" height="24" alt="Text Box: عام شهر يوم" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1044" type="#_x0000_t75"
   style='width:309pt;height:177.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><![endif]--><img width="412" height="237" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>۲. الاستعداد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج عبوة أبريلادا الكرتونية من الثلاجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح العبوة الكرتونية وأخرج الحاوية التي تحتوي على محقنتك مسبقة التعبئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص العبوة الكرتونية والحاوية؛ <strong>لا </strong>تستخدمها إذا:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقضى تاريخ انتهاء الصلاحية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تجميدها أو إذابتها</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقطت، حتى وإن كانت تبدو غير تالفة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت موجودة خارج الثلاجة لأكثر من ٣٠ يومًا</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت تبدو تالفة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت الأغلفة المحكمة على العبوة الكرتونية الجديدة تالفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انطبقت أي حالة مما ورد أعلاه، فتخلص من محقنتك مسبقة التعبئة بنفس طريقة التخلص من محقنة مستخدمة. ستحتاج إلى محقنة مسبقة التعبئة جديدة لإعطاء حقنتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك بالماء والصابون، وجففهما تمامًا.</p><p dir="RTL">&nbsp;إذا كانت لديك أي أسئلة بشأن دوائك، يرجى التحدث مع طبيبك أو الممرضة أو الصيدلي.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_992629531" o:spid="_x0000_s1078" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:39.05pt;
   margin-top:4.4pt;width:188.75pt;height:14.15pt;z-index:251666432;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">أخرج محقنتك مسبقة التعبئة من العبوة</p></td></tr></tbody></table></td></tr></tbody></table><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_243139777"
   o:spid="_x0000_s1077" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:9.75pt;margin-top:5.35pt;width:17.55pt;height:21.7pt;
   z-index:251665408;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAtYMsMzMDAABJCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVVFv2jAQfp+0/2D5vSUEAhQ1VJSN
aVLVVtCqz1fHIVEdO7MNDf07+1X7Nzs7CTA2berWl6lSOfvOn+/7fHc5v6gKQTZcm1zJmHZPA0q4
ZCrJ5Sqm93fzkxElxoJMQCjJY7rlhl5M3r87h/FKQ5nljCCCNGOIaWZtOe50DMt4AeZUlVyiL1W6
AItLveokGp4RuRCdMAgGnQJySSd7qA9ggax1/hdQQrEnnsxAbsAgpGDjw50mR8H+HRnGcvNJl8vy
VrvM2fXmVpM8iSkqJ6FAiWincTRhuOwcnVrtAapUFy5epSmpYhqF3UEURpRs8TW6UTQMghqPV5Yw
DAjDcDRCP8OAcBhFZ42fZTd/QGDZx99iYJJ1MmgcJGhKl57c/Mw47Pe6vbPhcNgyv3NJXqqK7D2t
Fu40sRU6kZdj5CVpMU2j5tuIsSMC41Ib+4mrgjgjppoz6wsONlfG1lm0IY6lUSJP5rkQfuHqmM+E
JhsQMRW2zfuHKCHJc0wHvSjwwFK54zWykA6GpyneuruupWqrpRfWaZJsXeAj/qJIWmGiWEymZPMc
s74CY29BY3/hJnaqvcF/qVB4KxN5SUmm9MvxnovDWkcPJc/YpzE1X9agOSXiszQeyraGbo3H1pDr
YqaQctdn4U28W1vRmqlWxYPSydTdgi6QDO+KqW3NmcUVOrD5GZ9Ovc1UUYK9kssS27Dr1XLa31UP
oMvmgSxW0LVaZlDyX71THevEkmq6tirNm0estXMOYezSbgX3hecVdpVXgL7ySaCxqFMWKxx4zGpP
rClKGGuHofGEADcBQZ8sp6jCCwb0sRWd9/BB8T6wuSR2W/IUGHb/VOcgKClBKoPLIAwug0HQx9/2
r4/e3LJsDkUusIt7uMEy0IZ7MX3iHN4YEnsCWbn07eTbV9d91veg3+IycRW22NHm8uR+WdMe/ees
99w8X6wIx33XdGvDl+UCG7Ru2bYrjSshX05ywVOc7zi26tf3X7f9VADGuNxNBuGi3bEUh8BrDjbx
+/J6zeG6INublbS7w0UulfZFe5R28tQOs7SO97I0rFEgN/Q7Rx9RH9J89N2X+nA9+Q4AAP//AwBQ
SwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZ
S28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrroSgaoAEa
9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6xMYmDtv9o
sP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjISt1iCY3g2
YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY8VFVIcRM
dCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGwWLReb9Sb
m4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfhNSiVX1/A
b293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTHCV9r1Ldb
q5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBcWa1sV2rw
X/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1taiLL4dFAcm
3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD+iZHQxM+
IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8N31qKdwP
+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbUPKQolijA
MZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR16638LGN
hHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/AGnG7fY9
OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGWu8/PBo8g
w5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRYYtm8VPp+
CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtcAXBAR0cm
cJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB2wwQtRYo
A2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpftevodt2Ar
WV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3GTSfjQ4dx
08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRwqcocLGDh
Ao40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW90ijoMKiS
KbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasWtADVCq/A
B7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfwtKWEEW62
EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knbb9YaEDIj
lLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iBxjqHaN2q
q5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3yhwhCrNGq
KgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZftGQxqmCQr
hMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazwaeqeT7lr
ea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JGOJcD4pUq
P/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcXOQWep5QC
U8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8DAFBLAwQU
AAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5n
MS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN
+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa
0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcW
oIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAA
AAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAA
ADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQC1gywzMwMA
AEkIAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsB
Ai0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAAAAAAkAUAAGNsaXBib2FyZC90aGVt
ZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAA5QwA
AGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcB
AADoDQAAAAA=
" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٣</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="27" height="31" alt="Text Box: ٣" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_34" o:spid="_x0000_i1043" type="#_x0000_t75" style='width:305pt;
   height:160.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.png"
    o:title=""/>
  </v:shape><![endif]--><img width="407" height="214" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.jpg" /><p>&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الغلاف الورقي المحكم الموجود على الحاوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج محقنة واحدة مسبقة التعبئة من الحاوية وأعد وضع العبوة الكرتونية الأصلية مع أي محاقن مسبقة التعبئة غير مستخدمة في الثلاجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>تستخدم محقنتك إذا بدت تالفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام محقنتك مسبقة التعبئة بعد إخراجها من الثلاجة مباشرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تجد أن استخدام محقنتك مسبقة التعبئة في درجة حرارة الغرفة يقلل الشعور بالحرقة أو الانزعاج. اترك محقنتك مسبقة التعبئة في درجة حرارة الغرفة بعيدًا عن ضوء الشمس المباشر لمدة ١٥ إلى ٣٠ دقيقة قبل الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تنزع غطاء الإبرة عن محقنتك مسبقة التعبئة حتى تكون مستعدًا للحقن.</p><p dir="RTL"><strong>أمسك المحقنة مسبقة التعبئة من جسم المحقنة الأسطواني دائمًا لمنع تلفها.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_537388763" o:spid="_x0000_s1076" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:53.1pt;
   margin-top:10.35pt;width:132pt;height:14.15pt;z-index:251668480;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">افحص دواءك</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1885121255"
   o:spid="_x0000_s1075" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:12.75pt;margin-top:6.05pt;width:19.3pt;height:23.4pt;
   z-index:251667456;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٤</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:8.0pt'><o:p>&nbsp;</o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="29" height="34" alt="Text Box: ٤

" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_35" o:spid="_x0000_i1042" type="#_x0000_t75" style='width:302pt;
   height:196pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png"
    o:title=""/>
  </v:shape><![endif]--><img width="403" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص دواءك بعناية بالنظر إليه عبر النافذة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قم بإمالة محقنتك مسبقة التعبئة برفق للأمام والخلف لفحص الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>ترج محقنتك مسبقة التعبئة. يمكن أن يؤدي الرج إلى إتلاف دوائك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من أن الدواء الموجود في المحقنة مسبقة التعبئة صافٍ، وتتراوح درجة لونه من عديم اللون إلى بني فاتح جدًا، وأنه خالٍ من الرقائق أو الجسيمات. من الطبيعي أن ترى واحدة أو أكثر من فقاعات الهواء في النافذة. <strong>لا </strong>تحاول إزالة فقاعات الهواء.</p><p dir="RTL">إذا كانت لديك أي أسئلة بشأن دوائك، يرجى التحدث مع طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1436635046" o:spid="_x0000_s1074" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:164.35pt;
   margin-top:105.45pt;width:100.65pt;height:28.7pt;z-index:251672576;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" fillcolor="white [3212]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:12.0pt;mso-ansi-font-size:8.0pt;color:#ED7C60;
      mso-ansi-font-weight:bold'><span dir=RTL></span><span
      style='mso-spacerun:yes'> </span>الفخذان:</span><b style='mso-bidi-font-weight:
      normal'><span dir=LTR style='color:#ED7C60'><o:p></o:p></span></b></p>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:8.0pt;mso-ansi-font-weight:bold'>الجزء الأمامي العلوي
      من الفخذ</span><b style='mso-bidi-font-weight:normal'><span dir=LTR><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="137" height="41" alt="Text Box:  الفخذان:
الجزء الأمامي العلوي من الفخذ
" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image014.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1281969938" o:spid="_x0000_s1073" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:160.5pt;
   margin-top:35.8pt;width:129pt;height:42.45pt;z-index:251671552;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:8.0pt;color:#ED7C60;mso-ansi-font-weight:bold'>البطن:</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='color:#ED7C60'><o:p></o:p></span></b></p>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:12.0pt;
      mso-ansi-font-size:8.0pt;mso-ansi-font-weight:bold'>ابتعد عن السرة بمسافة
      ٥ سم على الأقل</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="175" height="59" alt="Text Box: البطن:
ابتعد عن السرة بمسافة ٥ سم على الأقل
" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_39434141" o:spid="_x0000_s1072" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:33.75pt;
   margin-top:7.55pt;width:205.3pt;height:14.15pt;z-index:251670528;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">اختر موضع الحقن وجهزه</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1591739020"
   o:spid="_x0000_s1071" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:5.7pt;margin-top:6.55pt;width:18.1pt;height:16.95pt;
   z-index:251669504;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٥</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="27" height="25" alt="Text Box: ٥" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image016.png" /><!--[if gte vml 1]><v:shape
   id="_x0000_i1041" type="#_x0000_t75" style='width:314.5pt;height:165.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image017.png"
    o:title=""/>
  </v:shape><![endif]--><img width="419" height="221" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image018.jpg" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختر موضعًا مختلفًا في كل مرة تعطي حقنة لنفسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>تحقن الدواء في مناطق عظمية، أو مناطق متكدمة أو حمراء أو متقرحة (مؤلمة) أو صلبة في جلدك. تجنب الحقن في مناطق بها ندبات أو علامات تمدد.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالصدفية، <strong>فلا </strong>تحقن مباشرة في أي بقع جلدية بارزة، أو سميكة، أو حمراء، أو قشرية، أو أي آفات على جلدك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>تحقن الدواء عبر ملابسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امسح موضع الحقن بالمسحة الكحولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك موضع الحقن ليجف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1235343573" o:spid="_x0000_s1070" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:50.45pt;
   margin-top:10.45pt;width:131.3pt;height:14.15pt;z-index:251674624;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">انزع غطاء الإبرة</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_611806877"
   o:spid="_x0000_s1069" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:15.75pt;margin-top:8.75pt;width:19.9pt;height:19.3pt;
   z-index:251673600;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٦</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="29" height="29" alt="Text Box: ٦" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image019.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_28" o:spid="_x0000_i1040" type="#_x0000_t75" style='width:300.5pt;
   height:198pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.png"
    o:title=""/>
  </v:shape><![endif]--><img width="401" height="264" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك المحقنة مسبقة التعبئة من جسم المحقنة الأسطواني. اسحب غطاء الإبرة بحذر في خط مستقيم وبعيدًا عن جسمك عندما تصبح مستعدًا للحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الطبيعي أن ترى بضع قطرات من الدواء عند طرف الإبرة عندما تنزع غطاء الإبرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من غطاء الإبرة في حاوية مخصصة للأدوات الحادة.</p><p dir="RTL"><strong>ملحوظة</strong>: كن حذرًا عند التعامل مع محقنتك مسبقة التعبئة لتجنب الإصابة بوخزة الإبرة عن طريق الخطأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1584086331" o:spid="_x0000_s1068" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:14pt;
   margin-top:6.35pt;width:21.3pt;height:24pt;z-index:251675648;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٧</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="31" height="35" alt="Text Box: ٧" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image021.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_2134279376" o:spid="_x0000_s1067" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:49.1pt;
   margin-top:7.15pt;width:98.65pt;height:14.15pt;z-index:251676672;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAHTwh2V8DAACUCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVs1uEzEQviPxDpbvbXbT5oeIbZUW
UiFVpUqKep56vdlVvbaxnTTpuW+CEHAB8TbhbRh7d9O0VKBCLyRSdrzz428+z4zzcn9RCjLnxhZK
JjTejijhkqm0kNOEvjsbbfUpsQ5kCkJJntAlt3R/7/mzlzCYGtB5wQhGkHYACc2d04NWy7Kcl2C3
leYSdZkyJThcmmkrNXCFkUvRakdRt1VCIenebahX4IDMTPEXoYRilzw9BDkHiyEFG2y+qTEK9u+R
YSDnR0ZP9KnxyNnJ/NSQIk0oMiehRIpoq1bUZrhs3fOa3gZYZKb09irLyCKhnV7cbfcw1hJPI+71
O92oiscXjjA0iNuddr/ToYR5i37cjWsDlr/9QwiWv/59EIRZwUFhA6LVHqCc/5pzO97Zbfde7PS6
TfJnHueBWpANVcOH9ydugVpE7rMKtDRRbc3oExGyzgUG2lh3xFVJvJBQw5kLVQfzY+sqGI2JT9Qq
UaSjQoiwMNOLQ2HIHERCuwf+WyO/YyYkuUL9TicKkaXy/lVoIX0cnmW47Xq/Jlm3mARyPSvp0hte
4BNpMgqRYhlYzUYFwj4G607BYJfhS+xX9xZ/MqFwVyYKTUmuzPX9d94OKx41lFxhtybUvp+B4ZSI
N9KGUK4RTCNcNIKclYcKs44DiiDi3saJRsyMKs+VSYd+F1SBZLhXQl0jHjpcoQJHAOPDYZCZKjW4
YznR2IxxYMuTf7Y4B6PrE3JYRCdqkoPmDx1UZRtORw9nDrmuT7HiziuEdRO3FDyUXmDY114J5jiA
QGFcQRZTHHsmpFUXJQyMj2DQXoCfgmC2JkPk4BoNcGwFRHcO327WyCh8HqqRzRJAhOAKSdxS8wwY
To2hKUBQokEqi8uoHR1E3WgXn813F7WFY/kIykJg8+/gC5aDsTzQH1Ll8MQhsY2QCU+I21t9WH1b
ff1xQ1afftysPq4+r76vvvgmdqGVgxWXqS/T8Zo9LrfeTSr2+jV5/ysRt7mFfLGsfO7rzp1ZPtFj
7PKq75vWtr4OQ03KMc/wqsDpVxeRvyj5eroAY1y6ZjAKb+3dMpwkj3Gs7b1rRfRjnNceYWcl3dq5
LKQyVe3fhZ1eNpCzyj7QUmeNBPnbo3XvPg4m9f8Hf+lvrvd+AgAA//8DAFBLAwQUAAYACAAAACEA
kn2H4B0HAABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2x
ZL1iI3JgyXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9S
ouIHXCAobAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb
/gwL/+7Gp5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI
6MpqpdJciRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4
mfQ9ioSEB22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1m
IU8D0GgEO011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf
6Kx1tmz5GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJi
uSzWIvSU8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9
QBOxQFL6eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34
/uW36dLzeGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQ
Hw/55TgGISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMd
xp1WeKDWMsw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGW
XffIiDPBJtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNT
iSKXyAGKqGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYi
t9hRN0RR4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cw
s+K3P6MThF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3H
WGBPNzeLeXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlG
cC+Vehgiq4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+y
qOKq2aZOvon90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4
+a6my/iYfPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoa
NfBIBz167BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IE
pkNVXwkJRCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAet
uQKK9zJKGIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5
HDTnY+Wn1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amo
F1Hjsr5eK11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT6
5kI0gOOWkeTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB
020n48kEj6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHD
sCKRlfE3V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaq
w9Kqez6TspyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7Oeo
uhcoCIZq5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe06
2N5DiTcMqm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgp
jZzSzClN39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZB
uwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/N
CsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFB
p7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKj
YUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2B
iYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAA
AABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAA
AAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAB08IdlfAwAAlAgAAB8AAAAAAAAA
AAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEA
kn2H4B0HAABJIAAAGgAAAAAAAAAAAAAAAAC8BQAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQ
SwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAAARDQAAY2xpcGJvYXJkL2Ry
YXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAABQOAAAAAA==
" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">أدخل الإبرة</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape
   id="Picture_x0020_29" o:spid="_x0000_i1039" type="#_x0000_t75" style='width:300.5pt;
   height:196.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image022.png"
    o:title=""/>
  </v:shape><![endif]--><img width="401" height="262" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image022.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك برفق ثنية من الجلد بمنطقة موضع الحقن الذي قمت بتنظيفه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل الإبرة بالكامل في الجلد، بزاوية ٤٥ درجة، كما هو موضح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بعد إدخال الإبرة، اترك ثنية الجلد.</p><p dir="RTL"><strong>مهم: لا </strong>تعد إدخال الإبرة في جلدك. إذا أدخلت الإبرة بالفعل في الجلد ثم غيرت رأيك بشأن مكان الحقن، فستحتاج إلى محقنة مسبقة التعبئة بديلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_853491144" o:spid="_x0000_s1066" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:51.15pt;
   margin-top:8.35pt;width:108.5pt;height:14.15pt;z-index:251678720;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">احقن الدواء</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1589578657"
   o:spid="_x0000_s1065" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:13.5pt;margin-top:7.45pt;width:20.4pt;height:18.1pt;
   z-index:251677696;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٨</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="30" height="27" alt="Text Box: ٨" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image023.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_36" o:spid="_x0000_i1038" type="#_x0000_t75" style='width:300pt;
   height:195pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.png"
    o:title=""/>
  </v:shape><![endif]--><img width="400" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.png" /><p>&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال الضغط ببطء وثبات، ادفع مقبض المكبس إلى الداخل بالكامل حتى يفرغ الجسم الأسطواني. عادة ما يستغرق إعطاء الجرعة من ثانيتين إلى ٥ ثوانٍ.</p><p dir="RTL"><strong>ملحوظة</strong>: يوصى بإبقاء محقنتك مسبقة التعبئة في الجلد لمدة ٥ ثوانٍ إضافية بعد دفع المكبس للأسفل تمامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب الإبرة من الجلد بنفس الزاوية التي أدخلتها بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_943776882" o:spid="_x0000_s1064" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:47.5pt;
   margin-top:11.95pt;width:112pt;height:14.15pt;z-index:251680768;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">افحص محقنتك</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1885087754"
   o:spid="_x0000_s1063" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:14.85pt;margin-top:9.5pt;width:18.1pt;height:18.7pt;
   z-index:251679744;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>٩</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="27" height="28" alt="Text Box: ٩" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image025.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_31" o:spid="_x0000_i1037" type="#_x0000_t75" style='width:300.5pt;
   height:197pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.png"
    o:title=""/>
  </v:shape><![endif]--><img width="401" height="263" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.png" /><p>&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من إفراغ الدواء بالكامل من محقنتك مسبقة التعبئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تُدخل</strong> <strong>الإبرة مرة أخرى أبدًا</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تُعد</strong> <strong>تغطية الإبرة مرة أخرى أبدًا</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ملحوظة:</strong> إذا لم تكن السدادة الرمادية في الوضع الموضح، فربما <strong>لم </strong>تحقن جرعة دوائك بالكامل. تحدث إلى طبيبك أو الممرضة أو الصيدلي فورًا.</p><p dir="LTR">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_482622091" o:spid="_x0000_s1062" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:49.8pt;
   margin-top:8.95pt;width:147.3pt;height:14.15pt;z-index:251682816;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">تخلص من المحقنة المستخدمة</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_757396791"
   o:spid="_x0000_s1061" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:13pt;margin-top:9.95pt;width:24pt;height:17.55pt;
   z-index:251681792;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>١٠</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="35" height="26" alt="Text Box: ١٠" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image027.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_38" o:spid="_x0000_i1036" type="#_x0000_t75" style='width:300pt;
   height:196.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image028.png"
    o:title=""/>
  </v:shape><![endif]--><img width="400" height="262" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image028.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من المحقنة فورًا وفقًا لتوجيهات طبيبك أو الممرضة أو الصيدلي ووفقًا لقوانين الصحة والسلامة المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_350160594" o:spid="_x0000_s1060" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:46.5pt;
   margin-top:8.8pt;width:113pt;height:14.15pt;z-index:251684864;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA7hROdFkDAACOCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVs1OGzEQvlfqO1i+Q3YJiSBiQSFt
UKWoIALiPHi92RVe27WdkHCsqr5Ke6l67puEt+nYu5sEilrRcmkiZcc7P/7m88w4B0fzUpAZN7ZQ
MqHxdkQJl0ylhZwk9PJiuLVHiXUgUxBK8oQuuKVHh69fHUBvYkDnBSMYQdoeJDR3TvdaLctyXoLd
VppL1GXKlOBwaSat1MAtRi5FayeKuq0SCkkP16HegAMyNcVfhBKK3fB0AHIGFkMK1tt8U2MU7N8j
Q0/OTowe6zPjkbP3szNDijShyJyEEimirVpRm+Gy9chrsg4wz0zp7VWWkXlCO9299k4HYy3wNOL9
/U7cqeLxuSMMDeLddieO0IB5i724G0f1hvnpH0Kw/O3vgyDMCg4KGxCt9gDl7Nec250o7kad/d0m
9wsP81jNyVrTsOG9iZujEnF7yIGUJqat+XwhOlaZQE8b6064KokXEmo4c6HmYDayroLRmPg0rRJF
OiyECAszuR4IQ2YgEto99t8a+QMzIckt6jHnEFkq71+FFtLH4VmG2672a5J183Gg1rOSLrzhNT6R
JqMQKZ6x1WxYIOwRWHcGBnsMX2K3ulP8yYTCXZkoNCW5MneP33k7rHfUUHKLvZpQ+2EKhlMi3kkb
QrlGMI1w3QhyWg4UZh0HFEHEvY0TjZgZVV4pk/b9LqgCyXCvhLpGHDhcoQIHAOP9fpCZKjW4kRxr
bMU4sOXJv5hfgdH1CTmsofdqnIPmTx1UZRtOR/enDrmuT7HiziuEdWO3EDyUXmDY114JZhRAoHBe
QRYTHHompFUXJfSMj2DQXoCfgWC2xn3k4A4NcGgFRA8O327WyDB8nqqRzRJAhOAKSdxC8wwYzoy+
KUBQokEqi8toJzqOutEuPpsvtpguHMuHUBYCW7+NL1gOxvJAf0iVwwuHxDZCJjwh7nD5dflj+Z0s
v9x/Wn67/3j/2TewC20cLLhMfYmer5jjcutyXDG3VxP3v5Kwzi3kiyXlc1917dTysT7HDq96vmlr
62sw1KM85xleEjj56gLyVyRfTRZgjEvXDEXhrb1bhlPkOY61vXetiH6O88oj7KykWzmXhVSmqvuH
sNObBnJW2Qda6qyRIH9vtB7dxMGk/ufgr/vN9eFPAAAA//8DAFBLAwQUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1iI3Jg
yXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIHXCAo
bAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL/+7G
p5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6MpqpdJc
iRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9ioSE
B22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D0GgE
O011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1tmz5
GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzWIvSU
8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOxQFL6
eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW36dLz
eGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/55TgG
ISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1WeKDW
Msw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffIiDPB
JtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKXyAGK
qGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hRN0RR
4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3P6MT
hF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBPNzeL
eXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+Vehgi
q4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq2aZO
von90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6my/iY
fPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBIBz16
7BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNVXwkJ
RCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK9zJK
GIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTnY+Wn
1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hjsr5e
K11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0gOOW
keTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n48kE
j6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKRlfE3
V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kqez6T
spyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7OeouhcoCIZq
5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5DiTcM
qm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzSzClN
39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQB
AAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITv
gu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw
6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI
9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/Sbe
AAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29u
dGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAA
NgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAO4UTnRZAwAAjggAAB8AAAAAAAAAAAAAAAAA
IAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAAAAAAAAAAAAAAC2BQAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAU
AAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAAALDQAAY2xpcGJvYXJkL2RyYXdpbmdz
L19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAAA4OAAAAAA==
" fillcolor="#6b6b6b" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">بعد الحقن</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_64425029"
   o:spid="_x0000_s1059" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:8.7pt;margin-top:8.35pt;width:25.3pt;height:21.3pt;
   z-index:251683840;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAoUUIujQDAABJCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVd1O2zAUvp+0d7B8D0l/BxUpKt2K
JlWAGhDXB8dpIhw7s92S8jY8Fm+zYydpu27axMbNhESPff6+8/mck7PzqhBkzbXJlYxo5zikhEum
klwuI3p3Ozs6ocRYkAkIJXlEN9zQ8/HHD2cwWmoos5wRjCDNCCKaWVuOgsCwjBdgjlXJJepSpQuw
eNTLINHwhJELEXTDcBgUkEs63oX6DBbISud/EUoo9siTKcg1GAwp2Gj/psEo2L9HhpFcX+oyLm+0
Q86u1jea5ElEkTkJBVJEg0bRmOExOPBa7gJUqS6cvUpTUkV00A17nVOMtcHX6Jz2TsKwjscrSxga
9LqdXgf1DA26n8IBynW+7PoPEVj25bcxEGQNBoU9gKZ08OT654qH/X53EHZP28JvHcYLVZGtomXC
+RJboQ6rcng9IW1E03D5PlRsy4BRqY295KogToio5sz6doP13NgaRWviajRK5MksF8IfXBfzqdBk
DSKiwra4f7ASkjxFdNgbhD6wVM69jiykC8PTFLNu07Wl2ir2tDpOko0zfMBfJEkrBIrPa0o2yxH1
HIy9AY3ThZc4p/Ya/6VCYVYm8pKSTOnnwztnh52OGkqecEojar6tQHNKxFdpfCjbCroVHlpBroqp
wpI7HoUXMbe2ohVTrYp7pZOJy4IqkAxzRdS24tTiCRU4+oxPJl5mqijBzmVc4hB2PFuO+9vqHnTZ
PJDFBrpScQYl/9U71baOLKkmK6vSvHnEmjunEMbGdiO4bzzPsOu8AvTcg0BhUUMWS1x3zGpfWNOU
MNIuhkYPAW7/gT6KJ8jCMxr0cRCddv9BMR/YXBK7KXkKDGd/onMQlJQglcFj2A0vwmHYx9/2r4/a
3LJsBkUucIZ7eMEy0IZ7Mj1wDu8cEmcCq3Lw7fj15fXFzZ/1U+gvuUxcjy22hXN5dBfXhbsF9D/X
vavN14s94Wrfjt3K8Lhc4IjWQ9vOpXFN5MoWcsFT3O+4uGoe/NdttxeAMS63u8FbO7cU18BbHBv7
HdFvca5bEj18ZiXt1rnIpdL++Q5gJ4/tOktre09LUzUS5JZ+cPAR9SbNR999qffP4+8AAAD//wMA
UEsDBBQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzs
WUtvGzcQvhfof1jsvbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqObkVy6qVAgbTooQF666EoGqAB
GvTSH2PAQZv+iA65L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWOMReExW2/eqviezgesTGJg7b/
aLD92W3fExLFY0RZjNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSLddT2QymT9ZUVMQIyErdYgmN4
NmE8QhJuebAy5ugEFojoymql0lyJEIn9DZAolaAehX+xFIoworyvxGAvRhGsfjCZkBHW2PFRVSHE
THQp944Rbfsgc8xOBviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3rf8yvoxhfLSq1+TBsFi0Xm/U
m5uFfA2gchHXa/WavWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZWrWrhDfm1BZ03G+pn4TUolV9f
wG9vd8GKFl6DUnxjAd/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0gK40mrVuvtsCMmF0xwlfa9S3
W6uZ8BIF0VBEl1piwmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJkBNvlwQhBF6CYiaAXFmtbFdq
8F/96vpKexStY2RwK71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785ff776YsXp89/zdbWoiy+HRQH
Jt/7n77559WX3t+//fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPvXr978/rs+6//+vmlQ/omR0MT
PiARFt4+PvEesgg26NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+GKHLgOti242MOqcYFvDd9ainc
D/lUEofEB2FkAfcYox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx5eXeNIEcS1wiuyG21DykKJYo
wDGWnnrGjjB27O4JIZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tgl5lLQfC3ZZu9x16HUdeut/Cx
jYR3A1GH8gNMLTPeQ1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT5vXGWAgXzwGH/RpOfwBpxu32
PTqLbCSX5MglcxcxZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY/Yaoe/ADipe6+zHBlrvPzwaP
IMOaKpUBop5MucOX9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYuxhSdoDHG3qPPHRp0WGLZvFT6
fghZZQe7Aus+smNV3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYojxJdJ3gevmzbvQamLXAFwQEdH
JnCfQL8H8eI0yoEAGUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5YaF3gvgQdfmgcSu8nzQdsMELUW
KANmgKDLcKVbYLHcX7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+jf+u94EO4+yHV46X7Xr6Hbdg
K1ldstNZlkx25vqbZbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa/3/f0yx7n286mWX9xk0n40OH
cdPJZMOV6+lkyuYF+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z8TYQFZ+ebuJiCpiEcKnKHCxg
4QKONI/HmfyCyLAfogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPjdNhZrarBZlpZBZIlvdIo6DCo
kim62SoHeIV4rW2gB625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEronV2LFmsOLW4r8bmrFrQA1Qqv
wAe3B5/pbb9RBxZggnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSUnl5Tui7dntpdGmoX8LSlhBFu
thLaMrrBEyF8BmfRqagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1NfDN5wYam5mCxt5J22/WGhAy
I5S0/QkMjeEySiB2hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNmg4hIzD1Koravtl+4gcY6h2jd
qquQED5a5dYgrXxsyoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86WHGyKbi7H45PvCGd8ocIQqzR
qioDjomAs4Nqas0xgcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnMU7hO5YU6+q6wgXGX7RkMapgk
K4TDQBVY06hWNS2qRqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNztrxakTe0yk0MOc2s8Gnqnk+5
a3mum+sTiioBBi/s56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNUu0iRMLJ+Mxc7Z7eiRjiXA+KV
Kj/wzUctkCZ5X6kt7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0qGlzBmTOUi/SguO1nFzkFnqeU
AlPLKbUcU88p9ZzSyCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBmvYV9+r/xLwAAAP//AwBQSwME
FAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2lu
ZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7Dez
TfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aS
GtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UX
FqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMA
AAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEA
AAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAoUUIujQD
AABJCAAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBL
AQItABQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAAAJEFAABjbGlwYm9hcmQvdGhl
bWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAOYM
AABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBn
AQAA6Q0AAAAA
" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center'><span
      dir=RTL></span><span lang=AR-SA style='font-size:14.0pt;mso-ansi-font-weight:
      bold'><span dir=RTL></span>١١</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:14.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="37" height="31" alt="Text Box: ١١" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image029.png" /><!--[if gte vml 1]><v:shape
   id="_x0000_i1035" type="#_x0000_t75" style='width:306pt;height:196pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image030.png"
    o:title=""/>
  </v:shape><![endif]--><img width="408" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image030.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص موضع الحقن عن كثب. إذا كان هناك دم، فاستخدم كرة قطن أو ضمادة شاش نظيفة للضغط برفق على مكان الحقن لبضع ثوانٍ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>تفرك الموضع.</p><p dir="RTL"><strong>ملحوظة</strong>: خزن أي محاقن غير مستخدمة في الثلاجة في العبوة الكرتونية الأصلية.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL">انظر للخلف للاطلاع على</p><p dir="RTL">معلومات لمستخدم الدواء &ndash; النشرة الداخلية للمستحضر الصيدلاني</p>&nbsp;<p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL">أبريلادا (أداليموماب)</p><p dir="RTL">&nbsp;٤۰ ملجم</p><p dir="RTL">قلم حقن مسبق التعبئة بجرعة فردية للحقن تحت الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتفظ بهذه النشرة. توضح هذه التعليمات كيفية تحضير وإعطاء الحقنة خطوة بخطوة.</strong></p><p dir="RTL"><strong>خزن قلم أبريلادا الخاص بك في الثلاجة في درجة حرارة تتراوح بين درجتين مئويتين و٨ درجات مئوية.</strong></p><p dir="RTL"><strong>خزن قلم أبريلادا في العبوة الكرتونية الأصلية حتى استخدامه لحمايته من ضوء الشمس المباشر.</strong></p><p dir="RTL"><strong>إذا لزم الأمر، على سبيل المثال، إذا كنت مسافرًا، يمكنك تخزين قلم أبريلادا في درجة حرارة الغرفة حتى ٣٠ درجة مئوية لمدة تصل إلى ٣٠ يومًا.</strong></p><p dir="RTL"><strong>احفظ أبريلادا ومستلزمات الحقن وجميع الأدوية الأخرى بعيدًا عن متناول الأطفال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر أبريلادا المخصص للحقن في قلم يُستخدم لمرة واحدة ثم يتم التخلص منه، ويحتوي على جرعة فردية من الدواء.</p><p dir="RTL"><strong>لا</strong> تحاول حقن أبريلادا بنفسك إلا بعد أن تقرأ تعليمات الاستخدام وتفهمها. إذا قرر طبيبك أو الممرضة أو الصيدلي أنه يمكنك، أنت أو أحد القائمين على الرعاية، إعطاء حقن أبريلادا في المنزل، فينبغي أن تتلقيا تدريبًا على الطريقة الصحيحة لتحضير وحقن أبريلادا.</p><p dir="RTL">من المهم أيضًا أن تتحدث مع طبيبك أو الممرضة أو الصيدلي للتأكد من فهم تعليمات جرعاتك من أبريلادا. لمساعدتك على تذكر موعد حقن أبريلادا، يمكنك وضع علامة في التقويم الذي تستخدمه قبل موعد الحقن. تحدث إلى طبيبك أو الممرضة أو الصيدلي إذا كان لديك أو لدى القائم على رعايتك أي أسئلة حول الطريقة الصحيحة لحقن أبريلادا.</p><p dir="RTL">بعد تلقي تدريب سليم، يمكن أن يقوم المريض بإعطاء أبريلادا المخصص للحقن بنفسه، أو أن يتولى القائم على الرعاية ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>۱. المستلزمات التي تحتاج إليها</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحتاج إلى المستلزمات التالية في كل مرة تحقن أبريلادا. ابحث عن سطح نظيف ومستوٍ لتضع عليه المستلزمات.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلم أبريلادا واحد داخل العبوة الكرتونية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحة كحولية واحدة داخل العبوة الكرتونية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرة قطن أو ضمادة شاش واحدة (غير متضمنة في عبوة أبريلادا الكرتونية الخاصة بك)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاوية مناسبة للأدوات الحادة (غير متضمنة في عبوة أبريلادا الكرتونية الخاصة بك).</p><p dir="RTL"><strong>مهم:</strong> إذا كانت لديك أي أسئلة بشأن قلم أبريلادا أو دوائك، فتحدث إلى طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>۲. الاستعداد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج عبوة أبريلادا الكرتونية من الثلاجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج قلمًا واحدًا من أقلام أبريلادا والمسحة الكحولية. احفظ قلمك بعيدًا عن ضوء الشمس المباشر. أعد العبوة الكرتونية الأصلية مع أي أقلام غير مستخدمة إلى الثلاجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا </strong>تستخدم قلمك إذا:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقط قلمك أو العبوة الكرتونية الحاوية للقلم، حتى وإن كانت تبدو غير تالفة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تجميده أو إذابته</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان يبدو تالفًا</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت الأغلفة المحكمة على العبوة الكرتونية الجديدة مفتوحة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقي خارج الثلاجة لأكثر من ٣٠ يومًا</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقضى تاريخ انتهاء الصلاحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انطبقت أي حالة مما ورد أعلاه، فتخلص من قلمك بنفس طريقة التخلص من قلم مستخدم. ستحتاج إلى قلم جديد لإعطاء حقنتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن استخدام قلمك بعد إخراجه من الثلاجة مباشرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تجد أن استخدام قلمك في درجة حرارة الغرفة يقلل من الشعور بالحرقة أو الانزعاج. اترك قلمك في درجة حرارة الغرفة بعيدًا عن ضوء الشمس المباشر لمدة ۱٥ إلى ٣٠ دقيقة قبل الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك بالماء والصابون، وجففهما تمامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تنزع الغطاء حتى تكون مستعدًا للحقن.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_2019964100" o:spid="_x0000_s1058" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:205.05pt;
   margin-top:37.75pt;width:58.3pt;height:8.6pt;z-index:251685888;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:7.0pt'><span dir=RTL></span><span
      style='mso-spacerun:yes'> </span>تاريخ انتهاء الصلاحية</span><span
      dir=LTR style='font-size:7.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="81" height="14" alt="Text Box:  تاريخ انتهاء الصلاحية" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image031.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_2068311264" o:spid="_x0000_s1057" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:139.15pt;
   margin-top:59.6pt;width:63.35pt;height:9.7pt;z-index:251686912;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:7.0pt'>زر
      الحقن</span><span dir=LTR style='font-size:7.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="87" height="15" alt="Text Box: زر الحقن" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image032.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_297242154" o:spid="_x0000_s1056" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:70.6pt;
   margin-top:71.05pt;width:32.3pt;height:8.6pt;z-index:251687936;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:7.0pt'>النافذة</span><span
      dir=LTR style='font-size:7.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="46" height="14" alt="Text Box: النافذة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image033.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_386021188" o:spid="_x0000_s1055" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:27.2pt;
   margin-top:73.45pt;width:25.65pt;height:8.6pt;z-index:251688960;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span lang=AR-SA style='font-size:7.0pt'>الغطاء</span><span
      dir=LTR style='font-size:7.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="37" height="15" alt="Text Box: الغطاء" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image034.png" /><!--[if gte vml 1]><v:shape id="Picture_x0020_17" o:spid="_x0000_i1034"
   type="#_x0000_t75" style='width:276pt;height:88pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image035.png"
    o:title=""/>
  </v:shape><![endif]--><img width="368" height="117" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image036.jpg" /></p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1143847369" o:spid="_x0000_s1054" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:26.5pt;
   margin-top:.75pt;width:111.65pt;height:14.15pt;z-index:251689984;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#767171;mso-background-themecolor:
      background2;mso-background-themeshade:128'><span lang=AR-SA
      style='font-size:12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:
      background1;mso-ansi-font-weight:bold'>افحص دواءك</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='mso-bidi-font-size:
      8.0pt;color:white;mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="151" height="22" alt="Text Box: افحص دواءك" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image037.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_687224386" o:spid="_x0000_s1053" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:2.65pt;
   margin-top:-.55pt;width:16.4pt;height:23.15pt;z-index:251691008;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>٣</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="25" height="33" alt="Text Box: ٣" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image038.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_18" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:309pt;
   height:130pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image039.png"
    o:title=""/>
  </v:shape><![endif]--><img width="412" height="173" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image040.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص دواءك بعناية عن طريق النظر إليه عبر النافذة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإمالة قلمك برفق للأمام والخلف لفحص الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> ترج قلمك. يمكن أن يؤدي الرج إلى إتلاف دوائك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من أن الدواء الموجود في القلم صافٍ ويتراوح من عديم اللون إلى بني فاتح جدًا، وخالٍ من الرقائق أو الجسيمات. من الطبيعي أن ترى واحدة أو أكثر من فقاعات الهواء في النافذة. <strong>لا</strong> تحاول إزالة فقاعات الهواء.</p><p dir="RTL">إذا كانت لديك أي أسئلة بشأن دوائك، يرجى التحدث مع طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1743625459" o:spid="_x0000_s1052" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:1.75pt;
   margin-top:12.05pt;width:17.35pt;height:23.15pt;z-index:251705344;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>٤</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="26" height="33" alt="Text Box: ٤" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image041.png" /></td></tr></tbody></table> &nbsp;<p>&nbsp;</p>&nbsp;<p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_383164541" o:spid="_x0000_s1051" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:212.05pt;
   margin-top:92.4pt;width:84.65pt;height:26pt;z-index:251701248;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:white;mso-background-themecolor:
      background1'><span lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:
      10.0pt;color:black;mso-themecolor:text1'>الجزء الأمامي العلوي من الفخذ</span><span
      dir=LTR style='font-size:10.0pt;mso-bidi-font-size:8.0pt;color:black;
      mso-themecolor:text1'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="115" height="37" alt="Text Box: الجزء الأمامي العلوي من الفخذ" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image042.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_899003425" o:spid="_x0000_s1050" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:237.8pt;
   margin-top:80.6pt;width:41.35pt;height:14pt;z-index:251703296;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:white;mso-background-themecolor:
      background1'><span lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:
      10.0pt;color:red;mso-ansi-font-weight:bold'>الفخذان:</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:10.0pt;
      mso-bidi-font-size:8.0pt;color:red'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="57" height="21" alt="Text Box: الفخذان:" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image043.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_162337923" o:spid="_x0000_s1049" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:17.5pt;
   margin-top:49.3pt;width:51.65pt;height:14pt;z-index:251704320;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:white;mso-background-themecolor:
      background1'><span lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:
      10.0pt;color:red;mso-ansi-font-weight:bold'>البطن:</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:10.0pt;
      mso-bidi-font-size:8.0pt;color:red'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="71" height="21" alt="Text Box: البطن:" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image044.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_429297174" o:spid="_x0000_s1048" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:12.7pt;
   margin-top:61.1pt;width:90pt;height:27.3pt;z-index:251700224;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:white;mso-background-themecolor:
      background1'><span lang=AR-SA style='font-size:12.0pt;mso-ansi-font-size:
      10.0pt;color:black;mso-themecolor:text1'>ابتعد عن السرة بمسافة ٥ سم على
      الأقل</span><span dir=LTR style='font-size:10.0pt;mso-bidi-font-size:
      8.0pt;color:black;mso-themecolor:text1'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="123" height="39" alt="Text Box: ابتعد عن السرة بمسافة ٥ سم على الأقل" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image045.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1960996234" o:spid="_x0000_s1047" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:25.8pt;
   margin-top:3pt;width:206.65pt;height:14.15pt;z-index:251699200;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#767171;mso-background-themecolor:
      background2;mso-background-themeshade:128'><span lang=AR-SA
      style='font-size:12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:
      background1;mso-ansi-font-weight:bold'>اختر موضع الحقن وقم بتحضيره</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='mso-bidi-font-size:
      8.0pt;color:white;mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="278" height="21" alt="Text Box: اختر موضع الحقن وقم بتحضيره" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image046.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_19" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:313pt;
   height:128.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image047.png"
    o:title=""/>
  </v:shape><![endif]--><img width="417" height="171" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image048.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختر موضعًا مختلفًا في كل مرة تعطي حقنة لنفسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تحقن الدواء في مناطق عظمية، أو مناطق متكدمة أو حمراء أو متقرحة (مؤلمة) أو صلبة من جلدك. تجنب الحقن في مناطق بها ندبات أو علامات تمدد.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالصدفية، <strong>فلا</strong> تحقن مباشرة في أي بقع جلدية بارزة، أو سميكة، أو حمراء، أو قشرية، أو أي آفات على جلدك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تحقن الدواء عبر ملابسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امسح موضع الحقن بالمسحة الكحولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اترك موضع الحقن ليجف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_293091078" o:spid="_x0000_s1046" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:85.1pt;
   margin-top:9.85pt;width:96pt;height:14.15pt;z-index:251708416;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#767171;mso-background-themecolor:
      background2;mso-background-themeshade:128'><span lang=AR-SA
      style='font-size:12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:
      background1;mso-ansi-font-weight:bold'>انزع الغطاء</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='mso-bidi-font-size:
      8.0pt;color:white;mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="131" height="21" alt="Text Box: انزع الغطاء" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image049.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_2111262755" o:spid="_x0000_s1045" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:46.6pt;
   margin-top:6.55pt;width:19.55pt;height:23.15pt;z-index:251709440;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>٥</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="29" height="34" alt="Text Box: ٥" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image050.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_20" o:spid="_x0000_i1031" type="#_x0000_t75" style='width:235pt;
   height:196pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image051.png"
    o:title=""/>
  </v:shape><![endif]--><img width="313" height="261" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image051.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لف الغطاء واسحبه للخارج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من الغطاء في حاوية للتخلص من الأدوات الحادة؛ لا توجد حاجة إلى استخدامه مرة أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الطبيعي أن ترى بضع قطرات من الدواء عند طرف الإبرة عندما تزيل الغطاء.</p><p dir="RTL"><strong>تنبيه:</strong> تعامل مع قلمك بحذر لتجنب الإصابة بوخزة الإبرة عن طريق الخطأ.</p><p dir="RTL"><strong>ملحوظة:</strong> يبقى غطاء الإبرة داخل غطاء القلم بعد نزعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1837328100" o:spid="_x0000_s1044" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:82.1pt;
   margin-top:7.9pt;width:96.3pt;height:14.15pt;z-index:251706368;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#767171;mso-background-themecolor:
      background2;mso-background-themeshade:128'><span lang=AR-SA
      style='font-size:12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:
      background1;mso-ansi-font-weight:bold'>أدخل الإبرة</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='mso-bidi-font-size:
      8.0pt;color:white;mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="131" height="21" alt="Text Box: أدخل الإبرة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image052.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_235248236" o:spid="_x0000_s1043" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:49.75pt;
   margin-top:6.05pt;width:15.8pt;height:23.15pt;z-index:251692032;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAOc80ej0DAABeCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVstu2zgU3Q8w/0Bwn1pxbE9qVCnc
tCkKGG0Qp+j6lqIsoRTJkrRj54Pmn+ZvekhKdpoWM+hjMzAgXfK+z33Iz57vOsW20vnW6JKfPik4
k1qYqtXrkr+/vTo558wH0hUpo2XJ99Lz5xd//vGM5mtHtmkFgwXt51TyJgQ7H428aGRH/omxUoNX
G9dRwNGtR5WjO1ju1GhcFLNRR63mF0dTLykQ27j2J0wpIz7J6pL0ljxMKjF/eNPHqMSvW6a53r52
dmWvXYxcvN1eO9ZWJQdymjpAxEc9oxfDcfRIa300sKtdF+VNXbNdyad/jSfT8ZSzPapxOptMnxbZ
ntwFJiAQgZvBl4DA+On5ZNrzRfPuPyyI5tW/2kCQORgQDwL0Noant99mPD6bjifn47PZkPltDPKF
2bEjZ8AiarOwAxN5pZp7u0TNfEYHMGb7CanBle9B/j0YHfKjuXU+vJamY5EouZMipJhou/QhRzSI
xOS9UW111SqVDrG95aVybEuq5CqcxgLB+FdSSrO7ks/OUJ4En4nqWU7peCPrGl4P7oZUw26V8I5Q
Vfso+BFvYOcMAkXdvRVXLaJekg/X5DB2uMQAh3d41MrAq1Ct5awx7v7xXZTDCIDD2R3Gt+T+84ac
5Ey90T6ZCgPhBuLjQOhNd2mQ8mmKIpHw7YIayNqZ7oNx1SJ6AYu0gK+Sh4G8DDiBgZ0g5GKRaGE6
S2GpVxbTmVsjYn+7+0DO9gUKaKy3ZtWQld+rU5ZNxbGLTQDWfREzdpGhfFiFvZIoAcqfHgC1I7dM
QYC4ySGrNfagS2nFcJK8i/IO8oriWiR3sloAg/s0jbnAD8sJbxRazcLeypoEVsLCtaQ4s6SNx7EY
Fy+KWTHBe/hNwG2DaK6oaxVG+wwXoiHnZYIyhSHpN5tE0yKrmFy4+Ofv2MMhdXK6krqK/XVzSFvq
k/ernPZ58f/O+phbyhf9EHM/jNzGy5W9wXjmgR1m0scGimgpfSNrLH3ssoxD+uQddwIJIfVhLyTp
qFZjBfyIYi8fVXN7/YjyQSN5NjoclLtWG5fG6FHY1adhldVZPq+1nHVccBGnR1/WJNL/E4if74fn
iy8AAAD//wMAUEsDBBQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3Ro
ZW1lMS54bWzsWUtvGzcQvhfof1jsvbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqObkVy6qVAgbTo
oQF666EoGqABGvTSH2PAQZv+iA65L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWOMReExW2/eqvi
ezgesTGJg7b/aLD92W3fExLFY0RZjNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSLddT2QymT9ZUV
MQIyErdYgmN4NmE8QhJuebAy5ugEFojoymql0lyJEIn9DZAolaAehX+xFIoworyvxGAvRhGsfjCZ
kBHW2PFRVSHETHQp944Rbfsgc8xOBviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3rf8yvoxhfLSq
1+TBsFi0Xm/Um5uFfA2gchHXa/WavWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZWrWrhDfm1BZ03
G+pn4TUolV9fwG9vd8GKFl6DUnxjAd/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0gK40mrVuvtsC
MmF0xwlfa9S3W6uZ8BIF0VBEl1piwmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJkBNvlwQhBF6C
YiaAXFmtbFdq8F/96vpKexStY2RwK71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785ff776YsXp89/
zdbWoiy+HRQHJt/7n77559WX3t+//fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPvXr978/rs+6//
+vmlQ/omR0MTPiARFt4+PvEesgg26NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+GKHLgOti242MO
qcYFvDd9aincD/lUEofEB2FkAfcYox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx5eXeNIEcS1wi
uyG21DykKJYowDGWnnrGjjB27O4JIZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tgl5lLQfC3ZZu9
x16HUdeut/CxjYR3A1GH8gNMLTPeQ1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT5vXGWAgXzwGH
/RpOfwBpxu32PTqLbCSX5MglcxcxZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY/Yaoe/ADipe6
+zHBlrvPzwaPIMOaKpUBop5MucOX9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYuxhSdoDHG3qPP
HRp0WGLZvFT6fghZZQe7Aus+smNV3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYojxJdJ3gevmzbv
QamLXAFwQEdHJnCfQL8H8eI0yoEAGUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5YaF3gvgQdfmgcS
u8nzQdsMELUWKANmgKDLcKVbYLHcX7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+jf+u94EO4+yH
V46X7Xr6HbdgK1ldstNZlkx25vqbZbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa/3/f0yx7n286
mWX9xk0n40OHcdPJZMOV6+lkyuYF+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z8TYQFZ+ebuJi
CpiEcKnKHCxg4QKONI/HmfyCyLAfogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPjdNhZrarBZlpZ
BZIlvdIo6DCokim62SoHeIV4rW2gB625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEronV2LFmsOLW4r
8bmrFrQA1QqvwAe3B5/pbb9RBxZggnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSUnl5Tui7dntpd
GmoX8LSlhBFuthLaMrrBEyF8BmfRqagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1NfDN5wYam5mC
xt5J22/WGhAyI5S0/QkMjeEySiB2hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNmg4hIzD1Korav
tl+4gcY6h2jdqquQED5a5dYgrXxsyoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86WHGyKbi7H45P
vCGd8ocIQqzRqioDjomAs4Nqas0xgcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnMU7hO5YU6+q6w
gXGX7RkMapgkK4TDQBVY06hWNS2qRqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNztrxakTe0yk0M
Oc2s8Gnqnk+5a3mum+sTiioBBi/s56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNUu0iRMLJ+Mxc7
Z7eiRjiXA+KVKj/wzUctkCZ5X6kt7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0qGlzBmTOUi/Sg
uO1nFzkFnqeUAlPLKbUcU88p9ZzSyCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBmvYV9+r/xLwAA
AP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3Jl
bHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvo
RUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRS
KC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69
elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQF
AQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAA
ACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAA
ACEAOc80ej0DAABeCAAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdp
bmcxLnhtbFBLAQItABQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAAAJoFAABjbGlw
Ym9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAA
AAAAAAAAAO8MAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUG
AAAAAAUABQBnAQAA8g0AAAAA
" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>٦</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="24" height="34" alt="Text Box: ٦" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image053.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_96691494" o:spid="_x0000_s1042" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:166.5pt;
   margin-top:31.5pt;width:63.1pt;height:14.15pt;z-index:251693056;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#e74c37" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">اضغط للأسفل</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Picture_x0020_21" o:spid="_x0000_i1030"
   type="#_x0000_t75" style='width:235.5pt;height:193pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image054.png"
    o:title=""/>
  </v:shape><![endif]--><img width="314" height="257" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image054.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضغط</strong> بقلمك بقوة على الجلد بزاوية ۹۰ درجة، كما هو موضح.</p><p dir="RTL"><strong>ملحوظة:</strong> ستدخل الإبرة في الجلد أثناء ضغطك بالقلم لأسفل. سيُفتح قفل زر الحقن عندما تضغط بالقلم لأسفل بقوة كافية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استمر في الضغط بقلمك على الجلد حتى الخطوة ۸.</strong></p><p dir="RTL"><strong>ملحوظة: لا</strong> تُعد إدخال الإبرة في جلدك إذا غيرت رأيك بشأن مكان الحقن. ستحتاج إلى قلم بديل إذا دخلت الإبرة في الجلد بالفعل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1813397157" o:spid="_x0000_s1041" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:62.85pt;
   margin-top:45.6pt;width:24.75pt;height:7.95pt;z-index:251707392;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#e74c37" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0"/>
  </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">انتظرصوت طقطقة</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_805210798"
   o:spid="_x0000_s1040" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:179.3pt;margin-top:47.35pt;width:41.3pt;
   height:9.3pt;z-index:251702272;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3212]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='margin-right:-13.5pt;background:white;
      mso-background-themecolor:background1'><span lang=AR-SA style='font-size:
      6.0pt;color:white;mso-themecolor:background1'>انتظر</span><span
      lang=AR-SA style='font-size:6.0pt;color:black;mso-themecolor:text1'> صوت
      الطقطقة الثاني</span><span dir=LTR style='font-size:6.0pt;color:black;
      mso-themecolor:text1'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="57" height="15" alt="Text Box: انتظر صوت الطقطقة الثاني" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image055.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1572768215" o:spid="_x0000_s1039" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:193.35pt;
   margin-top:78.35pt;width:46.65pt;height:33.3pt;z-index:251710464;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3212]" stroked="f" strokeweight=".5pt">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      background:white;mso-background-themecolor:background1'><span lang=AR-SA
      style='font-size:9.0pt;color:black;mso-themecolor:text1;mso-ansi-font-weight:
      bold'>استمر في الإمساك لمدة </span><span lang=AR-SA style='font-size:
      9.0pt;color:#FF5050;mso-ansi-font-weight:bold'>٥</span><span lang=AR-SA
      style='font-size:9.0pt;color:black;mso-themecolor:text1;mso-ansi-font-weight:
      bold'> ثوانٍ أخرى</span><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:9.0pt;color:black;mso-themecolor:text1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="65" height="47" alt="Text Box: استمر في الإمساك لمدة ٥ ثوانٍ أخرى" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image056.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_306126054" o:spid="_x0000_s1038" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:201.45pt;
   margin-top:22.4pt;width:42.65pt;height:14.15pt;z-index:251696128;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#e74c37" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">انتظر</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_758723719"
   o:spid="_x0000_s1037" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:118.1pt;margin-top:23pt;width:71.35pt;height:14.15pt;
   z-index:251697152;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:page;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#ed7c6d" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">استمر في الإمساك</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1346209929"
   o:spid="_x0000_s1036" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:44.1pt;margin-top:22.35pt;width:38pt;height:14.15pt;
   z-index:251698176;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:page;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="#e74c37" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0"/>
  </v:shape><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">اضغط</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_2056725772"
   o:spid="_x0000_s1035" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:36.45pt;margin-top:6.05pt;width:119.3pt;
   height:14.15pt;z-index:251694080;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#595959;mso-background-themecolor:
      text1;mso-background-themetint:166'><span lang=AR-SA style='font-size:
      12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:background1;
      mso-ansi-font-weight:bold'>احقن الدواء</span><b style='mso-bidi-font-weight:
      normal'><span dir=LTR style='mso-bidi-font-size:8.0pt;color:white;
      mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="161" height="21" alt="Text Box: احقن الدواء" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image057.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_252635943" o:spid="_x0000_s1034" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:11.65pt;
   margin-top:5.6pt;width:16.8pt;height:23.15pt;z-index:251695104;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>٧</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="25" height="33" alt="Text Box: ٧" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image058.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_25" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:318.5pt;
   height:135.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image059.png"
    o:title=""/>
  </v:shape><![endif]--><img width="425" height="181" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image060.png" /><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضغط</strong> على زر الحقن لأسفل إلى آخره وستسمع صوت طقطقة. يمكنك رفع إصبعك عن زر الحقن عند بدء الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استمر في الإمساك</strong> بقلمك بإحكام على الجلد بينما يتحرك الشريط البرتقالي عبر النافذة. عادةً ما يستغرق توصيل الجرعة ۳ إلى ۱۰ ثوانٍ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انتظر</strong> لمدة ٥ ثوانٍ أخرى على الأقل بعد صوت الطقطقة الثاني حتى تسمح بامتصاص الدواء.</p><p dir="RTL"><strong>ملحوظة:</strong> إذا لم تستطع الضغط على زر الحقن لأسفل، فهذا لأنك لا تضغط بالقلم بقوة كافية لأسفل. ارفع إصبعك عن زر الحقن واضغط بقلمك لأسفل بقوة أكبر على الجلد. ثم حاول ضغط الزر مرة أخرى. إذا لم ينجح هذا، يمكن شد الجلد أو ثنيه حتى يصبح موضع الحقن أكثر ثباتًا مما يجعل ضغط زر الحقن أسهل.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_263092962" o:spid="_x0000_s1033" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:83.4pt;
   margin-top:10.8pt;width:119.3pt;height:14.15pt;z-index:251713536;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#7F7F7F;mso-background-themecolor:
      text1;mso-background-themetint:128'><span lang=AR-SA style='font-size:
      12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:background1;
      mso-ansi-font-weight:bold'>ارفع قلمك</span><b style='mso-bidi-font-weight:
      normal'><span dir=LTR style='mso-bidi-font-size:8.0pt;color:white;
      mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="161" height="21" alt="Text Box: ارفع قلمك" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image061.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1595204194" o:spid="_x0000_s1032" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:49.1pt;
   margin-top:6.25pt;width:17.65pt;height:23.15pt;z-index:251714560;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>۸</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="26" height="33" alt="Text Box: ۸" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image062.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_23" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:234pt;
   height:195pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image063.png"
    o:title=""/>
  </v:shape><![endif]--><img width="312" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image063.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا ترفع قلمك إلّا بعد انتظار ٥ ثوانٍ على الأقل بعد صوت الطقطقة الثاني.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارفع قلمك من على الجلد.</p><p dir="RTL"><strong>ملحوظة:</strong> بعد رفع قلمك من على الجلد، ستكون الإبرة مغطاة تلقائيًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا رأيت أكثر من قطرة دواء صغيرة على الجلد بعد الحقن، فانتظر فترة أطول قليلًا في مرة الحقن التالية قبل رفع القلم من على الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1192498323" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:45pt;
   margin-top:7pt;width:18.35pt;height:23.15pt;z-index:251712512;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>۹</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="27" height="34" alt="Text Box: ۹" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image064.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_806264164" o:spid="_x0000_s1030" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:80.75pt;
   margin-top:7.7pt;width:119.3pt;height:14.15pt;z-index:251711488;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#7F7F7F;mso-background-themecolor:
      text1;mso-background-themetint:128'><span lang=AR-SA style='font-size:
      12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:background1;
      mso-ansi-font-weight:bold'>افحص النافذة</span><b style='mso-bidi-font-weight:
      normal'><span dir=LTR style='mso-bidi-font-size:8.0pt;color:white;
      mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="162" height="21" alt="Text Box: افحص النافذة" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image065.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_27" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:235pt;
   height:195pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image066.png"
    o:title=""/>
  </v:shape><![endif]--><img width="313" height="260" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image066.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المفترض أن ترى شريطًا برتقالي اللون في النافذة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتحول النافذة إلى اللون البرتقالي، أو إذا كان يبدو أن الدواء لا يزال يُحقن، فهذا يعني أنك لم تتلق جرعة كاملة. تحدث إلى طبيبك أو الممرضة أو الصيدلي فورًا.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تحقن جرعة أخرى.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_572719271" o:spid="_x0000_s1029" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:82.35pt;
   margin-top:10.25pt;width:119.3pt;height:14.15pt;z-index:251715584;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#7F7F7F;mso-background-themecolor:
      text1;mso-background-themetint:128'><span lang=AR-SA style='font-size:
      12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:background1;
      mso-ansi-font-weight:bold'>تخلص من القلم المستخدم</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='mso-bidi-font-size:
      8.0pt;color:white;mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="161" height="21" alt="Text Box: تخلص من القلم المستخدم" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image067.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_166522518" o:spid="_x0000_s1028" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:46.6pt;
   margin-top:6.65pt;width:23.75pt;height:23.15pt;z-index:251716608;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>۱۰</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="35" height="34" alt="Text Box: ۱۰" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image068.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_32" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:235pt;
   height:194pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image069.png"
    o:title=""/>
  </v:shape><![endif]--><img width="313" height="259" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image069.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من القلم فورًا وفقًا لتعليمات طبيبك أو الممرضة أو الصيدلي ووفقًا لقوانين الصحة والسلامة المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_263466532" o:spid="_x0000_s1027" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:78.7pt;
   margin-top:11.6pt;width:119.3pt;height:14.15pt;z-index:251717632;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#7f7f7f [1612]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='background:#7F7F7F;mso-background-themecolor:
      text1;mso-background-themetint:128'><span lang=AR-SA style='font-size:
      12.0pt;mso-ansi-font-size:8.0pt;color:white;mso-themecolor:background1;
      mso-ansi-font-weight:bold'>بعد الحقن</span><b style='mso-bidi-font-weight:
      normal'><span dir=LTR style='mso-bidi-font-size:8.0pt;color:white;
      mso-themecolor:background1'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="162" height="21" alt="Text Box: بعد الحقن" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image070.png" /><!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_1772326840" o:spid="_x0000_s1026" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:42.55pt;
   margin-top:9.7pt;width:24.45pt;height:23.15pt;z-index:251718656;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL><span dir=RTL></span><span lang=AR-SA
      style='font-size:20.0pt;mso-ansi-font-weight:bold'><span dir=RTL></span>۱۱</span><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:20.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="35" height="33" alt="Text Box: ۱۱" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image071.png" /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_33" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:236.5pt;
   height:194pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image072.png"
    o:title=""/>
  </v:shape><![endif]--><img width="315" height="259" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image072.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص موضع الحقن في جسمك عن كثب. إذا كان هناك دم، فاستخدم كرة قطن أو ضمادة شاش نظيفة للضغط برفق على مكان الحقن لبضع ثوانٍ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تُدلِّك موضع الحقن.</p><p dir="RTL"><strong>ملحوظة:</strong> خزن أي أقلام غير مستخدمة في البراد (الثلاجة) في العبوة الكرتونية الأصلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من أبريلادا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حقنت أبريلادا بمعدل أكثر تكرارًا مما ينبغي عن طريق الخطأ، فاتصل بطبيبك أو الصيدلي واشرح له أنك أخذت كمية أكبر من اللازم. احتفظ معك دائمًا بعبوة الدواء الكرتونية الخارجية، حتى وإن كانت فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة أبريلادا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت إعطاء حقنة لنفسك، ينبغي أن تحقن الجرعة التالية من أبريلادا بمجرد أن تتذكر. ثم تناول جرعتك التالية كما كنت لتفعل في يوم جرعتك المقرر في الأصل إذا لم تكن قد نسيت إحدى الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول أبريلادا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي مناقشة قرار التوقف عن استخدام أبريلادا مع طبيبك. قد تعود الأعراض التي تعاني منها عند إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع. معظم الآثار الجانبية خفيفة إلى متوسطة. بالرغم من ذلك، قد يكون بعضها خطيرًا ويستلزم علاجًا. قد تحدث الآثار الجانبية بعد آخر حقنة بأبريلادا بفترة تصل إلى ٤ أشهر على الأقل.</p><p>&nbsp;</p><p dir="RTL"><strong>اطلب الرعاية الطبية فورًا</strong>، إذا لاحظت أيًا من العلامات التالية:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الشديد، أو الشرى، أو علامات تفاعل الحساسية الأخرى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، اليدين، القدمين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس، البلع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس مع بذل المجهود أو عند الاستلقاء، أو تورم القدمين.</p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك في أقرب وقت ممكن</strong>، إذا لاحظت أيًا مما يلي:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض العدوى مثل الحمى، أو الشعور بالغثيان، أو الجروح، أو مشكلات الأسنان، أو الشعور بالحرقة عند التبول، أو الشعور بالضعف أو التعب، أو السعال؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشكلات الأعصاب مثل الوخز، أو الخدر، أو ازدواج الرؤية، أو ضعف الذراع أو الساق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات سرطان الجلد مثل ظهور نتوء أو قرحة مفتوحة لا تلتئم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض تشير إلى الإصابة باضطرابات في الدم مثل الحمى المستمرة، التكدم، النزيف، الشحوب</p><p>&nbsp;</p><p dir="RTL">العلامات والأعراض الموضحة أعلاه يمكن أن تمثل الأعراض الجانبية المدرجة أدناه التي لوحظت مع أداليموماب:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع الحقن (بما في ذلك الألم، أو التورم، أو الاحمرار، أو الحكة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي (بما في ذلك نزلات البرد، سيلان الأنف، عدوى الجيوب الأنفية، الالتهاب الرئوي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن (المعدة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والقيء؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الخطيرة (بما في ذلك تسمم الدم والإنفلونزا)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المعوية (بما في ذلك الالتهاب المعدي المعوي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد (بما في ذلك التهاب النسيج الخلوي والهربس النطاقي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأذن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الفم (بما في ذلك حالات عدوى الأسنان وقرح البرد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التناسلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المفاصل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأورام الحميدة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (بما في ذلك الحساسية الموسمية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقلبات المزاجية (بما في ذلك الاكتئاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الإحساس مثل الشعور بالوخز، أو التنميل، أو الخدر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انضغاط جذر العصب (بما في ذلك ألم أسفل الظهر وألم الساق)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب جفن العين وتورم العين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة (الإحساس بدوران الغرفة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بضربات القلب السريعة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم الدموي (تورم صلب مصحوب بدم متخثر)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف المعدي المعوي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوء الهضم (عسر الهضم، الانتفاخ، حرقة المعدة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض ارتجاع حمض المعدة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة سيكا (بما في ذلك جفاف العينين وجفاف الفم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المثير للحكة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد (مثل الإكزيما)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكسر أظافر اليدين والقدمين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة العرق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء حالة جديدة من الصدفية أو تفاقم الحالة الموجودة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الكلى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم (تراكم السوائل في الجسم مما يسبب تورم الأنسجة المصابة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية مما يزيد خطر النزيف أو التكدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف التئام الجروح.</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الانتهازية (غير المعتادة) (التي تتضمن مرض السل وحالات العدوى الأخرى) التي تحدث عند انخفاض مستوى مقاومة المرض؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى العصبية (بما في ذلك التهاب السحايا الفيروسي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى العين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى البكتيرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرَّتج (التهاب وعدوى الأمعاء الغليظة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرطان، بما في ذلك السرطان الذي يصيب الجهاز الليمفاوي (سرطان الغدد الليمفاوية) والورم الميلانيني (نوع من سرطان الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المناعة التي قد تصيب الرئتين، والجلد، والعقد الليمفاوية (الحالة الأكثر شيوعًا تسمى الساركويد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الوعائي (التهاب الأوعية الدموية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش (الارتجاف)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاعتلال العصبي (تلف الأعصاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زدواج الرؤية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع، الطنين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بعدم انتظام ضربات القلب مثل تخطي بعض النبضات؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات القلب التي يمكن أن تسبب ضيق التنفس أو تورم الكاحل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزمة القلبية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كيس في جدار أحد الشرايين الرئيسية، التهاب وجلطة في أحد الأوردة؛ انسداد أحد الأوعية الدموية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الرئة التي تسبب ضيق التنفس (بما في ذلك الالتهاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانصمام الرئوي (انسداد في أحد شرايين الرئة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانصباب الجنبي (تجمع غير طبيعي للسوائل في الحيز الجنبي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي يسبب ألمًا شديدًا في البطن والظهر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة، حصوات المرارة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكبد الدهني (تراكم الدهون في خلايا الكبد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق الليلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الندوب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلل العضلات بشكل غير طبيعي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيستمك لوباس ايريثماتوزيس (اضطراب مناعي بما في ذلك، التهاب الجلد، والقلب، والرئة، والمفاصل، وأجهزة أعضاء الجسم الأخرى)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز الجنسي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابيضاض الدم (سرطان يصيب الدم ونخاع العظم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد مصحوب بصدمة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصلب المتعدد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأعصاب (مثل التهاب العصب البصري بالعين ومتلازمة جيلان باريه؛ وهي حالة قد تسبب ضعف العضلات، وأحاسيس غير طبيعية، والشعور بالوخز في الذراعين والجزء العلوي من الجسم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب عن ضخ الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الرئوي (تندب الرئة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انثقاب الأمعاء (ثقب في جدار الأمعاء)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الوبائي (التهاب الكبد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعادة تنشيط عدوى التهاب الكبد الوبائي B؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد المناعي الذاتي (التهاب الكبد الذي يسببه الجهاز المناعي للجسم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الجلدية (التهاب الأوعية الدموية في الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز-جونسون (تفاعل مهدد للحياة مصحوب بأعراض شبيهة بالإنفلونزا وطفح جلدي متبثر)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه المصحوب بتفاعلات حساسية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء متعددة الأشكال (طفح جلدي التهابي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة شبيهة بالذئبة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الوعائي (تورم موضعي في الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل جلدي حزازي الشكل (طفح جلدي أرجواني مائل للأحمر ومثير للحكة).</p><p>&nbsp;</p><p dir="RTL"><strong>ذات معدل تكرار غير معروف</strong> (لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدد الليمفاوية بالخلايا التائية الكبدية الطحالية (سرطان دم نادر غالبًا ما يكون مميتًا)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانة خلايا ميركل (أحد أنواع سرطان الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساركومة كابوزي، وهو سرطان نادر يرتبط بالعدوى بفيروس الهربس البشري ٨. غالبًا ما تظهر ساركومة كابوزي في صورة آفات أرجوانية على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة تسمى التهاب الجلد والعضلات (تظهر في صورة طفح جلدي مصحوب بضعف العضلات)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن (بالنسبة لمعظم المرضى، كانت زيادة الوزن طفيفة).</p><p>&nbsp;</p><p dir="RTL">بعض الأعراض الجانبية التي لوحظت مع أداليموماب قد لا تظهر لها أعراض ويمكن اكتشافها من خلال فحوصات الدم فقط. وهي تتضمن ما يلي:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات خلايا الدم البيضاء في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات خلايا الدم الحمراء في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الشحميات في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة إنزيمات الكبد.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قياسات خلايا الدم البيضاء في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات الصفائح الدموية في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى حمض اليوريك في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال قياسات الصوديوم في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات الكالسيوم في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات الفوسفات في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى سكر الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قياسات إنزيم نازعة هيدروجين اللاكتات في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود أجسام مضادة ذاتية في الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البوتاسيوم في الدم.</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قياس البيليروبين (فحص الدم فيما يتعلق بوظائف الكبد).</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض قياسات خلايا الدم البيضاء وخلايا الدم الحمراء وتعداد الصفائح الدموية في الدم.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp; </em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة الصلاحية: ٣ أعوام</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق أو شريط البليستر أو العبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في الثلاجة (من درجتين مئويتين إلى ٨ درجات مئوية). لا تقم بتجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ المحقنة مسبقة التعبئة أو القلم مسبق التعبئة في العبوة الكرتونية الخارجية لحمايتهما من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>ظروف التخزين البديلة:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند الحاجة (على سبيل المثال، إذا كنت مسافرًا)، يمكن تخزين محقنة واحدة مسبقة التعبئة أو قلم واحد مسبق التعبئة من أبريلادا في درجة حرارة الغرفة (حتى ۳۰ درجة مئوية) لفترة أقصاها ۳۰ يومًا &ndash; احرص على حمايتهما من الضوء. بمجرد إخراج المحقنة أو القلم من الثلاجة للتخزين في درجة حرارة الغرفة، <strong>يجب استخدامهما خلال ۳۰ يومًا</strong> <strong>أو التخلص منهما</strong>، حتى إذا تمت إعادتهما إلى الثلاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تسجل تاريخ إخراج المحقنة أو القلم من الثلاجة أول مرة، والتاريخ الذي ينبغي بعده التخلص منهما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل طبيبك أو الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي أداليموماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي إل‑هستيدين، وهيدروكلوريد إل‑هستيدين أحادي الهيدرات، وسكروز، وإيديتات ثنائي الصوديوم ثنائي الهيدرات، وإل‑ميثيونين، وبولي سوربات ۸۰، وماء للحقن.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><u>محقنة أبريلادا مسبقة التعبئة</u></p><p dir="RTL">محلول أبريلادا ٤۰ ملجم المخصص للحقن في محقنة مسبقة التعبئة يتوفر في صورة محلول معقم مكون من ٤۰ ملجم أداليموماب مذابًا في محلول ٠.٨ مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">محقنة أبريلادا مسبقة التعبئة هي محقنة زجاجية تحتوي على محلول صافٍ عديم اللون إلى بني فاتح جدًا من أداليموماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على محقنتين مسبقتي التعبئة ليستخدمها المريض مع منديلين كحوليين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قلم أبريلادا مسبق التعبئة</u></p><p dir="RTL">محلول أبريلادا ٤۰ ملجم المخصص للحقن في قلم مسبق التعبئة يتوفر في صورة محلول معقم مكون من ٤۰ ملجم من أداليموماب مذابًا في محلول ٠.٨ مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي قلم أبريلادا مسبق التعبئة على محلول صافٍ عديم اللون إلى بني فاتح جدًا من أداليموماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قلمين مسبقة التعبئة ليستخدمها المريض مع منديلين كحوليين.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer AG, Switzerland، سويسرا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">Catalent Indiana, LLC</p><p dir="RTL">United States (USA)، الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL">و</p><p dir="RTL">&nbsp;</p><p dir="RTL">SHL Pharma LLC</p><p dir="RTL">United States، الولايات المتحدة</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر ۲۰۲٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ABRILADA 40 mg solution for injection in pre filled syringe 
ABRILADA 40 mg solution for injection in pre filled pen 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ABRILADA 40 mg solution for injection in pre filled syringe 

Each 0.8 ml single dose pre filled syringe contains 40 mg of adalimumab. 

ABRILADA 40 mg solution for injection in pre filled pen 

Each 0.8 ml single dose pre filled pen contains 40 mg of adalimumab. 

Adalimumab is a recombinant human monoclonal antibody produced in Chinese hamster ovary cells. 

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Solution for injection (injection).

Clear, colourless to very light brown solution. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Rheumatoid arthritis </u></p><p>&nbsp;</p><p>ABRILADA in combination with methotrexate, is indicated for:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease‑modifying anti‑rheumatic drugs including methotrexate has been inadequate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</p><p>&nbsp;</p><p>ABRILADA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</p><p>&nbsp;</p><p>Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X‑ray and to improve physical function, when given in combination with methotrexate.</p><p>&nbsp;</p><p><u>Juvenile idiopathic arthritis</u></p><p>&nbsp;</p><p><em>Polyarticular juvenile idiopathic arthritis </em></p><p>&nbsp;</p><p>ABRILADA in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2&nbsp;years who have had an inadequate response to one or more disease‑modifying anti‑rheumatic drugs (DMARDs). ABRILADA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section&nbsp;5.1). Adalimumab has not been studied in patients aged less than 2&nbsp;years.</p><p>&nbsp;</p><p><em>Enthesitis‑related arthritis </em></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of active enthesitis‑related arthritis in patients, 6&nbsp;years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Axial spondyloarthritis</u></p><p>&nbsp;</p><p><em>Ankylosing spondylitis (AS) </em></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</p><p>&nbsp;</p><p><em>Axial spondyloarthritis without radiographic evidence of AS </em></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti‑inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease‑modifying anti‑rheumatic drug therapy has been inadequate. Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X‑ray in patients with polyarticular symmetrical subtypes of the disease (see section&nbsp;5.1) and to improve physical function.</p><p>&nbsp;</p><p><u>Psoriasis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Paediatric plaque psoriasis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4&nbsp;years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults and adolescents from 12&nbsp;years of age with an inadequate response to conventional systemic HS therapy (see sections&nbsp;5.1 and 5.2).</p><p>&nbsp;</p><p><u>Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>ABRILADA is indicated for treatment of moderately to severely active Crohn&rsquo;s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.</p><p>&nbsp;</p><p><u>Paediatric Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of moderately to severely active Crohn&rsquo;s disease in paediatric patients (from 6&nbsp;years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</p><p>&nbsp;</p><p><u>Paediatric ulcerative colitis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6&nbsp;years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</p><p>&nbsp;</p><p><u>Uveitis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of non‑infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid‑sparing, or in whom corticosteroid treatment is inappropriate.</p><p>&nbsp;</p><p><u>Paediatric uveitis</u></p><p>&nbsp;</p><p>ABRILADA is indicated for the treatment of paediatric chronic non‑infectious anterior uveitis in patients from 2&nbsp;years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ABRILADA treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which ABRILADA is indicated. Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with ABRILADA (see section&nbsp;4.4). Patients treated with ABRILADA should be given the patient reminder card.</p><p>&nbsp;</p><p>After proper training in injection technique, patients may self‑inject with ABRILADA if their physician determines that it is appropriate and with medical follow‑up as necessary.</p><p>&nbsp;</p><p>During treatment with ABRILADA, other concomitant therapies (e.g. corticosteroids and/or immunomodulatory agents) should be optimised.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Rheumatoid arthritis </em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for adult patients with rheumatoid arthritis is 40&nbsp;mg adalimumab administered every other week as a single dose via subcutaneous injection. Methotrexate should be continued during treatment with ABRILADA.</p><p>&nbsp;</p><p>Glucocorticoids, salicylates, non-steroidal anti‑inflammatory drugs, or analgesics can be continued during treatment with ABRILADA. Regarding combination with disease modifying anti‑rheumatic drugs other than methotrexate see sections&nbsp;4.4 and 5.1.</p><p>&nbsp;</p><p>In monotherapy, some patients who experience a decrease in their response to ABRILADA &nbsp;40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg adalimumab every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Available data suggest that the clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em><u>Dose interruption</u></em></p><p>&nbsp;</p><p>There may be a need for dose interruption, for instance before surgery or if a serious infection occurs. Available data suggest that re‑introduction of adalimumab after discontinuation for 70&nbsp;days or longer resulted in the same magnitudes of clinical response and similar safety profile as before dose interruption.</p><p>&nbsp;</p><p><em>Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis </em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40&nbsp;mg adalimumab administered every other week as a single dose via subcutaneous injection.</p><p>&nbsp;</p><p>Available data suggest that the clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p><em>Psoriasis </em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for adult patients is an initial dose of 80&nbsp;mg administered subcutaneously, followed by 40&nbsp;mg subcutaneously given every other week starting one week after the initial dose.</p><p>&nbsp;</p><p>Continued therapy beyond 16&nbsp;weeks should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>Beyond 16&nbsp;weeks, patients with inadequate response to ABRILADA 40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week. The benefits and risks of continued 40&nbsp;mg weekly or 80&nbsp;mg every other week therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosage (see section&nbsp;5.1). If adequate response is achieved with 40&nbsp;mg every week or 80&nbsp;mg every other week, the dosage may subsequently be reduced to 40&nbsp;mg every other week.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Hidradenitis suppurativa </em></p><p>&nbsp;</p><p>The recommended ABRILADA dose regimen for adult patients with hidradenitis suppurativa (HS) is 160&nbsp;mg initially at Day 1&nbsp;(given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days), followed by 80&nbsp;mg two weeks later at Day 15 (given as two 40&nbsp;mg injections in one day). Two weeks later (Day&nbsp;29) continue with a dose of 40&nbsp;mg every week or 80&nbsp;mg every other week (given as two 40&nbsp;mg injections in one day). Antibiotics may be continued during treatment with ABRILADA if necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with ABRILADA.</p><p>&nbsp;</p><p>Continued therapy beyond 12&nbsp;weeks should be carefully reconsidered in a patient with no improvement within this time period.</p><p>&nbsp;</p><p>Should treatment be interrupted, ABRILADA &nbsp;40&nbsp;mg every week or 80&nbsp;mg every other week may be re‑introduced (see section&nbsp;5.1).</p><p>&nbsp;</p><p>The benefit and risk of continued long‑term treatment should be periodically evaluated (see section&nbsp;5.1).</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Crohn&rsquo;s disease </em></p><p>&nbsp;</p><p>The recommended ABRILADA induction dose regimen for adult patients with moderately to severely active Crohn&rsquo;s disease is 80&nbsp;mg at Week&nbsp;0 followed by 40&nbsp;mg at Week&nbsp;2. In case there is a need for a more rapid response to therapy, the regimen 160&nbsp;mg at Week&nbsp;0 (given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days), followed by 80&nbsp;mg at Week&nbsp;2 (given as two 40&nbsp;mg injections in one day), can be used with the awareness that the risk for adverse events is higher during induction.</p><p>&nbsp;</p><p>After induction treatment, the recommended dose is 40&nbsp;mg every other week via subcutaneous injection. Alternatively, if a patient has stopped ABRILADA and signs and symptoms of disease recur, ABRILADA may be re‑administered. There is little experience from re‑administration after more than 8&nbsp;weeks since the previous dose.</p><p>&nbsp;</p><p>During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.</p><p>&nbsp;</p><p>Some patients who experience decrease in their response to ABRILADA &nbsp;40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg ABRILADA every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Some patients who have not responded by Week&nbsp;4 may benefit from continued maintenance therapy through Week&nbsp;12. Continued therapy should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Ulcerative colitis </em></p><p>&nbsp;</p><p>The recommended ABRILADA induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160&nbsp;mg at Week&nbsp;0&nbsp;(given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days) and 80&nbsp;mg at Week&nbsp;2 (given as two 40&nbsp;mg injections in one day). After induction treatment, the recommended dose is 40&nbsp;mg every other week via subcutaneous injection.</p><p>&nbsp;</p><p>During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.</p><p>&nbsp;</p><p>Some patients who experience decrease in their response to ABRILADA &nbsp;40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg ABRILADA every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Available data suggest that clinical response is usually achieved within 2‑8&nbsp;weeks of treatment. ABRILADA therapy should not be continued in patients failing to respond within this time period.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Uveitis </em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for adult patients with uveitis is an initial dose of 80&nbsp;mg, followed by 40&nbsp;mg given every other week starting one week after the initial dose. There is limited experience in the initiation of treatment with ABRILADA alone. Treatment with ABRILADA can be initiated in combination with corticosteroids and/or with other non‑biologic immunomodulatory agents. Concomitant corticosteroids may be tapered in accordance with clinical practice starting two&nbsp;weeks after initiating treatment with ABRILADA.</p><p>&nbsp;</p><p>It is recommended that the benefit and risk of continued long‑term treatment should be evaluated on a yearly basis (see section&nbsp;5.1).</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment is required.</p><p>&nbsp;</p><p><em>Renal and/or hepatic impairment</em></p><p>&nbsp;</p><p>Adalimumab has not been studied in these patient populations. No dose recommendations can be made.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Juvenile idiopathic arthritis </em></p><p>&nbsp;</p><p><em><u>Polyarticular juvenile idiopathic arthritis from 2&nbsp;years of age</u></em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for patients with polyarticular juvenile idiopathic arthritis from 2&nbsp;years of age is based on body weight (Table&nbsp;1). ABRILADA is administered every other week via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table 1. ABRILADA dose for patients with polyarticular juvenile idiopathic arthritis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Dosing regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>20&nbsp;mg every other week</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>40&nbsp;mg every other week</p></td></tr></tbody></table><p>&nbsp;</p><p>Available data suggest that clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in patients aged less than 2&nbsp;years for this indication.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em><u>Enthesitis‑related arthritis</u></em><em> </em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for patients with enthesitis‑related arthritis from 6&nbsp;years of age is based on body weight (Table&nbsp;2). ABRILADA is administered every other week via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table&nbsp;2. ABRILADA dose for patients with enthesitis‑related arthritis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Dosing regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>15&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>20&nbsp;mg every other week</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>40&nbsp;mg every other week</p></td></tr></tbody></table><p>&nbsp;</p><p>Adalimumab has not been studied in patients with enthesitis‑related arthritis aged less than 6&nbsp;years.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Psoriatic arthritis and axial spondyloarthritis including ankylosing spondyliti</em>s</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in the paediatric population for the indications of ankylosing spondylitis and psoriatic arthritis.</p><p>&nbsp;</p><p><em>Paediatric plaque psoriasis </em></p><p>&nbsp;</p><p>The recommended ABRILADA dose for patients with plaque psoriasis from 4 to 17&nbsp;years of age is based on body weight (Table&nbsp;3). ABRILADA is administered via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table&nbsp;3. ABRILADA dose for paediatric patients with plaque psoriasis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Dosing regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>15&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>Initial dose of 20&nbsp;mg, followed by 20&nbsp;mg given every other week starting one&nbsp;week after the initial dose</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>Initial dose of 40&nbsp;mg, followed by 40&nbsp;mg given every other week starting one&nbsp;week after the initial dose</p></td></tr></tbody></table><p>&nbsp;</p><p>Continued therapy beyond 16&nbsp;weeks should be carefully considered in a patient not responding within this time period.</p><p>&nbsp;</p><p>If retreatment with ABRILADA is indicated, the above guidance on dose and treatment duration should be followed.</p><p>&nbsp;</p><p>The safety of adalimumab in paediatric patients with plaque psoriasis has been assessed for a mean of 13&nbsp;months.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 4&nbsp;years for this indication.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Adolescent hidradenitis suppurativa (from 12&nbsp;years of age, weighing at least 30&nbsp;kg) </em></p><p>&nbsp;</p><p>There are no clinical trials with adalimumab in adolescent patients with HS. The posology of adalimumab in these patients has been determined from pharmacokinetic modelling and simulation (see section&nbsp;5.2).</p><p>&nbsp;</p><p>The recommended ABRILADA dose is 80&nbsp;mg at Week&nbsp;0&nbsp;followed by 40&nbsp;mg every other week starting at Week&nbsp;1&nbsp;via subcutaneous injection.</p><p>&nbsp;</p><p>In adolescent patients with inadequate response to ABRILADA &nbsp;40&nbsp;mg every other week, an increase in dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week may be considered.</p><p>&nbsp;</p><p>Antibiotics may be continued during treatment with ABRILADA if necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with ABRILADA.</p><p>&nbsp;</p><p>Continued therapy beyond 12&nbsp;weeks should be carefully reconsidered in a patient with no improvement within this time period.</p><p>&nbsp;</p><p>Should treatment be interrupted, ABRILADA may be re‑introduced as appropriate.</p><p>&nbsp;</p><p>The benefit and risk of continued long‑term treatment should be periodically evaluated (see adult data in section 5.1)</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 12&nbsp;years in this indication.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Paediatric Crohn&rsquo;s disease</em></p><p><em><u>&nbsp;</u></em></p><p>The recommended dose of ABRILADA for patients with Crohn&rsquo;s disease from 6 to 17&nbsp;years of age is based on body weight (Table&nbsp;4). ABRILADA is administered via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table&nbsp;4. ABRILADA dose for paediatric patients with Crohn&rsquo;s disease</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Induction dose</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose starting at Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;mg at Week&nbsp;0 and 20&nbsp;mg at Week&nbsp;2</p><p>&nbsp;</p><p>In case there is a need for a more rapid response to therapy with the awareness that the risk for adverse events may be higher with use of the higher induction dose, the following dose may be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80&nbsp;mg at Week&nbsp;0 and 40&nbsp;mg at Week&nbsp;2</p></td><td style="vertical-align:top"><p>20&nbsp;mg every other week</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80&nbsp;mg at Week&nbsp;0 and 40&nbsp;mg at Week&nbsp;2</p><p>&nbsp;</p><p>In case there is a need for a more rapid response to therapy with the awareness that the risk for adverse events may be higher with use of the higher induction dose, the following dose may be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 160&nbsp;mg at Week&nbsp;0 and 80&nbsp;mg at Week&nbsp;2</p></td><td style="vertical-align:top"><p>40&nbsp;mg every other week</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients who experience insufficient response may benefit from an increase in dosage:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;&nbsp;40&nbsp;kg: 20&nbsp;mg every week</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;40&nbsp;kg: 40&nbsp;mg every week or 80&nbsp;mg every other week</p><p>&nbsp;</p><p>Continued therapy should be carefully considered in a subject not responding by Week&nbsp;12.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 6&nbsp;years for this indication.</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><em>Paediatric ulcerative colitis</em></p><p><em>&nbsp;</em></p><p>The recommended dose of ABRILADA for patients from 6 to 17&nbsp;years of age with ulcerative colitis is based on body weight (Table&nbsp;5). ABRILADA is administered via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table&nbsp;5. ABRILADA dose for paediatric patients with ulcerative colitis</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Induction dose</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose starting at Week</strong>&nbsp;<strong>4*</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80&nbsp;mg at Week&nbsp;0 (given as two 40&nbsp;mg injections in one day) and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;mg at Week&nbsp;2 (given as one 40&nbsp;mg injection)</p></td><td style="vertical-align:top"><p>40&nbsp;mg every other week</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 160&nbsp;mg at Week&nbsp;0 (given as four 40&nbsp;mg injections in one day or two 40&nbsp;mg injections per day for two consecutive days) and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80&nbsp;mg at Week&nbsp;2 (given as two 40&nbsp;mg injections in one day)</p></td><td style="vertical-align:top"><p>80&nbsp;mg every other week</p></td></tr></tbody></table><p>* &nbsp; Paediatric patients who turn 18&nbsp;years of age while on ABRILADA should continue their prescribed maintenance dose.</p><p><em>&nbsp;</em></p><p>Continued therapy beyond 8&nbsp;weeks should be carefully considered in patients not showing signs of response within this time period.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 6&nbsp;years in this indication.</p><p>&nbsp;</p><p>ABRILADA may be available in different strengths and/or presentations depending on the individual treatment needs.</p><p><em>&nbsp;</em></p><p><em>Paediatric uveitis</em></p><p>&nbsp;</p><p>The recommended dose of ABRILADA for paediatric patients with uveitis from 2&nbsp;years of age is based on body weight (Table 6). ABRILADA is administered via subcutaneous injection.</p><p>&nbsp;</p><p>In paediatric uveitis, there is no experience in the treatment with adalimumab without concomitant treatment with methotrexate.</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;6. ABRILADA dose for paediatric patients with uveitis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Dosing regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>20&nbsp;mg every other week in combination with methotrexate</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>40&nbsp;mg every other week in combination with methotrexate</p></td></tr></tbody></table><p>&nbsp;</p><p>When ABRILADA therapy is initiated, a loading dose of 40&nbsp;mg for patients &lt;&nbsp;30&nbsp;kg or 80&nbsp;mg for patients &ge;&nbsp;30&nbsp;kg may be administered one week prior to the start of maintenance therapy. No clinical data are available on the use of an ABRILADA loading dose in children &lt;&nbsp;6&nbsp;years of age (see section&nbsp;5.2).</p><p><em><u>&nbsp;</u></em></p><p>There is no relevant use of adalimumab in children aged less than 2&nbsp;years in this indication.</p><p>&nbsp;</p><p>It is recommended that the benefit and risk of continued long‑term treatment should be evaluated on a yearly basis (see section&nbsp;5.1).</p><p>&nbsp;</p><p>ABRILADA may be available in other strengths and/or presentations depending on the individual treatment needs.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>ABRILADA is administered by subcutaneous injection. Full instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>ABRILADA is available in other strengths and presentations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4). 

Moderate to severe heart failure (NYHA class III/IV) (see section 4.4). 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Patients taking TNF‑antagonists are more susceptible to serious infections. Impaired lung function may increase the risk for developing infections. Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with ABRILADA. Because the elimination of adalimumab may take up to four months, monitoring should be continued throughout this period.</p><p>&nbsp;</p><p>Treatment with ABRILADA should not be initiated in patients with active infections including chronic or localised infections until infections are controlled. In patients who have been exposed to tuberculosis and patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with ABRILADA should be considered prior to initiating therapy (see <em>Other opportunistic infections</em>).</p><p>&nbsp;</p><p>Patients who develop a new infection while undergoing treatment with ABRILADA should be monitored closely and undergo a complete diagnostic evaluation. Administration of ABRILADA should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. Physicians should exercise caution when considering the use of ABRILADA in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p><p>&nbsp;</p><p><em>Serious infections </em></p><p>&nbsp;</p><p>Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in patients receiving adalimumab.</p><p>&nbsp;</p><p>Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.</p><p>&nbsp;</p><p><em>Tuberculosis </em></p><p>&nbsp;</p><p>Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving adalimumab. Reports included cases of pulmonary and extra‑pulmonary (i.e. disseminated) tuberculosis.</p><p>&nbsp;</p><p>Before initiation of therapy with ABRILADA, all patients must be evaluated for both active or inactive (&ldquo;latent&rdquo;) tuberculosis infection. This evaluation should include a detailed medical assessment of patient history of tuberculosis or possible previous exposure to people with active tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest X‑ray) should be performed in all patients (local recommendations may apply). It is recommended that the conduct and results of these tests are recorded in the patient reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>If active tuberculosis is diagnosed, ABRILADA therapy must not be initiated (see section&nbsp;4.3).</p><p>&nbsp;</p><p>In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p><p>&nbsp;</p><p>If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.</p><p>&nbsp;</p><p>If latent tuberculosis is diagnosed, appropriate treatment must be started with anti‑tuberculosis prophylaxis treatment before the initiation of ABRILADA, and in accordance with local recommendations.</p><p>&nbsp;</p><p>Use of anti‑tuberculosis prophylaxis treatment should also be considered before the initiation of ABRILADA in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.</p><p>&nbsp;</p><p>Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with adalimumab. Some patients who have been successfully treated for active tuberculosis have redeveloped tuberculosis while being treated with adalimumab.</p><p>&nbsp;</p><p>Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with ABRILADA .</p><p>&nbsp;</p><p><em>Other opportunistic infections </em></p><p>&nbsp;</p><p>Opportunistic infections, including invasive fungal infections have been observed in patients receiving adalimumab. These infections have not consistently been recognised in patients taking TNF‑antagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.</p><p>&nbsp;</p><p>For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of ABRILADA should be promptly discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the care of patients with invasive fungal infections.</p><p>&nbsp;</p><p><u>Hepatitis B reactivation</u></p><p>&nbsp;</p><p>Reactivation of hepatitis B has occurred in patients receiving a TNF‑antagonist including adalimumab, who are chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients should be tested for HBV infection before initiating treatment with ABRILADA. For patients who test positive for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.</p><p>&nbsp;</p><p>Carriers of HBV who require treatment with ABRILADA should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data from treating patients who are carriers of HBV with anti‑viral therapy in conjunction with TNF‑antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, ABRILADA should be stopped and effective anti‑viral therapy with appropriate supportive treatment should be initiated.</p><p>&nbsp;</p><p><u>Neurological events</u></p><p>&nbsp;</p><p>TNF‑antagonists including adalimumab have been associated in rare instances with new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain‑Barr&eacute; syndrome. Prescribers should exercise caution in considering the use of ABRILADA in patients with pre‑existing or recent‑onset central or peripheral nervous system demyelinating disorders; discontinuation of ABRILADA should be considered if any of these disorders develop. There is a known association between intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in patients with non‑infectious intermediate uveitis prior to the initiation of ABRILADA therapy and regularly during treatment to assess for pre‑existing or developing central demyelinating disorders.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>&nbsp;</p><p>Serious allergic reactions associated with adalimumab were rare during clinical trials. Non‑serious allergic reactions associated with adalimumab were uncommon during clinical trials. Reports of serious allergic reactions including anaphylaxis have been received following adalimumab administration. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ABRILADA should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p>&nbsp;</p><p>In a study of 64&nbsp;patients with rheumatoid arthritis that were treated with adalimumab, there was no evidence of depression of delayed‑type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T‑, B‑, NK‑cells, monocyte/macrophages, and neutrophils.</p><p>&nbsp;</p><p><u>Malignancies and lymphoproliferative disorders</u></p><p>&nbsp;</p><p>In the controlled portions of clinical trials of TNF‑antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF‑antagonist compared with control patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been reported in patients treated with a TNF‑antagonist. There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long‑standing, highly active, inflammatory disease, which complicates the risk estimation. With the current knowledge, a possible risk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a TNF‑antagonist cannot be excluded.</p><p>&nbsp;</p><p>Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&nbsp;years of age) treated with TNF‑antagonists (initiation of therapy &le;&nbsp;18&nbsp;years of age), including adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF‑antagonists cannot be excluded.</p><p>&nbsp;</p><p>Rare postmarketing cases of hepatosplenic T‑cell lymphoma have been identified in patients treated with adalimumab. This rare type of T‑cell lymphoma has a very aggressive disease course and is usually fatal. Some of these hepatosplenic T‑cell lymphomas with adalimumab have occurred in young adult patients on concomitant treatment with azathioprine or 6‑mercaptopurine used for inflammatory bowel disease. The potential risk with the combination of azathioprine or 6‑mercaptopurine and adalimumab should be carefully considered. A risk for the development of hepatosplenic T‑cell lymphoma in patients treated with ABRILADA cannot be excluded (see section&nbsp;4.8).</p><p>&nbsp;</p><p>No studies have been conducted that include patients with a history of malignancy or in whom treatment with adalimumab is continued following development of malignancy. Thus, additional caution should be exercised in considering adalimumab treatment of these patients (see section&nbsp;4.8).</p><p>&nbsp;</p><p>All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non‑melanoma skin cancer prior to and during treatment with ABRILADA. Melanoma and Merkel cell carcinoma have also been reported in patients treated with TNF‑antagonists including adalimumab (see section&nbsp;4.8).</p><p>&nbsp;</p><p>In an exploratory clinical trial evaluating the use of another TNF‑antagonist, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab‑treated patients compared with control patients. All patients had a history of heavy smoking. Therefore, caution should be exercised when using any TNF‑antagonist in COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p><p>&nbsp;</p><p>With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long‑standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations.</p><p>&nbsp;</p><p><u>Haematologic reactions</u></p><p>&nbsp;</p><p>Rare reports of pancytopenia including aplastic anaemia have been reported with TNF‑antagonists. Adverse events of the haematologic system, including medically significant cytopenia (e.g. thrombocytopenia, leukopenia) have been reported with adalimumab. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on ABRILADA. Discontinuation of ABRILADA therapy should be considered in patients with confirmed significant haematologic abnormalities.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>Similar antibody responses to the standard 23‑valent pneumococcal vaccine and the influenza trivalent virus vaccination were observed in a study in 226&nbsp;adult subjects with rheumatoid arthritis who were treated with adalimumab or placebo. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab.</p><p>&nbsp;</p><p>It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating adalimumab therapy.</p><p>&nbsp;</p><p>Patients on adalimumab may receive concurrent vaccinations, except for live vaccines. Administration of live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5&nbsp;months following the mother&rsquo;s last adalimumab injection during pregnancy.</p><p>&nbsp;</p><p><u>Congestive heart failure</u></p><p>&nbsp;</p><p>In a clinical trial with another TNF‑antagonist worsening congestive heart failure and increased mortality due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also been reported in patients receiving adalimumab. ABRILADA should be used with caution in patients with mild heart failure (NYHA class I/II). ABRILADA is contraindicated in moderate to severe heart failure (see section&nbsp;4.3). Treatment with ABRILADA must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.</p><p>&nbsp;</p><p><u>Autoimmune processes</u></p><p>&nbsp;</p><p>Treatment with ABRILADA may result in the formation of autoimmune antibodies. The impact of long‑term treatment with adalimumab on the development of autoimmune diseases is unknown. If a patient develops symptoms suggestive of a lupus‑like syndrome following treatment with ABRILADA and is positive for antibodies against double‑stranded DNA, further treatment with ABRILADA should not be given (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Concurrent administration of biologic DMARDS or TNF‑antagonists</u></p><p>&nbsp;</p><p>Serious infections were seen in clinical studies with concurrent use of anakinra and another TNF‑antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF‑antagonists. Therefore, the combination of adalimumab and anakinra is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Concomitant administration of adalimumab with other biologic DMARDS (e.g. anakinra and abatacept) or other TNF‑antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Surgery</u></p><p>&nbsp;</p><p>There is limited safety experience of surgical procedures in patients treated with adalimumab. The long half‑life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on ABRILADA should be closely monitored for infections, and appropriate actions should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving adalimumab.</p><p>&nbsp;</p><p><u>Small bowel obstruction</u></p><p>&nbsp;</p><p>Failure to respond to treatment for Crohn&rsquo;s disease may indicate the presence of fixed fibrotic stricture that may require surgical treatment. Available data suggest that adalimumab does not worsen or cause strictures.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>The frequency of serious infections among adalimumab‑treated subjects over 65&nbsp;years of age (3.7%) was higher than for those under 65&nbsp;years of age (1.5%). Some of those had a fatal outcome. Particular attention regarding the risk for infection should be paid when treating the elderly.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>See vaccinations above.</p><p><u>&nbsp;</u></p><p><u>Excipient with known effects</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol of sodium (23&nbsp;mg) per 0.8&nbsp;ml dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking adalimumab as monotherapy and those taking concomitant methotrexate. Antibody formation was lower when adalimumab was given together with methotrexate in comparison with use as monotherapy. Administration of adalimumab without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section&nbsp;5.1).</p><p>&nbsp;</p><p>The combination of ABRILADA and anakinra is not recommended (see section&nbsp;4.4&nbsp;&ldquo;Concurrent administration of biologic DMARDS or TNF‑antagonists&rdquo;).</p><p>&nbsp;</p><p>The combination of ABRILADA and abatacept is not recommended (see section&nbsp;4.4&nbsp;&ldquo;Concurrent administration of biologic DMARDS or TNF‑antagonists&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least five months after the last ABRILADA treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>A large number (approximately 2,100) of prospectively collected pregnancies exposed to adalimumab resulting in live birth with known outcomes, including more than 1,500 exposed during the first trimester, does not indicate an increase in the rate of malformation in the newborn.</p><p>&nbsp;</p><p>In a prospective cohort registry, 257&nbsp;women with rheumatoid arthritis (RA) or Crohn&rsquo;s disease (CD) treated with adalimumab at least during the first&nbsp;trimester and 120&nbsp;women with RA or CD not treated with adalimumab were enrolled. The primary endpoint was the birth prevalence of major birth defects. The rate of pregnancies ending with at least one&nbsp;live&nbsp;born infant with a major birth defect was 6/69&nbsp;(8.7%) in the adalimumab‑treated women with RA and 5/74&nbsp;(6.8%) in the untreated women with RA (unadjusted OR&nbsp;1.31, 95%&nbsp;CI&nbsp;0.38‑4.52) and 16/152&nbsp;(10.5%) in the adalimumab‑treated women with CD and 3/32&nbsp;(9.4%) in the untreated women with CD (unadjusted OR&nbsp;1.14, 95%&nbsp;CI&nbsp;0.31‑4.16). The adjusted OR (accounting for baseline differences) was 1.10&nbsp;(95% CI 0.45‑2.73) with RA and CD combined. There were no distinct differences between adalimumab‑treated and untreated women for the secondary endpoints spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non‑randomised design.</p><p>&nbsp;</p><p>In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Due to its inhibition of TNF&alpha;, adalimumab administered during pregnancy could affect normal immune responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.</p><p>&nbsp;</p><p>Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother&rsquo;s last adalimumab injection during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Limited information from the published literature indicates that adalimumab is excreted in breast milk at very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, ABRILADA can be used during breast‑feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Preclinical data on fertility effects of adalimumab are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adalimumab may have a minor influence on the ability to drive and use machines. Vertigo and visual impairment may occur following administration of ABRILADA (see section&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Adalimumab was studied in 9,506&nbsp;patients in pivotal controlled and open‑label trials for up to 60&nbsp;months or more. These trials included rheumatoid arthritis patients with short term and long standing disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis‑related arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn&rsquo;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis patients. The pivotal controlled studies involved 6,089&nbsp;patients receiving adalimumab and 3,801&nbsp;patients receiving placebo or active comparator during the controlled period.</p><p>&nbsp;</p><p>The proportion of patients who discontinued treatment due to adverse events during the double‑blind, controlled portion of pivotal studies was 5.9% for patients taking adalimumab and 5.4% for control treated patients.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache and musculoskeletal pain.</p><p>&nbsp;</p><p>Serious adverse reactions have been reported for adalimumab. TNF‑antagonists, such as adalimumab affect the immune system and their use may affect the body&rsquo;s defence against infection and cancer.</p><p>&nbsp;</p><p>Fatal and life‑threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use of adalimumab.</p><p>&nbsp;</p><p>Serious haematological, neurological and autoimmune reactions have also been reported. These include rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of lupus, lupus‑related conditions and Stevens‑Johnson syndrome.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adult patients.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 7&nbsp;below: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100&nbsp;to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000); and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the various indications has been included. An asterisk (*) appears in the SOC column if further information is found elsewhere in sections 4.3, 4.4&nbsp;and 4.8.</p><p>&nbsp;</p><p><strong>Table 7.&nbsp;Undesirable effects</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations*</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Systemic infections (including sepsis, candidiasis and influenza),</p><p>intestinal infections (including gastroenteritis viral),</p><p>skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster),</p><p>ear infections,</p><p>oral infections (including herpes simplex, oral herpes and tooth infections),</p><p>reproductive tract infections (including vulvovaginal mycotic infection),</p><p>urinary tract infections (including pyelonephritis),</p><p>fungal infections,</p><p>joint infections</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neurological infections (including viral meningitis),</p><p>opportunistic infections and tuberculosis (including coccidioidomycosis, histoplasmosis and mycobacterium avium complex infection),</p><p>bacterial infections,</p><p>eye infections,</p><p>diverticulitis<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)*</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Skin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma),</p><p>benign neoplasm</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lymphoma**,</p><p>solid organ neoplasm (including breast cancer, lung neoplasm and thyroid neoplasm),</p><p>melanoma**</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukaemia<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatosplenic T‑cell lymphoma<sup>1</sup>,</p><p>Merkel cell carcinoma (neuroendocrine carcinoma of the skin)<sup>1</sup>,</p><p>Kaposi&rsquo;s sarcoma</p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and the lymphatic system disorders*</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia (including neutropenia and agranulocytosis),</p><p>anaemia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leucocytosis,</p><p>thrombocytopenia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Idiopathic thrombocytopenic purpura</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders*</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity,</p><p>allergies (including seasonal allergy)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sarcoidosis<sup>1</sup>,</p><p>vasculitis</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylaxis<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lipids increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypokalaemia,</p><p>uric acid increased,</p><p>blood sodium abnormal,</p><p>hypocalcaemia,</p><p>hyperglycaemia,</p><p>hypophosphatemia,</p><p>dehydration</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mood alterations (including depression),</p><p>anxiety,</p><p>insomnia</p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders*</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesias (including hypoesthesia),</p><p>migraine,</p><p>nerve root compression</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebrovascular accident<sup>1</sup>,</p><p>tremor,</p><p>neuropathy</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Multiple sclerosis,</p><p>demyelinating disorders (e.g. optic neuritis,</p><p>Guillain‑Barr&eacute; syndrome)<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual impairment,</p><p>conjunctivitis,</p><p>blepharitis,</p><p>eye swelling</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diplopia</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Deafness</p><p>tinnitus</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders*</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction<sup>1</sup>,</p><p>arrhythmia,</p><p>congestive heart failure</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac arrest</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension,</p><p>flushing,</p><p>haematoma</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aortic aneurysm,</p><p>vascular arterial occlusion,</p><p>thrombophlebitis</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders*</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthma,</p><p>dyspnoea,</p><p>cough</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism<sup>1</sup>,</p><p>interstitial lung disease,</p><p>chronic obstructive pulmonary disease,</p><p>pneumonitis,</p><p>pleural effusion<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary fibrosis<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain,</p><p>nausea and vomiting</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>GI haemorrhage,</p><p>dyspepsia,</p><p>gastroesophageal reflux disease,</p><p>sicca syndrome</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis,</p><p>dysphagia,</p><p>face oedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intestinal perforation<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Hepato‑biliary disorders*</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevated liver enzymes</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cholecystitis and cholelithiasis,</p><p>hepatic steatosis,</p><p>bilirubin increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis</p><p>reactivation of hepatitis B<sup>1</sup></p><p>autoimmune hepatitis<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver failure<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash (including exfoliative rash)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Worsening or new onset of psoriasis (including palmoplantar pustular psoriasis)<sup>1</sup>,</p><p>urticaria,</p><p>bruising (including purpura),</p><p>dermatitis (including eczema),</p><p>onychoclasis,</p><p>hyperhidrosis,</p><p>alopecia<sup>1</sup>,</p><p>pruritus</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Night sweats,</p><p>scar</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema multiforme<sup>1</sup>,</p><p>Stevens‑Johnson syndrome<sup>1</sup>,</p><p>angioedema<sup>1</sup>,</p><p>cutaneous vasculitis<sup>1</sup>,</p><p>lichenoid skin reaction<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Worsening of symptoms of dermatomyositis<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms (including blood creatine phosphokinase increased)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhabdomyolysis,</p><p>systemic lupus erythematosus</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Lupus‑like syndrome<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal impairment,</p><p>haematuria</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nocturia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions*</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reaction (including injection site erythema)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain,</p><p>oedema,</p><p>pyrexia<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inflammation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged),</p><p>autoantibody test positive (including double‑stranded DNA antibody),</p><p>blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Weight increased<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Impaired healing</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp; further information is found elsewhere in sections 4.3, 4.4&nbsp;and 4.8&nbsp;</p><p>** &nbsp; including open‑label extension studies</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including spontaneous reporting data</p><p><sup>2</sup> &nbsp;&nbsp;&nbsp;&nbsp; The mean weight change from baseline for adalimumab ranged from 0.3&nbsp;kg to 1.0&nbsp;kg across adult indications compared to (minus) -0.4&nbsp;kg to 0.4&nbsp;kg for placebo over a treatment period of 4‑6&nbsp;months. Weight increase of 5‑6&nbsp;kg has also been observed in long-term extension studies with mean exposures of approximately 1‑2&nbsp;years without control group, particularly in patients with Crohn&rsquo;s disease and ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the anti-inflammatory effect of adalimumab.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Hidradenitis suppurativa</u></p><p>&nbsp;</p><p>The safety profile for patients with HS treated with adalimumab weekly was consistent with the known safety profile of adalimumab.</p><p>&nbsp;</p><p><u>Uveitis</u></p><p>&nbsp;</p><p>The safety profile for patients with uveitis treated with adalimumab every other week was consistent with the known safety profile of adalimumab.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Injection site reactions </em></p><p>&nbsp;</p><p>In the pivotal controlled trials in adults and children, 12.9% of patients treated with adalimumab developed injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of patients receiving placebo or active control. Injection site reactions generally did not necessitate discontinuation of the medicinal product.</p><p>&nbsp;</p><p><em>Infections </em></p><p>&nbsp;</p><p>In the pivotal controlled trials in adults and children, the rate of infection was 1.51&nbsp;per patient year in the adalimumab‑treated patients and 1.46&nbsp;per patient year in the placebo and active control‑treated patients. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most patients continued on adalimumab after the infection resolved.</p><p>&nbsp;</p><p>The incidence of serious infections was 0.04&nbsp;per patient year in adalimumab‑treated patients and 0.03&nbsp;per patient year in placebo and active control&minus;treated patients.</p><p>&nbsp;</p><p>In controlled and open‑label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra‑pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease.</p><p>&nbsp;</p><p><em>Malignancies and lymphoproliferative disorders </em></p><p>&nbsp;</p><p>No malignancies were observed in 249&nbsp;paediatric patients with an exposure of 655.6&nbsp;patient‑years during adalimumab trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis‑related arthritis). In addition, no malignancies were observed in 192&nbsp;paediatric patients with an exposure of 498.1&nbsp;patient‑years during adalimumab trials in paediatric patients with Crohn&rsquo;s disease. No malignancies were observed in 77&nbsp;paediatric patients with an exposure of 80.0&nbsp;patient‑years during an adalimumab trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 93&nbsp;paediatric patients with an exposure of 65.3&nbsp;patient years during an adalimumab trial in paediatric patients with ulcerative colitis. No malignancies were observed in 60&nbsp;paediatric patients with an exposure of 58.4 patient‑years during an adalimumab trial in paediatric patients with uveitis.</p><p>&nbsp;</p><p>During the controlled portions of pivotal adalimumab trials in adults of at least 12&nbsp;weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&rsquo;s disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non‑melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8&nbsp;(4.4, 10.5) per 1,000&nbsp;patient‑years among 5,291&nbsp;adalimumab‑treated patients versus a rate of 6.3&nbsp;(3.4, 11.8) per 1,000&nbsp;patient‑years among 3,444&nbsp;control patients (median duration of treatment was 4.0&nbsp;months for adalimumab and 3.8&nbsp;months for control‑treated patients). The rate (95% confidence interval) of non‑melanoma skin cancers was 8.8&nbsp;(6.0, 13.0) per 1,000&nbsp;patient‑years among adalimumab‑treated patients and 3.2&nbsp;(1.3, 7.6) per 1,000&nbsp;patient‑years among control patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7&nbsp;(1.4, 5.4) per 1,000&nbsp;patient‑years among adalimumab‑treated patients and 0.6&nbsp;(0.1, 4.5) per 1,000&nbsp;patient‑years among control patients. The rate (95% confidence interval) of lymphomas was 0.7&nbsp;(0.2, 2.7) per 1,000&nbsp;patient‑years among adalimumab‑treated patients and 0.6&nbsp;(0.1, 4.5) per 1,000&nbsp;patient‑years among control patients.</p><p>&nbsp;</p><p>When combining controlled portions of these trials and ongoing and completed open‑label extension studies with a median duration of approximately 3.3&nbsp;years including 6,427&nbsp;patients and over 26,439&nbsp;patient‑years of therapy, the observed rate of malignancies, other than lymphoma and non‑melanoma skin cancers is approximately 8.5&nbsp;per 1,000&nbsp;patient‑years. The observed rate of non‑melanoma skin cancers is approximately 9.6&nbsp;per 1,000&nbsp;patient‑years, and the observed rate of lymphomas is approximately 1.3&nbsp;per 1,000&nbsp;patient‑years.</p><p>&nbsp;</p><p>In post‑marketing experience from January 2003&nbsp;to December 2010, predominantly in patients with rheumatoid arthritis, the reported rate of malignancies is approximately 2.7&nbsp;per 1,000&nbsp;patient treatment years. The reported rates for non‑melanoma skin cancers and lymphomas are approximately 0.2&nbsp;and 0.3&nbsp;per 1,000&nbsp;patient treatment years, respectively (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Rare post‑marketing cases of hepatosplenic T‑cell lymphoma have been reported in patients treated with adalimumab (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Autoantibodies </em></p><p>&nbsp;</p><p>Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies I &minus; V. In these trials, 11.9% of patients treated with adalimumab and 8.1% of placebo and active control&minus;treated patients that had negative baseline anti‑nuclear antibody titres reported positive titres at Week&nbsp;24. Two patients out of 3,441&nbsp;treated with adalimumab in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new‑onset lupus‑like syndrome. The patients improved following discontinuation of therapy. No patients developed lupus nephritis or central nervous system symptoms.</p><p>&nbsp;</p><p><em>Hepato‑biliary events </em></p><p>&nbsp;</p><p>In controlled Phase 3&nbsp;trials of adalimumab in patients with rheumatoid arthritis and psoriatic arthritis with a control period duration ranging from 4&nbsp;to 104&nbsp;weeks, ALT elevations &ge; 3&nbsp;x ULN occurred in 3.7% of adalimumab‑treated patients and 1.6% of control‑treated patients.</p><p>&nbsp;</p><p>In controlled Phase 3&nbsp;trials of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 4&nbsp;to 17&nbsp;years and enthesitis‑related arthritis who were 6&nbsp;to 17&nbsp;years, ALT elevations &ge;&nbsp;3&nbsp;x&nbsp;ULN occurred in 6.1% of adalimumab‑treated patients and 1.3% of control‑treated patients. Most ALT elevations occurred with concomitant methotrexate use. No ALT elevations &ge;&nbsp;3&nbsp;x ULN occurred in the Phase 3&nbsp;trial of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 2&nbsp;to &lt;&nbsp;4&nbsp;years.</p><p>&nbsp;</p><p>In controlled Phase 3&nbsp;trials of adalimumab in patients with Crohn&rsquo;s disease and ulcerative colitis with a control period ranging from 4&nbsp;to 52&nbsp;weeks. ALT elevations &ge;&nbsp;3&nbsp;x ULN occurred in 0.9% of adalimumab‑treated patients and 0.9% of controlled‑treated patients.</p><p>&nbsp;</p><p>In the Phase 3&nbsp;trial of adalimumab in patients with paediatric Crohn&rsquo;s disease which evaluated efficacy and safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction therapy up to 52&nbsp;weeks of treatment, ALT elevations &ge;&nbsp;3&nbsp;x ULN occurred in 2.6% (5/192) of patients of whom 4&nbsp;were receiving concomitant immunosuppressants at baseline.</p><p>&nbsp;</p><p>In controlled Phase 3&nbsp;trials of adalimumab in patients with plaque psoriasis with a control period duration ranging from 12&nbsp;to 24&nbsp;weeks, ALT elevations &ge; 3&nbsp;x ULN occurred in 1.8% of adalimumab‑treated patients and 1.8% of control‑treated patients.</p><p>&nbsp;</p><p>No ALT elevations &ge;3&nbsp;x ULN occurred in the Phase 3&nbsp;trial of adalimumab in paediatric patients with plaque psoriasis.</p><p>&nbsp;</p><p>In controlled trials of adalimumab (initial doses of 160&nbsp;mg at Week&nbsp;0&nbsp;and 80&nbsp;mg at Week&nbsp;2, followed by 40&nbsp;mg every week starting at Week&nbsp;4), in patients with hidradenitis suppurativa with a control period duration ranging from 12&nbsp;to 16&nbsp;weeks, ALT elevations &ge; 3&nbsp;x ULN occurred in 0.3% of adalimumab‑treated patients and 0.6% of control‑treated patients.</p><p>&nbsp;</p><p>In controlled trials of adalimumab (initial doses of 80&nbsp;mg at Week&nbsp;0&nbsp;followed by 40&nbsp;mg every other week starting at Week&nbsp;1) in adult patients with uveitis up to 80&nbsp;weeks with a median exposure of 166.5&nbsp;days and 105.0&nbsp;days in adalimumab‑treated and control‑treated patients, respectively, ALT elevations &ge;&nbsp;3&nbsp;x ULN occurred in 2.4% of adalimumab‑treated patients and 2.4% of control‑treated patients.</p><p>&nbsp;</p><p>In the controlled Phase 3 trial of adalimumab in patients with paediatric ulcerative colitis (N&nbsp;=&nbsp;93) which evaluated efficacy and safety of a maintenance dose of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every other week (N&nbsp;=&nbsp;31) and a maintenance dose of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every week (N&nbsp;=&nbsp;32), following body weight adjusted induction dosing of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2 (N&nbsp;=&nbsp;63), or an induction dose of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0, placebo at Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2 (N&nbsp;=&nbsp;30), ALT elevations &ge;&nbsp;3&nbsp;x ULN occurred in 1.1% (1/93) of patients.</p><p>&nbsp;</p><p>Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases elevations were transient and resolved on continued treatment. However, there have also been post‑marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p><p>&nbsp;</p><p><u>Concurrent treatment with azathioprine/6‑mercaptopurine</u></p><p>&nbsp;</p><p>In adult Crohn&rsquo;s disease studies, higher incidences of malignant and serious infection‑related adverse events were seen with the combination of adalimumab and azathioprine/6‑mercaptopurine compared with adalimumab alone.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dose‑limiting toxicity was observed during clinical trials. The highest dose level evaluated has been multiple intravenous doses of 10&nbsp;mg/kg, which is approximately 15&nbsp;times the recommended dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF‑&alpha;) inhibitors. ATC code: L04AB04&nbsp;</p><p>&nbsp;</p><p>ABRILADA is a biosimilar medicinal product.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55&nbsp;and p75&nbsp;cell surface TNF receptors.</p><p>&nbsp;</p><p>Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM‑1, VCAM‑1, and ICAM‑1&nbsp;with an IC<sub>50</sub>&nbsp;of 0.1‑0.2&nbsp;nM).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL‑6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP‑1&nbsp;and MMP‑3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration. Patients treated with adalimumab usually experienced improvement in haematological signs of chronic inflammation.</p><p>&nbsp;</p><p>A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn&rsquo;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with adalimumab. In patients with Crohn&rsquo;s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNF&alpha; was seen. Endoscopic studies in intestinal mucosa have shown evidence of mucosal healing in adalimumab‑treated patients.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Rheumatoid arthritis </em></p><p>&nbsp;</p><p>Adalimumab was evaluated in over 3,000&nbsp;patients in all rheumatoid arthritis clinical trials. The efficacy and safety of adalimumab were assessed in five randomised, double‑blind and well‑controlled studies. Some patients were treated for up to 120&nbsp;months duration.</p><p>&nbsp;</p><p>RA study I evaluated 271&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge;&nbsp;18&nbsp;years old, had failed therapy with at least one disease‑modifying, anti‑rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5&nbsp;to 25&nbsp;mg (10&nbsp;mg if methotrexate‑intolerant) every week and whose methotrexate dose remained constant at 10&nbsp;to 25&nbsp;mg every week. Doses of 20, 40&nbsp;or 80&nbsp;mg of adalimumab or placebo were given every other week for 24&nbsp;weeks.</p><p>&nbsp;</p><p>RA study II evaluated 544&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge;&nbsp;18&nbsp;years old and had failed therapy with at least one disease‑modifying, anti‑rheumatic drugs. Doses of 20&nbsp;or 40&nbsp;mg of adalimumab were given by subcutaneous injection every other week with placebo on alternative weeks or every week for 26&nbsp;weeks; placebo was given every week for the same duration. No other disease‑modifying anti‑rheumatic drugs were allowed.</p><p>&nbsp;</p><p>RA study III evaluated 619&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge;&nbsp;18&nbsp;years old, and who had an ineffective response to methotrexate at doses of 12.5&nbsp;to 25&nbsp;mg or have been intolerant to 10&nbsp;mg of methotrexate every week. There were three groups in this study. The first received placebo injections every week for 52&nbsp;weeks. The second received 20&nbsp;mg of adalimumab every week for 52&nbsp;weeks. The third group received 40&nbsp;mg of adalimumab every other week with placebo injections on alternate weeks. Upon completion of the first 52&nbsp;weeks, 457&nbsp;patients enrolled in an open‑label extension phase in which 40&nbsp;mg of adalimumab/MTX was administered every other week up to 10&nbsp;years.</p><p>&nbsp;</p><p>RA study IV primarily assessed safety in 636&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge; 18&nbsp;years old. Patients were permitted to be either disease‑modifying, anti‑rheumatic drug‑na&iuml;ve or to remain on their pre‑existing rheumatologic therapy provided that therapy was stable for a minimum of 28&nbsp;days. These therapies include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and/or gold salts. Patients were randomised to 40&nbsp;mg of adalimumab or placebo every other week for 24&nbsp;weeks.</p><p>&nbsp;</p><p>RA study V evaluated 799&nbsp;methotrexate‑na&iuml;ve, adult patients with moderate to severely active early rheumatoid arthritis (mean disease duration less than 9&nbsp;months). This study evaluated the efficacy of adalimumab 40&nbsp;mg every other week/methotrexate combination therapy, adalimumab 40&nbsp;mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104&nbsp;weeks. Upon completion of the first 104&nbsp;weeks, 497&nbsp;patients enrolled in an open‑label extension phase in which 40&nbsp;mg of adalimumab was administered every other week up to 10&nbsp;years.</p><p>&nbsp;</p><p>The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percent of patients who achieved an ACR 20&nbsp;response at Week&nbsp;24&nbsp;or 26. The primary endpoint in RA study V was the percent of patients who achieved an ACR 50&nbsp;response at Week&nbsp;52. RA studies III and V had an additional primary endpoint at 52&nbsp;weeks of retardation of disease progression (as detected by X‑ray results). RA study III also had a primary endpoint of changes in quality of life.</p><p>&nbsp;</p><p><em><u>ACR response</u></em><em> </em></p><p>&nbsp;</p><p>The percent of adalimumab‑treated patients achieving ACR 20, 50&nbsp;and 70&nbsp;responses was consistent across RA studies I, II and III. The results for the 40&nbsp;mg every other week dose are summarised in Table 8.</p><p>&nbsp;</p><p><strong>Table 8. ACR responses in placebo‑controlled trials (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Response</strong></p></td><td colspan="2"><p><strong>RA study I<sup>a</sup>**</strong></p></td><td colspan="2"><p><strong>RA study II<sup>a</sup>**</strong></p></td><td colspan="2"><p><strong>RA study III<sup>a</sup>**</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo/ MTX<sup>c</sup></strong></p><p><strong>n&nbsp;=&nbsp;60</strong></p></td><td><p><strong>Adalimumab<sup>b</sup>/ MTX<sup>c</sup></strong></p><p><strong>n&nbsp;=&nbsp;63</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>n&nbsp;=&nbsp;110</strong></p></td><td><p><strong>Adalimumab<sup>b</sup></strong></p><p><strong>n&nbsp;=&nbsp;113</strong></p></td><td><p><strong>Placebo/ MTX<sup>c</sup></strong></p><p><strong>n&nbsp;=&nbsp;200</strong></p></td><td><p><strong>Adalimumab<sup>b</sup>/ MTX<sup>c</sup></strong></p><p><strong>n&nbsp;=&nbsp;207</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ACR 20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>13.3%</p></td><td style="vertical-align:top"><p>65.1%</p></td><td style="vertical-align:top"><p>19.1%</p></td><td style="vertical-align:top"><p>46.0%</p></td><td style="vertical-align:top"><p>29.5%</p></td><td style="vertical-align:top"><p>63.3%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;months</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>24.0%</p></td><td style="vertical-align:top"><p>58.9%</p></td></tr><tr><td style="vertical-align:top"><p>ACR 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>6.7%</p></td><td style="vertical-align:top"><p>52.4%</p></td><td style="vertical-align:top"><p>8.2%</p></td><td style="vertical-align:top"><p>22.1%</p></td><td style="vertical-align:top"><p>9.5%</p></td><td style="vertical-align:top"><p>39.1%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;months</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>9.5%</p></td><td style="vertical-align:top"><p>41.5%</p></td></tr><tr><td style="vertical-align:top"><p>ACR 70</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>3.3%</p></td><td style="vertical-align:top"><p>23.8%</p></td><td style="vertical-align:top"><p>1.8%</p></td><td style="vertical-align:top"><p>12.4%</p></td><td style="vertical-align:top"><p>2.5%</p></td><td style="vertical-align:top"><p>20.8%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;months</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>4.5%</p></td><td style="vertical-align:top"><p>23.2%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>RA study I at 24 weeks, RA study II at 26 weeks, and RA study III at 24 and 52 weeks</p><p><sup>b &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>40&nbsp;mg adalimumab administered every other week</p><p><sup>c &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>MTX&nbsp;=&nbsp;methotrexate</p><p>**<sup>&nbsp; </sup>p &lt;&nbsp;0.01, adalimumab <em>versus</em> placebo</p></td></tr></tbody></table><p>&nbsp;</p><p>In RA studies I‑IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24&nbsp;or 26&nbsp;weeks compared to placebo. In RA study III, these improvements were maintained throughout 52&nbsp;weeks.</p><p>&nbsp;</p><p>In the open‑label extension for RA study III, most patients who were ACR responders maintained response when followed for up to 10&nbsp;years. Of 207&nbsp;patients who were randomised to adalimumab 40&nbsp;mg every other week, 114&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 5&nbsp;years. Among those, 86&nbsp;patients (75.4%) had ACR 20&nbsp;responses; 72&nbsp;patients (63.2%) had ACR 50&nbsp;responses; and 41&nbsp;patients (36%) had ACR 70&nbsp;responses. Of 207&nbsp;patients, 81&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 10&nbsp;years. Among those, 64&nbsp;patients (79.0%) had ACR 20&nbsp;responses; 56&nbsp;patients (69.1%) had ACR 50&nbsp;responses; and 43&nbsp;patients (53.1%) had ACR 70&nbsp;responses.</p><p>&nbsp;</p><p>In RA study IV, the ACR 20&nbsp;response of patients treated with adalimumab plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p &lt;&nbsp;0.001).</p><p>&nbsp;</p><p>In RA studies I‑IV, adalimumab‑treated patients achieved statistically significant ACR 20&nbsp;and 50&nbsp;responses compared to placebo as early as one to two weeks after initiation of treatment.</p><p>&nbsp;</p><p>In RA study V with early rheumatoid arthritis patients who were methotrexate na&iuml;ve, combination therapy with adalimumab and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and adalimumab monotherapy at Week&nbsp;52&nbsp;and responses were sustained at Week&nbsp;104&nbsp;(see Table 9).</p><p>&nbsp;</p><p><strong>Table 9. ACR responses in RA study V (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>MTX</strong></p><p><strong>n&nbsp;=&nbsp;257</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>n&nbsp;=&nbsp;274</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab/MTX</strong></p><p><strong>n&nbsp;=&nbsp;268</strong></p></td><td><p><strong>p‑value<sup>a</sup></strong></p></td><td><p><strong>p‑value<sup>b</sup></strong></p></td><td><p><strong>p‑value<sup>c</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ACR 20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>62.6%</p></td><td style="vertical-align:top"><p>54.4%</p></td><td style="vertical-align:top"><p>72.8%</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.043</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;104</p></td><td style="vertical-align:top"><p>56.0%</p></td><td style="vertical-align:top"><p>49.3%</p></td><td style="vertical-align:top"><p>69.4%</p></td><td style="vertical-align:top"><p>0.002</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.140</p></td></tr><tr><td style="vertical-align:top"><p>ACR 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>45.9%</p></td><td style="vertical-align:top"><p>41.2%</p></td><td style="vertical-align:top"><p>61.6%</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.317</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;104</p></td><td style="vertical-align:top"><p>42.8%</p></td><td style="vertical-align:top"><p>36.9%</p></td><td style="vertical-align:top"><p>59.0%</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.162</p></td></tr><tr><td style="vertical-align:top"><p>ACR 70</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>27.2%</p></td><td style="vertical-align:top"><p>25.9%</p></td><td style="vertical-align:top"><p>45.5%</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.656</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;104</p></td><td style="vertical-align:top"><p>28.4%</p></td><td style="vertical-align:top"><p>28.1%</p></td><td style="vertical-align:top"><p>46.6%</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>0.864</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann‑Whitney U test.</p><p><sup>b</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann‑Whitney U test.</p><p><sup>c</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann‑Whitney U test.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the open‑label extension for RA study V, ACR response rates were maintained when followed for up to 10&nbsp;years. Of 542&nbsp;patients who were randomised to adalimumab 40&nbsp;mg every other week, 170&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 10&nbsp;years. Among those, 154&nbsp;patients (90.6%) had ACR 20&nbsp;responses; 127&nbsp;patients (74.7%) had ACR 50&nbsp;responses; and 102&nbsp;patients (60.0%) had ACR 70&nbsp;responses.</p><p>&nbsp;</p><p>At Week&nbsp;52, 42.9% of patients who received adalimumab/methotrexate combination therapy achieved clinical remission (DAS28&nbsp;(CRP) &lt;&nbsp;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving adalimumab monotherapy. Adalimumab/methotrexate combination therapy was clinically and statistically superior to methotrexate (p&nbsp;&lt;&nbsp;0.001) and adalimumab monotherapy (p&nbsp;&lt;&nbsp;0.001) in achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. The response for the two monotherapy arms was similar (p&nbsp;=&nbsp;0.447). Of 342&nbsp;subjects originally randomised to adalimumab monotherapy or adalimumab/methotrexate combination therapy who entered the open‑label extension study, 171&nbsp;subjects completed 10&nbsp;years of adalimumab treatment. Among those, 109&nbsp;subjects (63.7%) were reported to be in remission at 10&nbsp;years.</p><p>&nbsp;</p><p><em><u>Radiographic response</u></em><em> </em></p><p>&nbsp;</p><p>In RA study III, where adalimumab‑treated patients had a mean duration of rheumatoid arthritis of approximately 11&nbsp;years, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. Adalimumab/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6&nbsp;and 12&nbsp;months (see Table 10).</p><p>&nbsp;</p><p>In the open‑label extension of RA Study III, the reduction in rate of progression of structural damage is maintained for 8&nbsp;and 10&nbsp;years in a subset of patients. At 8&nbsp;years, 81&nbsp;of 207&nbsp;patients originally treated with 40&nbsp;mg adalimumab every other week were evaluated radiographically. Among those, 48&nbsp;patients showed no progression of structural damage defined by a change from baseline in the mTSS of 0.5&nbsp;or less. At 10&nbsp;years, 79&nbsp;of 207&nbsp;patients originally treated with 40&nbsp;mg adalimumab every other week were evaluated radiographically. Among those, 40&nbsp;patients showed no progression of structural damage defined by a change from baseline in the mTSS of 0.5&nbsp;or less.</p><p>&nbsp;</p><p><strong>Table 10. Radiographic mean changes over 12 months in RA study III</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo/ MTX<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab/MTX 40&nbsp;mg every other week</strong></p></td><td style="vertical-align:top"><p><strong>Placebo/MTX‑ Adalimumab/MTX (95% confidence interval<sup>b</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>p‑value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Sharp Score</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>2.6 (1.4, 3.8)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Erosion score</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>1.6 (0.9, 2.2)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>JSN<sup>d</sup> score</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.9 (0.3, 1.4)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; methotrexate</p><p><sup>b</sup> &nbsp;&nbsp; 95% confidence intervals for the differences in change scores between methotrexate and adalimumab.</p><p><sup>c</sup> &nbsp;&nbsp; Based on rank analysis</p><p><sup>d</sup> &nbsp;&nbsp; Joint Space Narrowing</p></td></tr></tbody></table><p>&nbsp;</p><p>In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 11).</p><p>&nbsp;</p><p><strong>Table 11. Radiographic mean changes at Week 52 in RA study V</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>MTX</strong></p><p><strong>n&nbsp;=&nbsp;257</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>n&nbsp;=&nbsp;274</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>Adalimumab/MTX</strong></p><p><strong>n&nbsp;=&nbsp;268</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>p‑value<sup>a</sup></strong></p></td><td><p><strong>p‑value<sup>b</sup></strong></p></td><td><p><strong>p‑value<sup>c</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Total Sharp Score</p></td><td><p>5.7 (4.2‑7.3)</p></td><td><p>3.0 (1.7‑4.3)</p></td><td><p>1.3 (0.5‑2.1)</p></td><td><p>&lt;&nbsp;0.001</p></td><td><p>0.0020</p></td><td><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Erosion score</p></td><td><p>3.7 (2.7‑4.7)</p></td><td><p>1.7 (1.0‑2.4)</p></td><td><p>0.8 (0.4‑1.2)</p></td><td><p>&lt;&nbsp;0.001</p></td><td><p>0.0082</p></td><td><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>JSN score</p></td><td><p>2.0 (1.2‑2.8)</p></td><td><p>1.3 (0.5‑2.1)</p></td><td><p>0.5 (0‑1.0)</p></td><td><p>&lt;&nbsp;0.001</p></td><td><p>0.0037</p></td><td><p>0.151</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann‑Whitney U test.</p><p><sup>b</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann‑Whitney U test</p><p><sup>c</sup> &nbsp;&nbsp; p‑value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann‑Whitney U test</p></td></tr></tbody></table><p>&nbsp;</p><p>Following 52&nbsp;weeks and 104&nbsp;weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score &le;&nbsp;0.5) was significantly higher with adalimumab/methotrexate combination therapy (63.8% and 61.2%, respectively) compared to methotrexate monotherapy (37.4% and 33.5%, respectively, p &lt;&nbsp;0.001) and adalimumab monotherapy (50.7%, p&nbsp;&lt;&nbsp;0.002&nbsp;and 44.5%, p&nbsp;&lt;&nbsp;0.001,&nbsp;respectively).</p><p>&nbsp;</p><p>In the open‑label extension of RA study V, the mean change from baseline at Year 10&nbsp;in the modified Total Sharp Score was 10.8, 9.2&nbsp;and 3.9&nbsp;in patients originally randomised to methotrexate monotherapy, adalimumab monotherapy and adalimumab/methotrexate combination therapy, respectively. The corresponding proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7%, respectively.</p><p>&nbsp;</p><p><em><u>Quality of life and physical function</u></em><em> </em></p><p>&nbsp;</p><p>Health‑related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well‑controlled trials, which was a pre‑specified primary endpoint at Week&nbsp;52&nbsp;in RA study III. All doses/schedules of adalimumab in all four studies showed statistically significantly greater improvement in the disability index of the HAQ from baseline to Month 6&nbsp;compared to placebo and in RA study III the same was seen at Week&nbsp;52. Results from the Short Form Health Survey (SF 36) for all doses/schedules of adalimumab in all four studies support these findings, with statistically significant physical component summary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40&nbsp;mg every other week dose. A statistically significant decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was seen in all three studies in which it was assessed (RA studies I, III, IV).</p><p>&nbsp;</p><p>In RA study III, most subjects who achieved improvement in physical function and continued treatment maintained improvement through Week&nbsp;520&nbsp;(120&nbsp;months) of open‑label treatment. Improvement in quality of life was measured up to Week&nbsp;156&nbsp;(36&nbsp;months) and improvement was maintained through that time.</p><p>&nbsp;</p><p>In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36&nbsp;showed greater improvement (p &lt;&nbsp;0.001) for adalimumab/methotrexate combination therapy versus methotrexate monotherapy and adalimumab monotherapy at Week&nbsp;52, which was maintained through Week&nbsp;104. Among the 250&nbsp;subjects who completed the open‑label extension study, improvements in physical function were maintained through 10&nbsp;years of treatment.</p><p>&nbsp;</p><p><em>Axial spondyloarthritis </em></p><p>&nbsp;</p><p><em><u>Ankylosing spondylitis (AS)</u></em><em> </em></p><p>&nbsp;</p><p>Adalimumab 40&nbsp;mg every other week was assessed in 393&nbsp;patients in two randomised, 24&nbsp;week double‑blind, placebo‑controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3&nbsp;in all groups) who have had an inadequate response to conventional therapy. Seventy‑nine (20.1%) patients were treated concomitantly with disease modifying anti&minus;rheumatic drugs, and 37&nbsp;(9.4%) patients with glucocorticoids. The blinded period was followed by an open&minus;label period during which patients received adalimumab 40&nbsp;mg every other week subcutaneously for up to an additional 28&nbsp;weeks. Subjects (n&nbsp;=&nbsp;215, 54.7%) who failed to achieve ASAS 20&nbsp;at Weeks 12, or 16&nbsp;or 20&nbsp;received early escape open‑label adalimumab 40&nbsp;mg every other week subcutaneously and were subsequently treated as non‑responders in the double‑blind statistical analyses.</p><p>&nbsp;</p><p>In the larger AS study I with 315&nbsp;patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with adalimumab compared to placebo. Significant response was first observed at Week&nbsp;2&nbsp;and maintained through 24&nbsp;weeks (Table&nbsp;12).</p><p>&nbsp;</p><p><strong>Table 12. Efficacy responses in placebo‑controlled AS study &ndash; study I &ndash; reduction of signs and symptoms</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>107</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>208</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ASAS<sup>a</sup> 20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;2</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>42%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>58%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>51%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;2</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>16%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>38%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>35%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS 70</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;2</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>7%**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>23%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>24%***</p></td></tr><tr><td style="vertical-align:top"><p>BASDAI<sup>b</sup> 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;2</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>20%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>45%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>42%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>***,** Statistically significant at p &lt;&nbsp;0.001, &lt;&nbsp;0.01&nbsp;for all comparisons between adalimumab and placebo at Weeks 2, 12&nbsp;and 24&nbsp;</p><p><sup>a</sup> &nbsp;&nbsp; Assessments in Ankylosing Spondylitis</p><p><sup>b</sup> &nbsp;&nbsp; Bath Ankylosing Spondylitis Disease Activity Index</p></td></tr></tbody></table><p>&nbsp;</p><p>Adalimumab treated patients had significantly greater improvement at Week&nbsp;12&nbsp;which was maintained through Week&nbsp;24&nbsp;in both the SF36&nbsp;and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</p><p>&nbsp;</p><p>Similar trends (not all statistically significant) were seen in the smaller randomised, double&minus;blind, placebo‑controlled AS study II of 82&nbsp;adult patients with active ankylosing spondylitis.</p><p>&nbsp;</p><p><em><u>Axial spondyloarthritis without radiographic evidence of AS</u></em><em> </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in two randomised, double‑blind placebo‑controlled studies in patients with non‑radiographic axial spondyloarthritis (nr‑axSpA). Study&nbsp;nr‑axSpA I evaluated patients with active nr‑axSpA. Study nr‑axSpA II was a treatment withdrawal study in active nr‑axSpA patients who achieved remission during open‑label treatment with adalimumab.</p><p>&nbsp;</p><p>Study nr‑axSpA I</p><p>&nbsp;</p><p>In Study nr‑axSpA I, adalimumab 40&nbsp;mg every other week was assessed in 185&nbsp;patients in a randomised, 12&nbsp;week double‑blind, placebo‑controlled study in patients with active nr‑axSpA (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4&nbsp;for patients treated with adalimumab and 6.5&nbsp;for those on placebo) who have had an inadequate response to or intolerance to &ge; 1&nbsp;NSAIDs, or a contraindication for NSAIDs.</p><p>&nbsp;</p><p>Thirty‑three (18%) patients were treated concomitantly with disease modifying anti‑rheumatic drugs, and 146&nbsp;(79%) patients with NSAIDs at baseline. The double‑blind period was followed by an open‑label period during which patients receive adalimumab 40&nbsp;mg every other week subcutaneously for up to an additional 144&nbsp;weeks. Week&nbsp;12&nbsp;results showed statistically significant improvement of the signs and symptoms of active nr‑axSpA in patients treated with adalimumab compared to placebo (Table 13).</p><p>&nbsp;</p><p><strong>Table 13. Efficacy response in placebo‑controlled study nr‑axSpA I</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Double‑blind</strong></p><p><strong>Response at Week&nbsp;12</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>94</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>91</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ASAS<sup>a</sup> 40</p></td><td><p>15%</p></td><td><p>36%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS 20</p></td><td><p>31%</p></td><td><p>52%**</p></td></tr><tr><td style="vertical-align:top"><p>ASAS 5/6</p></td><td><p>6%</p></td><td><p>31%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS Partial Remission</p></td><td><p>5%</p></td><td><p>16%*</p></td></tr><tr><td style="vertical-align:top"><p>BASDAI<sup>b</sup> 50</p></td><td><p>15%</p></td><td><p>35%**</p></td></tr><tr><td style="vertical-align:top"><p>ASDAS<sup>c,d,e</sup></p></td><td><p>‑0.3</p></td><td><p>‑1.0***</p></td></tr><tr><td style="vertical-align:top"><p>ASDAS Inactive Disease</p></td><td><p>4%</p></td><td><p>24%***</p></td></tr><tr><td style="vertical-align:top"><p>hs‑CRP<sup>d,f,g</sup></p></td><td><p>‑0.3</p></td><td><p>‑4.7***</p></td></tr><tr><td style="vertical-align:top"><p>SPARCC<sup>h</sup> MRI Sacroiliac Joints<sup>d,i</sup></p></td><td><p>‑0.6</p></td><td><p>‑3.2**</p></td></tr><tr><td style="vertical-align:top"><p>SPARCC MRI Spine<sup>d,j</sup></p></td><td><p>‑0.2</p></td><td><p>‑1.8**</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; Assessment of SpondyloArthritis International Society</p><p><sup>b</sup> &nbsp;&nbsp; Bath Ankylosing Spondylitis Disease Activity Index</p><p><sup>c</sup> &nbsp;&nbsp; Ankylosing Spondylitis Disease Activity Score</p><p><sup>d</sup> &nbsp;&nbsp; mean change from baseline</p><p><sup>e</sup> &nbsp;&nbsp; n&nbsp;=&nbsp;91&nbsp;placebo and n&nbsp;=&nbsp;87&nbsp;adalimumab</p><p><sup>f</sup> &nbsp;&nbsp;&nbsp; high sensitivity C‑Reactive Protein (mg/L)</p><p><sup>g</sup> &nbsp;&nbsp; n&nbsp;=&nbsp;73&nbsp;placebo and n&nbsp;=&nbsp;70&nbsp;adalimumab</p><p><sup>h</sup> &nbsp;&nbsp; Spondyloarthritis Research Consortium of Canada</p><p><sup>i</sup> &nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;84&nbsp;placebo and adalimumab</p><p><sup>j</sup> &nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;82&nbsp;placebo and n&nbsp;=&nbsp;85&nbsp;adalimumab</p><p>***, **, * Statistically significant at p &lt;&nbsp;0.001, &lt;&nbsp;0.01, and &lt;&nbsp;0.05, respectively, for all comparisons between adalimumab and placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the open‑label extension, improvement in the signs and symptoms was maintained with adalimumab therapy through Week&nbsp;156.</p><p>&nbsp;</p><p>Inhibition of inflammation</p><p>&nbsp;</p><p>Significant improvement of signs of inflammation as measured by hs‑CRP and MRI of both Sacroiliac Joints and the Spine was maintained in adalimumab‑treated patients through Week&nbsp;156&nbsp;and Week&nbsp;104, respectively.</p><p>&nbsp;</p><p>Quality of life and physical function</p><p>&nbsp;</p><p>Health‑related quality of life and physical function were assessed using the HAQ‑S and the SF‑36&nbsp;questionnaires. Adalimumab showed statistically significantly greater improvement in the HAQ‑S total score and the SF‑36&nbsp;Physical Component Score (PCS) from baseline to Week&nbsp;12&nbsp;compared to placebo. Improvement in health‑related quality of life and physical function was maintained during the open‑label extension through Week&nbsp;156.</p><p>&nbsp;</p><p>Study nr‑axSpA II</p><p>&nbsp;</p><p>673 patients with active nr‑axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to &ge;&nbsp;2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open‑label period of Study nr‑axSpA II during which they received adalimumab 40&nbsp;mg eow for 28 weeks.</p><p>&nbsp;</p><p>These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or elevated hs‑CRP. Patients who achieved sustained remission for at least 12 weeks (N&nbsp;=&nbsp;305) (ASDAS &lt;&nbsp;1.3 at Weeks 16, 20, 24, and 28) during the open‑label period were then randomised to receive either continued treatment with adalimumab 40&nbsp;mg eow (N&nbsp;=&nbsp;152) or placebo (N&nbsp;=&nbsp;153) for an additional 40&nbsp;weeks in a double‑blind, placebo‑controlled period (total study duration 68 weeks). Subjects who flared during the double‑blind period were allowed adalimumab 40&nbsp;mg eow rescue therapy for at least 12 weeks.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the proportion of patients with no flare by Week 68 of the study. Flare was defined as ASDAS &ge; 2.1 at two consecutive visits four weeks apart. A greater proportion of patients on adalimumab had no disease flare during the double‑blind period, when compared with those on placebo (70.4% vs. 47.1%, p&lt;0.001) (Figure 1).</p><p>&nbsp;</p><p><strong>Figure 1. Kaplan‑Meier curves summarizing time to flare in study nr‑axSpA II</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_189" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:5.4pt;margin-top:3.3pt;width:12pt;height:142.1pt;z-index:251668480;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" o:allowincell="f" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-left:1.0pt;line-height:11.2pt;
    mso-line-height-rule:exactly;punctuation-wrap:simple;mso-line-break-override:
    restrictions'><b><span style='font-size:10.0pt;font-family:"Times New Roman Bold",serif'>PROBABILITY
    OF NO FLARE</span></b><span style='font-size:10.0pt;font-family:"Times New Roman Bold",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="19" height="192" alt="Text Box: PROBABILITY OF NO FLARE" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_52189673" o:spid="_x0000_i1028"
 type="#_x0000_t75" style='width:297.5pt;height:169.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png"
  o:title=""/>
</v:shape><![endif]--><img width="397" height="226" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.jpg" /></p><p><strong>TIME (WEEKS)</strong></p><p><!--[if gte vml 1]><v:polyline id="Freeform_x0020_190"
 o:spid="_x0000_s1026" style='position:absolute;z-index:-251629568;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' points="214.15pt,8pt,244.15pt,8pt"
 coordsize="600,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" o:allowincell="f" filled="f" strokecolor="#595958" strokeweight="2.25pt">
 <v:stroke dashstyle="dash"/>
 <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;381000,0"
  o:connectangles="0,0"/>
 <w:wrap anchorx="page"/>
</v:polyline><![endif]--><img width="43" height="3" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" />Treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo&nbsp;&nbsp; <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u>Adalimumab&nbsp;&nbsp; ∆ Censored</p><p>Note: P&nbsp;=&nbsp;Placebo (Number at Risk (flared)); A&nbsp;=&nbsp;Adalimumab (Number at Risk (flared)).</p><p>&nbsp;</p><p>Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12&nbsp;weeks of rescue therapy with adalimumab, out of which 37 (56.9%) had regained remission (ASDAS&nbsp;&lt; 1.3) after 12 weeks of restarting the open‑label treatment.</p><p>&nbsp;</p><p>By Week 68, patients receiving continuous adalimumab treatment showed statistically significant greater improvement of the signs and symptoms of active nr‑axSpA as compared to patients allocated to treatment withdrawal during the double‑blind period of the study (Table 14).</p><p>&nbsp;</p><p><strong>Table 14. Efficacy response in placebo‑controlled period for study nr‑axSpA II</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Double‑blind </strong></p><p><strong>Response at Week 68</strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>153</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>152</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ASAS<sup>a,b</sup> 20</p></td><td style="vertical-align:top"><p>47.1%</p></td><td style="vertical-align:top"><p>70.4%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS<sup>a,b</sup> 40</p></td><td style="vertical-align:top"><p>45.8%</p></td><td style="vertical-align:top"><p>65.8%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS<sup>a</sup> Partial Remission</p></td><td style="vertical-align:top"><p>26.8%</p></td><td style="vertical-align:top"><p>42.1%**</p></td></tr><tr><td style="vertical-align:top"><p>ASDAS<sup>c</sup> Inactive Disease</p></td><td style="vertical-align:top"><p>33.3%</p></td><td style="vertical-align:top"><p>57.2%***</p></td></tr><tr><td style="vertical-align:top"><p>Partial Flare<sup>d</sup></p></td><td style="vertical-align:top"><p>64.1%</p></td><td style="vertical-align:top"><p>40.8%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; Assessment of SpondyloArthritis international Society</p><p><sup>b &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Baseline is defined as open‑label baseline when patients have active disease.</p><p><sup>c</sup> &nbsp;&nbsp; Ankylosing Spondylitis Disease Activity Score</p><p><sup>d</sup> &nbsp;&nbsp; Partial flare is defined as ASDAS &ge; 1.3 but &lt;&nbsp;2.1 at 2 consecutive visits.</p><p>***, ** Statistically significant at p &lt;&nbsp;0.001 and &lt;&nbsp;0.01, respectively, for all comparisons between adalimumab and placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Psoriatic arthritis </em></p><p>&nbsp;</p><p>Adalimumab, 40&nbsp;mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo‑controlled studies, PsA studies I and II. PsA study I with 24&nbsp;week duration, treated 313&nbsp;adult patients who had an inadequate response to non‑steroidal anti‑inflammatory drug therapy and of these, approximately 50% were taking methotrexate. PsA study II with 12‑week duration, treated 100&nbsp;patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383&nbsp;patients enrolled in an open‑label extension study, in which 40&nbsp;mg adalimumab was administered every other week.</p><p>&nbsp;</p><p>There is insufficient evidence of the efficacy of adalimumab in patients with ankylosing spondylitis‑like psoriatic arthropathy due to the small number of patients studied.</p><p>&nbsp;</p><p><strong>Table 15. ACR response in placebo‑controlled psoriatic arthritis studies (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA study I</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA study II</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>162</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>151</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>49</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>51</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ACR 20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>58%***</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>39%*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>57%***</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>ACR 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>36%***</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>25%***</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>39%***</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p>ACR 70</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;12</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>20%***</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>14%*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;24</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>23%***</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>N/A</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>***&nbsp;&nbsp;&nbsp;&nbsp; p &lt;&nbsp;0.001&nbsp;for all comparisons between adalimumab and placebo</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p &lt;&nbsp;0.05&nbsp;for all comparisons between adalimumab and placebo</p><p>N/A&nbsp;&nbsp;&nbsp; not applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>ACR responses in PsA study I were similar with and without concomitant methotrexate therapy. ACR responses were maintained in the open‑label extension study for up to 136&nbsp;weeks.</p><p>&nbsp;</p><p>Radiographic changes were assessed in the psoriatic arthritis studies. Radiographs of hands, wrists, and feet were obtained at baseline and Week&nbsp;24&nbsp;during the double‑blind period when patients were on adalimumab or placebo and at Week&nbsp;48&nbsp;when all patients were on open‑label adalimumab. A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid arthritis), was used.</p><p>&nbsp;</p><p>Adalimumab treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment as measured by change from baseline in mTSS (mean &plusmn; SD) 0.8&nbsp;&plusmn; 2.5&nbsp;in the placebo group (at Week&nbsp;24) compared with 0.0&nbsp;&plusmn; 1.9; (p&nbsp;&lt;&nbsp;0.001) in the adalimumab group (at Week&nbsp;48).</p><p>&nbsp;</p><p>In subjects treated with adalimumab with no radiographic progression from baseline to Week&nbsp;48&nbsp;(n&nbsp;=&nbsp;102), 84% continued to show no radiographic progression through 144&nbsp;weeks of treatment. Adalimumab treated patients demonstrated statistically significant improvement in physical function as assessed by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week&nbsp;24. Improved physical function continued during the open‑label extension up to Week&nbsp;136.</p><p>&nbsp;</p><p><em>Psoriasis </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were studied in adult patients with chronic plaque psoriasis (&ge;&nbsp;10% BSA involvement and Psoriasis Area and Severity Index (PASI) &ge; 12&nbsp;or &ge; 10) who were candidates for systemic therapy or phototherapy in randomised, double‑blind studies. 73% of patients enrolled in Psoriasis Studies I and II had received prior systemic therapy or phototherapy. The safety and efficacy of adalimumab were also studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double‑blind study (Psoriasis Study III).</p><p>&nbsp;</p><p>Psoriasis Study I (REVEAL) evaluated 1,212&nbsp;patients within three treatment periods. In period A, patients received placebo or adalimumab at an initial dose of 80&nbsp;mg followed by 40&nbsp;mg every other week starting one week after the initial dose. After 16&nbsp;weeks of therapy, patients who achieved at least a PASI 75&nbsp;response (PASI score improvement of at least 75% relative to baseline), entered period B and received open‑label 40&nbsp;mg adalimumab every other week. Patients who maintained &ge;&nbsp;PASI&nbsp;75&nbsp;response at Week&nbsp;33&nbsp;and were originally randomised to active therapy in Period A, were re‑randomised in period C to receive 40&nbsp;mg adalimumab every other week or placebo for an additional 19&nbsp;weeks. Across all treatment groups, the mean baseline PASI score was 18.9&nbsp;and the baseline Physician&rsquo;s Global Assessment (PGA) score ranged from &ldquo;moderate&rdquo; (53% of subjects included) to &ldquo;severe&rdquo; (41%) to &ldquo;very severe&rdquo; (6%).</p><p>&nbsp;</p><p>Psoriasis Study II (CHAMPION) compared the efficacy and safety of adalimumab versus methotrexate and placebo in 271&nbsp;patients. Patients received placebo, an initial dose of MTX 7.5&nbsp;mg and thereafter dose increases up to Week&nbsp;12, with a maximum dose of 25&nbsp;mg or an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) for 16&nbsp;weeks. There are no data available comparing adalimumab and MTX beyond 16&nbsp;weeks of therapy. Patients receiving MTX who achieved a &ge;&nbsp;PASI 50&nbsp;response at Week&nbsp;8&nbsp;and/or 12&nbsp;did not receive further dose increases. Across all treatment groups, the mean baseline PASI score was 19.7&nbsp;and the baseline PGA score ranged from &ldquo;mild&rdquo; (&lt;1%) to &ldquo;moderate&rdquo; (48%) to &ldquo;severe&rdquo; (46%) to &ldquo;very severe&rdquo; (6%).</p><p>&nbsp;</p><p>Patients participating in all Phase 2&nbsp;and Phase 3&nbsp;psoriasis studies were eligible to enrol into an open‑label extension trial, where adalimumab was given for at least an additional 108&nbsp;weeks.</p><p>&nbsp;</p><p>In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI&nbsp;75&nbsp;response from baseline at Week&nbsp;16&nbsp;(see Tables 16&nbsp;and 17).</p><p>&nbsp;</p><p><strong>Table 16. Ps study I (REVEAL) efficacy results at 16&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>398</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 40</strong><strong>&nbsp;mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>814</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&ge; PASI 75<sup>a</sup></p></td><td style="vertical-align:top"><p>26 (6.5)</p></td><td style="vertical-align:top"><p>578 (70.9)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>PASI 100</p></td><td style="vertical-align:top"><p>3 (0.8)</p></td><td style="vertical-align:top"><p>163 (20.0)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>PGA: Clear/minimal</p></td><td style="vertical-align:top"><p>17 (4.3)</p></td><td style="vertical-align:top"><p>506 (62.2)<sup>b</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; Percent of patients achieving PASI&nbsp;75 response was calculated as centre‑adjusted rate</p><p><sup>b &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>p &lt;&nbsp;0.001, adalimumab vs. placebo</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 17. Ps study II (CHAMPION) efficacy results at 16&nbsp;weeks</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>53 </strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>MTX </strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>110 </strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 40</strong><strong>&nbsp;mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>108</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&ge; PASI 75</p></td><td style="vertical-align:top"><p>10 (18.9)</p></td><td style="vertical-align:top"><p>39 (35.5)</p></td><td style="vertical-align:top"><p>86 (79.6)<sup>a,b</sup></p></td></tr><tr><td style="vertical-align:top"><p>PASI 100</p></td><td style="vertical-align:top"><p>1 (1.9)</p></td><td style="vertical-align:top"><p>8 (7.3)</p></td><td style="vertical-align:top"><p>18 (16.7)<sup>c,d</sup></p></td></tr><tr><td style="vertical-align:top"><p>PGA: Clear/minimal</p></td><td style="vertical-align:top"><p>6 (11.3)</p></td><td style="vertical-align:top"><p>33 (30.0)</p></td><td style="vertical-align:top"><p>79 (73.1)<sup>a,b</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; p &lt;&nbsp;0.001 adalimumab vs. placebo</p><p><sup>b</sup> &nbsp;&nbsp; p &lt;&nbsp;0.001 adalimumab vs. methotrexate</p><p><sup>c</sup> &nbsp;&nbsp; p &lt;&nbsp;0.01 adalimumab vs. placebo</p><p><sup>d</sup> &nbsp;&nbsp; p &lt;&nbsp;0.05 adalimumab vs. methotrexate</p></td></tr></tbody></table><p>&nbsp;</p><p>In Psoriasis Study I, 28% of patients who were PASI 75&nbsp;responders and were re‑randomised to placebo at Week&nbsp;33&nbsp;compared to 5% continuing on adalimumab, p&nbsp;&lt;&nbsp;0.001, experienced &ldquo;loss of adequate response&rdquo; (PASI score after Week&nbsp;33&nbsp;and on or before Week&nbsp;52&nbsp;that resulted in a &lt;&nbsp;PASI 50&nbsp;response relative to baseline with a minimum of a 6‑point increase in PASI score relative to Week&nbsp;33). Of the patients who lost adequate response after re‑randomisation to placebo who then enrolled into the open‑label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75&nbsp;response after 12&nbsp;and 24&nbsp;weeks of re‑treatment, respectively.</p><p>&nbsp;</p><p>A total of 233&nbsp;PASI 75&nbsp;responders at Week&nbsp;16&nbsp;and Week&nbsp;33&nbsp;received continuous adalimumab therapy for 52&nbsp;weeks in Psoriasis Study I, and continued adalimumab in the open‑label extension trial. PASI&nbsp;75&nbsp;and PGA of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an additional 108&nbsp;weeks of open‑label therapy (total of 160&nbsp;weeks). In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose‑escalated, were considered non‑responders, PASI 75&nbsp;and PGA of clear or minimal response rates in these patients were 69.6% and 55.7%, respectively, after an additional 108&nbsp;weeks of open‑label therapy (total of 160&nbsp;weeks).</p><p>&nbsp;</p><p>A total of 347&nbsp;stable responders participated in a withdrawal and retreatment evaluation in an open‑label extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median time to relapse (decline to PGA &ldquo;moderate&rdquo; or worse) of approximately 5&nbsp;months. None of these patients experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA &ldquo;clear&rdquo; or &ldquo;minimal&rdquo; after 16&nbsp;weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1% [123/178] and 88.8% [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was observed during retreatment as before withdrawal.</p><p>&nbsp;</p><p>Significant improvements at Week&nbsp;16&nbsp;from baseline compared to placebo (Studies I and II) and MTX (Study&nbsp;II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in the physical and mental component summary scores of the SF‑36&nbsp;were also significant compared to placebo.</p><p>&nbsp;</p><p>In an open‑label extension study, for patients who dose escalated from 40&nbsp;mg every other week to 40&nbsp;mg weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved PASI 75&nbsp;response at Week&nbsp;12&nbsp;and 24, respectively.</p><p>&nbsp;</p><p>Psoriasis Study III (REACH) compared the efficacy and safety of adalimumab versus placebo in 72&nbsp;patients with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) or placebo for 16&nbsp;weeks. At Week&nbsp;16, a statistically significantly greater proportion of patients who received adalimumab achieved PGA of &lsquo;clear&rsquo; or &lsquo;almost clear&rsquo; for the hands and/or feet compared to patients who received placebo (30.6% versus 4.3%, respectively [P&nbsp;=&nbsp;0.014]).</p><p>&nbsp;</p><p>Psoriasis Study IV compared efficacy and safety of adalimumab versus placebo in 217&nbsp;adult patients with moderate to severe nail psoriasis. Patients received an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) or placebo for 26&nbsp;weeks followed by open‑label adalimumab treatment for an additional 26&nbsp;weeks. Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician&rsquo;s Global Assessment of Fingernail Psoriasis (PGA‑F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 18). Adalimumab demonstrated a treatment benefit in nail psoriasis patients with different extents of skin involvement (BSA&nbsp;&ge;&nbsp;10% (60% of patients) and BSA&nbsp;&lt;&nbsp;10% and &ge;&nbsp;5% (40% of patients)).</p><p>&nbsp;</p><p><strong>Table 18. Ps study IV efficacy results at 16, 26&nbsp;and 52&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td colspan="2"><p><strong>Week&nbsp;16</strong></p><p><strong>Placebo‑controlled</strong></p></td><td colspan="2"><p><strong>Week&nbsp;26</strong></p><p><strong>Placebo‑controlled</strong></p></td><td><p><strong>Week&nbsp;52</strong></p><p><strong>Open‑label</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>108</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40&nbsp;mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>109</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>108</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40&nbsp;mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>109</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40&nbsp;mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>80</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&sup3;&nbsp;mNAPSI&nbsp;75&nbsp;(%)</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>26.0<sup>a</sup></p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>46.6<sup>a</sup></p></td><td style="vertical-align:top"><p>65.0</p></td></tr><tr><td style="vertical-align:top"><p>PGA‑F clear/minimal and &sup3;&nbsp;2‑grade improvement (%)</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>29.7<sup>a</sup></p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>48.9<sup>a</sup></p></td><td style="vertical-align:top"><p>61.3</p></td></tr><tr><td style="vertical-align:top"><p>Percent Change in Total Fingernail NAPSI (%)</p></td><td style="vertical-align:top"><p>‑7.8</p></td><td style="vertical-align:top"><p>‑44.2<sup>a</sup></p></td><td style="vertical-align:top"><p>‑11.5</p></td><td style="vertical-align:top"><p>‑56.2<sup>a</sup></p></td><td style="vertical-align:top"><p>‑72.2</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; p&lt;0.001, adalimumab <em>vs.</em> placebo</p></td></tr></tbody></table><p>&nbsp;</p><p>Adalimumab treated patients showed statistically significant improvements at Week&nbsp;26&nbsp;compared with placebo in the DLQI.</p><p>&nbsp;</p><p><em>Hidradenitis suppurativa </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in randomised, double‑blind, placebo‑controlled studies and an open‑label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3‑month trial of systemic antibiotic therapy. The patients in HS‑I and HS‑II had Hurley Stage II or III disease with at least 3&nbsp;abscesses or inflammatory nodules.</p><p>&nbsp;</p><p>Study HS‑I (PIONEER I) evaluated 307&nbsp;patients with 2&nbsp;treatment periods. In Period A, patients received placebo or adalimumab at an initial dose of 160&nbsp;mg at Week&nbsp;0, 80&nbsp;mg at Week&nbsp;2, and 40&nbsp;mg every week starting at Week&nbsp;4&nbsp;to Week&nbsp;11. Concomitant antibiotic use was not allowed during the study. After 12&nbsp;weeks of therapy, patients who had received adalimumab in Period A were re‑randomised in Period B to 1&nbsp;of 3&nbsp;treatment groups (adalimumab 40&nbsp;mg every week, adalimumab 40&nbsp;mg every other week, or placebo from Week&nbsp;12&nbsp;to Week&nbsp;35). Patients who had been randomised to placebo in Period A were assigned to receive adalimumab 40&nbsp;mg every week in Period B.</p><p>&nbsp;</p><p>Study HS‑II (PIONEER II) evaluated 326&nbsp;patients with 2&nbsp;treatment periods. In Period A, patients received placebo or adalimumab at an initial dose of 160&nbsp;mg at Week&nbsp;0&nbsp;and 80&nbsp;mg at Week&nbsp;2&nbsp;and 40&nbsp;mg every week starting at Week&nbsp;4&nbsp;to Week&nbsp;11. 19.3% of patients had continued baseline oral antibiotic therapy during the study. After 12&nbsp;weeks of therapy, patients who had received adalimumab in Period A were re‑randomised in Period B to 1&nbsp;of 3&nbsp;treatment groups (adalimumab 40&nbsp;mg every week, adalimumab 40&nbsp;mg every other week, or placebo from Week&nbsp;12&nbsp;to Week&nbsp;35). Patients who had been randomised to placebo in Period A were assigned to receive placebo in Period B.</p><p>&nbsp;</p><p>Patients participating in Studies HS‑I and HS‑II were eligible to enrol into an open‑label extension study in which adalimumab 40&nbsp;mg was administered every week. Mean exposure in all adalimumab population was 762&nbsp;days. Throughout all 3&nbsp;studies patients used topical antiseptic wash daily.</p><p>&nbsp;</p><p><em><u>Clinical response</u></em></p><p>&nbsp;</p><p>Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline). Reduction in HS‑related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3&nbsp;or greater on a 11&nbsp;point scale.</p><p>&nbsp;</p><p>At Week&nbsp;12, a significantly higher proportion of patients treated with adalimumab versus placebo achieved HiSCR. At Week&nbsp;12, a significantly higher proportion of patients in Study HS‑II experienced a clinically relevant decrease in HS‑related skin pain (see Table 19). Patients treated with adalimumab had significantly reduced risk of disease flare during the initial 12&nbsp;weeks of treatment.</p><p>&nbsp;</p><p><strong>Table 19. Efficacy results at 12 weeks, HS studies I and II</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>HS Study I</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>HS Study II</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Adalimumab 40&nbsp;mg Weekly</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Adalimumab 40&nbsp;mg Weekly</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hidradenitis Suppurativa Clinical Response (HiSCR)<sup>a</sup></p></td><td><p>N&nbsp;=&nbsp;154</p><p>40 (26.0%)</p></td><td><p>N&nbsp;=&nbsp;153</p><p>64 (41.8%) <sup>*</sup></p></td><td><p>N&nbsp;=&nbsp;163</p><p>45 (27.6%)</p></td><td><p>N&nbsp;=&nbsp;163</p><p>96 (58.9%)<sup>***</sup></p></td></tr><tr><td style="vertical-align:top"><p>&ge;30% Reduction in Skin Pain<sup>b</sup></p></td><td><p>N&nbsp;=&nbsp;109</p><p>27 (24.8%)</p></td><td><p>N&nbsp;=&nbsp;122</p><p>34 (27.9%)</p></td><td><p>N&nbsp;=&nbsp;111</p><p>23 (20.7%)</p></td><td><p>N&nbsp;=&nbsp;105</p><p>48 (45.7%)<sup>***</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* <em>P</em> &lt;&nbsp;0.05, ***<em>P</em> &lt;&nbsp;0.001, adalimumab versus placebo</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Among all randomised patients.</p><p><sup>b</sup> &nbsp;&nbsp; Among patients with baseline HS‑related skin pain assessment &ge; 3, based on Numeric Rating</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Scale 0 &ndash; 10; 0&nbsp;=&nbsp;no skin pain, 10&nbsp;=&nbsp;skin pain as bad as you can imagine.</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment with adalimumab 40&nbsp;mg every week significantly reduced the risk of worsening of abscesses and draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12&nbsp;weeks of Studies HS‑I and HS‑II, compared with those in the adalimumab group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</p><p>&nbsp;</p><p>Greater improvements at Week&nbsp;12&nbsp;from baseline compared to placebo were demonstrated in skin‑specific health‑related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS‑I and HS‑II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire ‑ medication (TSQM; Studies HS‑I and HS‑II), and physical health as measured by the physical component summary score of the SF‑36&nbsp;(Study HS‑I).</p><p>&nbsp;</p><p>In patients with at least a partial response to adalimumab 40&nbsp;mg weekly at Week&nbsp;12, the HiSCR rate at Week&nbsp;36&nbsp;was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 20).</p><p>&nbsp;</p><p><strong>Table 20. Proportion of patients<sup>a</sup> achieving HiSCR<sup>b</sup> at Weeks&nbsp;24 and 36 after treatment reassignment from weekly adalimumab at Week&nbsp;12</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(treatment withdrawal)</strong></p><p><strong>N&nbsp;=&nbsp;73</strong></p></td><td><p><strong>Adalimumab 40&nbsp;mg</strong></p><p><strong>every other week</strong></p><p><strong>N&nbsp;=&nbsp;70</strong></p></td><td><p><strong>Adalimumab 40&nbsp;mg</strong></p><p><strong>weekly</strong></p><p><strong>N&nbsp;=&nbsp;70</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Week&nbsp;24</p></td><td><p>24 (32.9%)</p></td><td><p>36 (51.4%)</p></td><td><p>40 (57.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;36</p></td><td><p>22 (30.1%)</p></td><td><p>28 (40.0%)</p></td><td><p>39 (55.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Patients with at least a partial response to adalimumab 40&nbsp;mg weekly after 12&nbsp;weeks of treatment.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Patients meeting protocol‑specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients who were at least partial responders at Week&nbsp;12, and who received continuous weekly adalimumab therapy, the HiSCR rate at Week&nbsp;48&nbsp;was 68.3% and at Week&nbsp;96&nbsp;was 65.1%. Longer term treatment with adalimumab 40&nbsp;mg weekly for 96&nbsp;weeks identified no new safety findings.</p><p>&nbsp;</p><p>Among patients whose adalimumab treatment was withdrawn at Week&nbsp;12&nbsp;in Studies HS‑I and HS‑II, the HiSCR rate 12&nbsp;weeks after re‑introduction of adalimumab 40&nbsp;mg weekly returned to levels similar to that observed before withdrawal (56.0&nbsp;%).</p><p>&nbsp;</p><p><em>Crohn&rsquo;s disease </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in over 1500&nbsp;patients with moderately to severely active Crohn&rsquo;s disease (Crohn&rsquo;s Disease Activity Index (CDAI) &ge; 220&nbsp;and &le; 450) in randomised, double‑blind, placebo‑controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these medications.</p><p>&nbsp;</p><p>Induction of clinical remission (defined as CDAI &lt;&nbsp;150) was evaluated in two studies, CD Study I (CLASSIC I) and CD Study II (GAIN). In CD Study I, 299&nbsp;TNF‑antagonist na&iuml;ve patients were randomised to one of four treatment groups; placebo at Weeks 0&nbsp;and 2, 160&nbsp;mg adalimumab at Week&nbsp;0&nbsp;and 80&nbsp;mg at Week&nbsp;2, 80&nbsp;mg at Week 0&nbsp;and 40&nbsp;mg at Week&nbsp;2, and 40&nbsp;mg at Week 0&nbsp;and 20&nbsp;mg at Week&nbsp;2. In CD Study II, 325&nbsp;patients who had lost response or were intolerant to infliximab were randomised to receive either 160&nbsp;mg adalimumab at Week&nbsp;0 and 80&nbsp;mg at Week&nbsp;2&nbsp;or placebo at Weeks 0&nbsp;and 2. The primary non‑responders were excluded from the studies and therefore these patients were not further evaluated.</p><p>&nbsp;</p><p>Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III, 854&nbsp;patients received open‑label 80&nbsp;mg at Week&nbsp;0&nbsp;and 40&nbsp;mg at Week&nbsp;2. At Week&nbsp;4&nbsp;patients were randomised to 40&nbsp;mg every other week, 40&nbsp;mg every week, or placebo with a total study duration of 56&nbsp;weeks. Patients in clinical response (decrease in CDAI &ge; 70) at Week&nbsp;4&nbsp;were stratified and analysed separately from those not in clinical response at Week&nbsp;4. Corticosteroid taper was permitted after Week&nbsp;8.</p><p>&nbsp;</p><p>CD study I and CD study II induction of remission and response rates are presented in Table 21.</p><p>&nbsp;</p><p><strong>Table 21. Induction of clinical remission and response (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>CD study I: Infliximab na&iuml;ve patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>CD Study II: Infliximab experienced patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>74</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>80/40&nbsp;mg</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>75</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>160/80&nbsp;mg</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>76</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>166</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>160/80&nbsp;mg</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>159</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Week&nbsp;4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>12%</p></td><td><p>24%</p></td><td><p>36%*</p></td><td><p>7%</p></td><td><p>21%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response (CR‑100)</p></td><td><p>24%</p></td><td><p>37%</p></td><td><p>49%**</p></td><td><p>25%</p></td><td><p>38%**</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>All p‑values are pairwise comparisons of proportions for adalimumab <em>versus</em> placebo</p><p>*&nbsp;&nbsp; p &lt;&nbsp;0.001&nbsp;</p><p>** p&nbsp;&lt;&nbsp;0.01&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Similar remission rates were observed for the 160/80&nbsp;mg and 80/40&nbsp;mg induction regimens by Week&nbsp;8&nbsp;and adverse events were more frequently noted in the 160/80&nbsp;mg group.</p><p>&nbsp;</p><p>In CD Study III, at Week&nbsp;4, 58% (499/854) of patients were in clinical response and were assessed in the primary analysis. Of those in clinical response at Week&nbsp;4, 48% had been previously exposed to other TNF‑antagonists. Maintenance of remission and response rates are presented in Table 22. Clinical remission results remained relatively constant irrespective of previous TNF‑antagonist exposure.</p><p>&nbsp;</p><p>Disease‑related hospitalisations and surgeries were statistically significantly reduced with adalimumab compared with placebo at Week&nbsp;56.</p><p>&nbsp;</p><p><strong>Table 22. Maintenance of clinical remission and response (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>40&nbsp;mg Adalimumab</strong></p><p><strong>every other week</strong></p></td><td><p><strong>40&nbsp;mg Adalimumab</strong></p><p><strong>every week</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Week&nbsp;26</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>170</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>172</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>157</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>40%*</p></td><td style="vertical-align:top"><p>47%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response (CR‑100)</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top"><p>52%*</p></td><td style="vertical-align:top"><p>52%*</p></td></tr><tr><td style="vertical-align:top"><p>Patients in steroid‑free remission for &ge;&nbsp;90&nbsp;days<sup>a</sup></p></td><td style="vertical-align:top"><p>3%&nbsp;(2/66)</p></td><td style="vertical-align:top"><p>19%&nbsp;(11/58)**</p></td><td style="vertical-align:top"><p>15%&nbsp;(11/74)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;56</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>170</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>172</strong></p></td><td style="vertical-align:top"><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>157</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>36%*</p></td><td style="vertical-align:top"><p>41%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response (CR‑100)</p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>41%*</p></td><td style="vertical-align:top"><p>48%*</p></td></tr><tr><td style="vertical-align:top"><p>Patients in steroid‑free remission for &ge;&nbsp;90&nbsp;days<sup>a</sup></p></td><td style="vertical-align:top"><p>5% (3/66)</p></td><td style="vertical-align:top"><p>29% (17/58)*</p></td><td style="vertical-align:top"><p>20% (15/74)**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* &nbsp; p &lt;&nbsp;0.001&nbsp;for adalimumab <em>versus</em> placebo pairwise comparisons of proportions</p><p>** p &lt;&nbsp;0.02&nbsp;for adalimumab <em>versus</em> placebo pairwise comparisons of proportions</p><p><sup>a</sup> &nbsp;&nbsp; Of those receiving corticosteroids at baseline</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients who were not in response at Week&nbsp;4, 43% of adalimumab maintenance patients responded by Week&nbsp;12&nbsp;compared to 30% of placebo maintenance patients. These results suggest that some patients who have not responded by Week&nbsp;4&nbsp;benefit from continued maintenance therapy through Week&nbsp;12. Therapy continued beyond 12&nbsp;weeks did not result in significantly more responses (see section&nbsp;4.2).</p><p>&nbsp;</p><p>117/276&nbsp;patients from CD study I and 272/777&nbsp;patients from CD studies II and III were followed through at least 3&nbsp;years of open‑label adalimumab therapy. 88&nbsp;and 189&nbsp;patients, respectively, continued to be in clinical remission. Clinical response (CR‑100) was maintained in 102&nbsp;and 233&nbsp;patients, respectively.</p><p>&nbsp;</p><p><em><u>Quality of life</u></em><em> </em></p><p>&nbsp;</p><p>In CD Study I and CD Study II, statistically significant improvement in the disease‑specific inflammatory bowel disease questionnaire (IBDQ) total score was achieved at Week&nbsp;4&nbsp;in patients randomised to adalimumab 80/40&nbsp;mg and 160/80&nbsp;mg compared to placebo and was seen at Weeks&nbsp;26&nbsp;and 56&nbsp;in CD Study III as well among the adalimumab treatment groups compared to the placebo group.</p><p>&nbsp;</p><p><em>Ulcerative colitis </em></p><p>&nbsp;</p><p>The safety and efficacy of multiple doses of adalimumab were assessed in adult patients with moderately to severely active ulcerative colitis (Mayo score 6&nbsp;to 12&nbsp;with endoscopy subscore of 2&nbsp;to 3) in randomised, double‑blind, placebo‑controlled studies.</p><p>&nbsp;</p><p>In study UC‑I, 390&nbsp;TNF‑antagonist na&iuml;ve patients were randomised to receive either placebo at Weeks 0&nbsp;and 2, 160&nbsp;mg adalimumab at Week&nbsp;0 followed by 80&nbsp;mg at Week&nbsp;2, or 80&nbsp;mg adalimumab at Week&nbsp;0 followed by 40&nbsp;mg at Week&nbsp;2. After Week&nbsp;2, patients in both adalimumab arms received 40&nbsp;mg eow. Clinical remission (defined as Mayo score &le; 2&nbsp;with no subscore &gt;&nbsp;1) was assessed at Week&nbsp;8.</p><p>&nbsp;</p><p>In study UC‑II, 248&nbsp;patients received 160&nbsp;mg of adalimumab at Week&nbsp;0, 80&nbsp;mg at Week&nbsp;2&nbsp;and 40&nbsp;mg eow thereafter, and 246&nbsp;patients received placebo. Clinical results were assessed for induction of remission at Week&nbsp;8&nbsp;and for maintenance of remission at Week&nbsp;52.</p><p>&nbsp;</p><p>Patients induced with 160/80&nbsp;mg adalimumab achieved clinical remission versus placebo at Week&nbsp;8&nbsp;in statistically significantly greater percentages in study UC‑I (18% vs. 9% respectively, p&nbsp;=&nbsp;0.031) and study UC‑II (17% vs. 9% respectively, p&nbsp;=&nbsp;0.019). In study UC‑II, among those treated with adalimumab who were in remission at Week&nbsp;8, 21/41&nbsp;(51%) were in remission at Week&nbsp;52.</p><p>&nbsp;</p><p>Results from the overall UC‑II study population are shown in Table 23.</p><p>&nbsp;</p><p><strong>Table 23. Response, remission and mucosal healing in study UC‑II (percent of patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 40&nbsp;mg</strong></p><p><strong>eow</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;52</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>246</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>248</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical Response</p></td><td><p>18%</p></td><td><p>30%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Remission</p></td><td><p>9%</p></td><td><p>17%*</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal Healing</p></td><td><p>15%</p></td><td><p>25%*</p></td></tr><tr><td style="vertical-align:top"><p>Steroid‑free remission for &sup3;&nbsp;90&nbsp;days<sup>a</sup></p></td><td><p>6%</p></td><td><p>13%*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;8 and 52</strong></p></td><td><p><strong>(N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>140)</strong></p></td><td><p><strong>(N&nbsp;=&nbsp;150)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sustained Response</p></td><td><p>12%</p></td><td><p>24%**</p></td></tr><tr><td style="vertical-align:top"><p>Sustained Remission</p></td><td><p>4%</p></td><td><p>8%*</p></td></tr><tr><td style="vertical-align:top"><p>Sustained Mucosal Healing</p></td><td><p>11%</p></td><td><p>19%*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Clinical remission is Mayo score &le; 2&nbsp;with no subscore &gt;&nbsp;1;</p><p>Clinical response is decrease from baseline in Mayo score &ge;&nbsp;3&nbsp;points and &ge;&nbsp;30% plus a decrease in the rectal bleeding subscore [RBS] &ge;&nbsp;1&nbsp;or an absolute RBS of 0&nbsp;or 1;</p><p>*&nbsp;&nbsp; p&lt;0.05&nbsp;for adalimumab vs. placebo pairwise comparison of proportions</p><p>** p&lt;0.001&nbsp;for adalimumab vs. placebo pairwise comparison of proportions</p><p><sup>a</sup> &nbsp;&nbsp; Of those receiving corticosteroids at baseline</p></td></tr></tbody></table><p>&nbsp;</p><p>Of those patients who had a response at Week&nbsp;8, 47% were in response, 29% were in remission, 41% had mucosal healing, and 20% were in steroid‑free remission for &ge; 90&nbsp;days at Week&nbsp;52.</p><p>&nbsp;</p><p>Approximately 40% of patients in study UC‑II had failed prior anti‑TNF treatment with infliximab. The efficacy of adalimumab in those patients was reduced compared to that in anti‑TNF na&iuml;ve patients. Among patients who had failed prior anti‑TNF treatment, Week&nbsp;52&nbsp;remission was achieved by 3% on placebo and 10% on adalimumab.</p><p>&nbsp;</p><p>Patients from studies UC‑I and UC‑II had the option to roll over into an open‑label long‑term extension study (UC III). Following 3&nbsp;years of adalimumab therapy, 75% (301/402) continued to be in clinical remission per partial Mayo score.</p><p>&nbsp;</p><p><em><u>Hospitalisation rates</u></em><em> </em></p><p>&nbsp;</p><p>During 52&nbsp;weeks of studies UC‑I and UC‑II, lower rates of all‑cause hospitalisations and UC‑related hospitalisations were observed for the adalimumab‑treated arm compared to the placebo arm. The number of all cause hospitalisations in the adalimumab treatment group was 0.18&nbsp;per patient year vs. 0.26&nbsp;per patient year in the placebo group and the corresponding figures for UC‑related hospitalisations were 0.12&nbsp;per patient year <em>vs</em>. 0.22&nbsp;per patient year.</p><p>&nbsp;</p><p><em><u>Quality of life</u></em><em> </em></p><p>&nbsp;</p><p>In study UC‑II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease Questionnaire (IBDQ) score.</p><p>&nbsp;</p><p><em>Uveitis </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in adult patients with non‑infectious intermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double‑masked, placebo‑controlled studies (UV I and II). Patients received placebo or adalimumab at an initial dose of 80&nbsp;mg followed by 40&nbsp;mg every other week starting one week after the initial dose. Concomitant stable doses of one non‑biologic immunosuppressant were permitted.</p><p>&nbsp;</p><p>Study UV I evaluated 217&nbsp;patients with active uveitis despite treatment with corticosteroids (oral prednisone at a dose of 10&nbsp;to 60&nbsp;mg/day). All patients received a 2‑week standardised dose of prednisone 60&nbsp;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by Week&nbsp;15.</p><p>&nbsp;</p><p>Study UV II evaluated 226&nbsp;patients with inactive uveitis requiring chronic corticosteroid treatment (oral prednisone 10&nbsp;to 35&nbsp;mg/day) at baseline to control their disease. Patients subsequently underwent a mandatory taper schedule, with complete corticosteroid discontinuation by Week&nbsp;19.</p><p>&nbsp;</p><p>The primary efficacy endpoint in both studies was &lsquo;time to treatment failure&rsquo;. Treatment failure was defined by a multi‑component outcome based on inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual acuity (BCVA).</p><p>&nbsp;</p><p>Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on study medication beyond Week 78 until they had access to adalimumab.</p><p>&nbsp;</p><p><em><u>Clinical response</u></em><em> </em></p><p>&nbsp;</p><p>Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (see Table 24). Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versus placebo (see Figure 2).</p><p>&nbsp;</p><p><strong>Table 24. Time to treatment failure in studies UV I and UV II</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Analysis</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Failure</strong></p><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Median Time to Failure (months)</strong></p></td><td style="vertical-align:top"><p><strong>HR<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>CI 95% for HR<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong><em>P</em></strong><strong> Value<sup>b</sup></strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Time to treatment failure at or after Week&nbsp;6&nbsp;in study UV I&nbsp; </strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Primary analysis (ITT)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Placebo</p></td><td style="vertical-align:top"><p>107</p></td><td style="vertical-align:top"><p>84&nbsp;(78.5)</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>‑‑</p></td><td style="vertical-align:top"><p>‑‑</p></td><td style="vertical-align:top"><p>‑‑</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adalimumab</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>60&nbsp;(54.5)</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>0.36, 0.70</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Time to treatment failure at or after Week&nbsp;2&nbsp;in study UV II</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Primary analysis (ITT)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Placebo</p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>61&nbsp;(55.0)</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>‑‑</p></td><td style="vertical-align:top"><p>‑‑</p></td><td style="vertical-align:top"><p>‑‑</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adalimumab</p></td><td style="vertical-align:top"><p>115</p></td><td style="vertical-align:top"><p>45&nbsp;(39.1)</p></td><td style="vertical-align:top"><p>NE<sup>c</sup></p></td><td style="vertical-align:top"><p>0.57</p></td><td style="vertical-align:top"><p>0.39, 0.84</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Note: Treatment failure at or after Week&nbsp;6&nbsp;(Study UV I), or at or after Week&nbsp;2&nbsp;(Study UV II), was counted as event. Drop outs due to reasons other than treatment failure were censored at the time of dropping out.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp; HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; 2‑sided <em>P </em>value from log rank test.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; NE&nbsp;=&nbsp;not estimable. Fewer than half of at‑risk subjects had an event.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 2. Kaplan‑Meier curves summarizing time to treatment failure on or after Week&nbsp;6&nbsp;(study&nbsp;UV I) or Week&nbsp;2&nbsp;(study UV II)</strong></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:313pt;height:152.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="417" height="203" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_2" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:317.5pt;
 height:151.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="423" height="202" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.jpg" /></p><p>Note: P#&nbsp;=&nbsp;Placebo (Number of Events/Number at Risk); A#&nbsp;=&nbsp;Adalimumab (Number of Events/Number at Risk).</p><p>&nbsp;</p><p>In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed for each component of treatment failure. In Study UV II, statistically significant differences were observed for visual acuity only, but the other components were numerically in favour of adalimumab.</p><p>&nbsp;</p><p>Of the 424 subjects included in the uncontrolled long‑term extension of Studies UV I and UV II, 60&nbsp;subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open‑label adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active inflammatory lesions, AC cell grade &le; 0.5+, VH grade &le; 0.5+) with a concomitant steroid dose &le; 7.5&nbsp;mg per day, and 178 (66.2 %) were in steroid‑free quiescence. BCVA was either improved or maintained (&lt;&nbsp;5 letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent with these results but the number of enrolled subjects declined after this time. Overall, among the patients who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response to adalimumab treatment.</p><p>&nbsp;</p><p><em><u>Quality of life</u></em></p><p>&nbsp;</p><p>Patient reported outcomes regarding vision‑related functioning were measured in both clinical studies, using the NEI VFQ‑25. Adalimumab was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not numerically in favour of adalimumab for colour vision in Study UV&nbsp;I and for colour vision, peripheral vision and near vision in Study UV II.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>Anti‑adalimumab antibodies may develop during adalimumab treatment. Formation of anti‑adalimumab antibodies is associated with increased clearance and reduced efficacy of adalimumab. There is no apparent correlation between the presence of anti‑adalimumab antibodies and the occurrence of adverse events.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Juvenile idiopathic arthritis (JIA) </em></p><p>&nbsp;</p><p><em><u>Polyarticular juvenile idiopathic arthritis (pJIA)</u></em><em> </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in two studies (pJIA I and II) in children with active polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types (most frequently rheumatoid‑factor negative or positive polyarthritis and extended oligoarthritis).</p><p>&nbsp;</p><p>pJIA I</p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double‑blind, parallel &minus; group study in 171&nbsp;children (4‑17&nbsp;years old) with polyarticular JIA. In the open‑label lead in phase (OL LI) patients were stratified into two groups, MTX (methotrexate)‑treated or non‑MTX‑treated. Patients who were in the non‑MTX stratum were either na&iuml;ve to or had been withdrawn from MTX at least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or prednisone (&le;&nbsp;0.2&nbsp;mg /kg/day or 10&nbsp;mg/day maximum). In the OL LI phase all patients received 24&nbsp;mg/m<sup>2</sup>&nbsp;up to a maximum of 40&nbsp;mg adalimumab every other week for 16&nbsp;weeks. The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 25.</p><p>&nbsp;</p><p><strong>Table 25. Distribution of patients by age and adalimumab dose received during the OL LI phase</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients at baseline</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum, median and maximum dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>4 to 7&nbsp;years</p></td><td style="vertical-align:top"><p>31 (18.1)</p></td><td style="vertical-align:top"><p>10, 20 and 25&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>8 to 12&nbsp;years</p></td><td style="vertical-align:top"><p>71 (41.5)</p></td><td style="vertical-align:top"><p>20, 25 and 40&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>13 to 17&nbsp;years</p></td><td style="vertical-align:top"><p>69 (40.4)</p></td><td style="vertical-align:top"><p>25, 40 and 40&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients demonstrating a Paediatric ACR 30&nbsp;response at Week&nbsp;16&nbsp;were eligible to be randomised into the double‑blind (DB) phase and received either adalimumab 24&nbsp;mg/m<sup>2</sup>&nbsp;up to a maximum of 40&nbsp;mg, or placebo every other week for an additional 32&nbsp;weeks or until disease flare. Disease flare criteria were defined as a worsening of &ge; 30% from baseline in &ge; 3&nbsp;of 6&nbsp;Paediatric ACR core criteria, &ge; 2&nbsp;active joints, and improvement of &gt;&nbsp;30% in no more than 1&nbsp;of the 6&nbsp;criteria. After 32&nbsp;weeks or at disease flare, patients were eligible to enrol into the open‑label extension phase.</p><p>&nbsp;</p><p><strong>Table 26. Ped ACR 30&nbsp;responses in the JIA study</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Stratum</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MTX</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Without MTX</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Phase</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>OL‑LI 16&nbsp;weeks</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ped ACR 30 response (n/N)</p></td><td colspan="2" style="vertical-align:top"><p>94.1% (80/85)</p></td><td colspan="2" style="vertical-align:top"><p>74.4% (64/86)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Efficacy Outcomes</p></td></tr><tr><td style="vertical-align:top"><p>Double‑Blind 32&nbsp;weeks</p></td><td style="vertical-align:top"><p>Adalimumab / MTX</p><p>(N&nbsp;=&nbsp;38)</p></td><td style="vertical-align:top"><p>Placebo / MTX</p><p>(N&nbsp;=&nbsp;37)</p></td><td style="vertical-align:top"><p>Adalimumab</p><p>(N&nbsp;=&nbsp;30)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N&nbsp;=&nbsp;28)</p></td></tr><tr><td style="vertical-align:top"><p>Disease flares at the end of 32&nbsp;weeks<sup>a</sup> (n/N)</p></td><td style="vertical-align:top"><p>36.8% (14/38)</p></td><td style="vertical-align:top"><p>64.9% (24/37)<sup>b</sup></p></td><td style="vertical-align:top"><p>43.3% (13/30)</p></td><td style="vertical-align:top"><p>71.4% (20/28)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Median time to disease flare</p></td><td style="vertical-align:top"><p>&gt;32&nbsp;weeks</p></td><td style="vertical-align:top"><p>20&nbsp;weeks</p></td><td style="vertical-align:top"><p>&gt;32&nbsp;weeks</p></td><td style="vertical-align:top"><p>14&nbsp;weeks</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients</p><p><sup>b</sup> &nbsp;&nbsp; p&nbsp;=&nbsp;0.015</p><p><sup>c</sup> &nbsp;&nbsp; p&nbsp;=&nbsp;0.031</p></td></tr></tbody></table><p>&nbsp;</p><p>Amongst those who responded at Week&nbsp;16&nbsp;(n&nbsp;=&nbsp;144), the Paediatric ACR 30/50/70/90&nbsp;responses were maintained for up to six&nbsp;years in the OLE phase in patients who received adalimumab throughout the study. Over all 19&nbsp;subjects, of which 11&nbsp;of the baseline age group 4&nbsp;to 12&nbsp;and 8&nbsp;of the baseline age group 13&nbsp;to 17&nbsp;years were treated 6&nbsp;years or longer.</p><p>&nbsp;</p><p>Overall responses were generally better and, fewer patients developed antibodies when treated with the combination of adalimumab and MTX compared to adalimumab alone. Taking these results into consideration, adalimumab is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section&nbsp;4.2).</p><p>&nbsp;</p><p>pJIA II</p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in an open‑label, multicentre study in 32&nbsp;children (2&nbsp;‑&lt;&nbsp;4&nbsp;years old or aged 4&nbsp;and above weighing &lt;&nbsp;15&nbsp;kg) with moderately to severely active polyarticular JIA. The patients received 24&nbsp;mg/m<sup>2</sup>&nbsp;body surface area (BSA) of adalimumab up to a maximum of 20&nbsp;mg every other week as a single dose via SC injection for at least 24&nbsp;weeks. During the study, most subjects used concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</p><p>&nbsp;</p><p>At Week&nbsp;12&nbsp;and Week&nbsp;24, PedACR 30&nbsp;response was 93.5% and 90.0%, respectively, using the observed data approach. The proportions of subjects with PedACR 50/70/90&nbsp;at Week&nbsp;12&nbsp;and Week&nbsp;24&nbsp;were 90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric ACR 30) at Week&nbsp;24&nbsp;(n&nbsp;=&nbsp;27&nbsp;out of 30&nbsp;patients), the Paediatric ACR 30&nbsp;responses were maintained for up to 60&nbsp;weeks in the OLE phase in patients who received adalimumab throughout this time period. Overall, 20&nbsp;subjects were treated for 60&nbsp;weeks or longer.</p><p>&nbsp;</p><p><em><u>Enthesitis‑related arthritis</u></em><em> </em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double‑blind study in 46&nbsp;paediatric patients (6&nbsp;to 17&nbsp;years old) with moderate enthesitis‑related arthritis. Patients were randomised to receive either 24&nbsp;mg/m<sup>2</sup>&nbsp;body surface area (BSA) of adalimumab up to a maximum of 40&nbsp;mg, or placebo every other week for 12&nbsp;weeks. The double‑blind period is followed by an open‑label (OL) period during which patients received 24&nbsp;mg/m<sup>2</sup>&nbsp;BSA of adalimumab up to a maximum of 40&nbsp;mg every other week subcutaneously for up to an additional 192&nbsp;weeks. The primary endpoint was the percent change from Baseline to Week&nbsp;12&nbsp;in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of ‑62.6% (median percent change ‑88.9%) in patients in the adalimumab group compared to ‑11.6% (median percent change ‑50.0%) in patients in the placebo group. Improvement in number of active joints with arthritis was maintained during the OL period through Week&nbsp;156&nbsp;for the 26&nbsp;of 31&nbsp;(84%) patients in the adalimumab group who remained in the study. Although not statistically significant, the majority of patients demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender joint count (TJC), swollen joint count (SJC), Paediatric ACR 50&nbsp;response, and Paediatric ACR 70&nbsp;response.</p><p>&nbsp;</p><p><em>Paediatric plaque psoriasis </em></p><p>&nbsp;</p><p>The efficacy of adalimumab was assessed in a randomised, double‑blind, controlled study of 114&nbsp;paediatric patients from 4&nbsp;years of age with severe chronic plaque psoriasis (as defined by a PGA &ge;&nbsp;4 or &gt;&nbsp;20% BSA involvement or &gt;&nbsp;10% BSA involvement with very thick lesions or PASI &ge;&nbsp;20&nbsp;or &ge;&nbsp;10&nbsp;with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.</p><p>&nbsp;</p><p>Patients received adalimumab 0.8&nbsp;mg/kg eow (up to 40&nbsp;mg), 0.4&nbsp;mg/kg eow (up to 20&nbsp;mg), or methotrexate 0.1&nbsp;&ndash; 0.4&nbsp;mg/kg weekly (up to 25&nbsp;mg). At Week&nbsp;16, more patients randomised to adalimumab 0.8&nbsp;mg/kg had positive efficacy responses (e.g. PASI 75) than those randomised to 0.4&nbsp;mg/kg eow or MTX.</p><p>&nbsp;</p><p><strong>Table 27. Paediatric plaque psoriasis efficacy results at 16&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>MTX<sup>a</sup></strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>37</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 0.8&nbsp;mg/kg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>38</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>PASI 75<sup>b</sup></p></td><td style="vertical-align:top"><p>12&nbsp;(32.4%)</p></td><td style="vertical-align:top"><p>22&nbsp;(57.9%)</p></td></tr><tr><td style="vertical-align:top"><p>PGA: Clear/minimal<sup>c</sup></p></td><td style="vertical-align:top"><p>15&nbsp;(40.5%)</p></td><td style="vertical-align:top"><p>23&nbsp;(60.5%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; MTX&nbsp;=&nbsp;methotrexate</p><p><sup>b</sup> &nbsp;&nbsp; P&nbsp;=&nbsp;0.027, adalimumab 0.8&nbsp;mg/kg versus MTX</p><p><sup>c</sup> &nbsp;&nbsp; P&nbsp;=&nbsp;0.083, adalimumab 0.8&nbsp;mg/kg versus MTX</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients who achieved PASI 75&nbsp;and PGA clear or minimal were withdrawn from treatment for up to 36&nbsp;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2&nbsp;grades). Patients were then re‑treated with adalimumab 0.8&nbsp;mg/kg eow for an additional 16&nbsp;weeks and response rates observed during retreatment were similar to the previous double‑blind period: PASI 75&nbsp;response of 78.9% (15&nbsp;of 19&nbsp;subjects) and PGA clear or minimal of 52.6% (10&nbsp;of 19&nbsp;subjects).</p><p>&nbsp;</p><p>In the open‑label period of the study, PASI 75&nbsp;and PGA clear or minimal responses were maintained for up to an additional 52&nbsp;weeks with no new safety findings.</p><p>&nbsp;</p><p><em>Adolescent hidradenitis suppurativa </em></p><p>&nbsp;</p><p>There are no clinical trials with adalimumab in adolescent patients with HS. Efficacy of adalimumab for the treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure‑response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and drug effects are substantially similar to that of adults at the same exposure levels. Safety of the recommended adalimumab dose in the adolescent HS population is based on cross‑indication safety profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric Crohn&rsquo;s disease </em></p><p>&nbsp;</p><p>Adalimumab was assessed in a multicentre, randomised, double‑blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt;&nbsp;40&nbsp;kg or &ge; 40&nbsp;kg) in 192&nbsp;paediatric subjects between the ages of 6&nbsp;and 17&nbsp;(inclusive) years, with moderate to severe Crohn&rsquo;s disease (CD) defined as Paediatric Crohn&rsquo;s Disease Activity Index (PCDAI) score &gt;&nbsp;30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to infliximab.</p><p>&nbsp;</p><p>All subjects received open‑label induction therapy at a dose based on their Baseline body weight: 160&nbsp;mg at Week&nbsp;0 and 80&nbsp;mg at Week&nbsp;2 for subjects &ge; 40&nbsp;kg, and 80&nbsp;mg and 40&nbsp;mg, respectively, for subjects &lt;&nbsp;40&nbsp;kg.</p><p>&nbsp;</p><p>At Week&nbsp;4, subjects were randomised 1:1&nbsp;based on their body weight at the time to either the Low Dose or Standard Dose maintenance regimens as shown in Table 28.</p><p>&nbsp;</p><p><strong>Table 28. Maintenance regimen</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Patient weight</strong></p></td><td style="vertical-align:top"><p><strong>Low dose</strong></p></td><td style="vertical-align:top"><p><strong>Standard dose</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>10&nbsp;mg eow</p></td><td style="vertical-align:top"><p>20&nbsp;mg eow</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 40&nbsp;kg</p></td><td style="vertical-align:top"><p>20&nbsp;mg eow</p></td><td style="vertical-align:top"><p>40&nbsp;mg eow</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Efficacy results</u></em><em> </em></p><p>&nbsp;</p><p>The primary endpoint of the study was clinical remission at Week&nbsp;26, defined as PCDAI score &le; 10.</p><p>&nbsp;</p><p>Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15&nbsp;points from Baseline) rates are presented in Table 29. Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 30.</p><p>&nbsp;</p><p><strong>Table 29. Paediatric CD study &ndash; PCDAI clinical remission and response</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Standard Dose</strong></p><p><strong>40/20&nbsp;mg eow</strong></p><p><strong>N&nbsp;=&nbsp;93</strong></p></td><td><p><strong>Low Dose</strong></p><p><strong>20/10&nbsp;mg eow</strong></p><p><strong>N&nbsp;=&nbsp;95</strong></p></td><td style="vertical-align:top"><p><strong>P value*</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Week&nbsp;26</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>38.7%</p></td><td><p>28.4%</p></td><td><p>0.075</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response</p></td><td><p>59.1%</p></td><td><p>48.4%</p></td><td><p>0.073</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;52</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>33.3%</p></td><td><p>23.2%</p></td><td><p>0.100</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response</p></td><td><p>41.9%</p></td><td><p>28.4%</p></td><td><p>0.038</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* &nbsp;&nbsp; p value for Standard Dose <em>versus</em> Low Dose comparison.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 30. Paediatric CD study &ndash; Discontinuation of corticosteroids or immunomodulators and fistula remission</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Standard Dose</strong></p><p><strong>40/20&nbsp;mg eow</strong></p></td><td><p><strong>Low Dose</strong></p><p><strong>20/10&nbsp;mg eow</strong></p></td><td style="vertical-align:top"><p><strong>P value<sup>1</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Discontinued corticosteroids</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>33</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>38</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;26</p></td><td><p>84.8%</p></td><td><p>65.8%</p></td><td><p>0.066</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td><p>69.7%</p></td><td><p>60.5%</p></td><td><p>0.420</p></td></tr><tr><td style="vertical-align:top"><p><strong>Discontinuation of Immunomodulators<sup>2</sup></strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>60</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>57</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td><p>30.0%</p></td><td><p>29.8%</p></td><td><p>0.983</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fistula remission<sup>3</sup></strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>15</strong></p></td><td><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>21</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;26</p></td><td><p>46.7%</p></td><td><p>38.1%</p></td><td><p>0.608</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td><p>40.0%</p></td><td><p>23.8%</p></td><td><p>0.303</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>1</sup>&nbsp;&nbsp;&nbsp; p value for Standard Dose <em>versus</em> Low Dose comparison.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp; Immunosuppressant therapy could only be discontinued at or after Week&nbsp;26&nbsp;at the investigator&rsquo;s discretion if the subject met the clinical response criterion</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp; defined as a closure of all fistulas that were draining at Baseline for at least 2&nbsp;consecutive post‑Baseline visits</p></td></tr></tbody></table><p>&nbsp;</p><p>Statistically significant increases (improvement) from Baseline to Week&nbsp;26&nbsp;and 52&nbsp;in Body Mass Index and height velocity were observed for both treatment groups.</p><p>&nbsp;</p><p>Statistically and clinically significant improvements from Baseline were also observed in both treatment groups for quality of life parameters (including IMPACT III).</p><p>&nbsp;</p><p>One hundred patients (n&nbsp;=&nbsp;100) from the Paediatric CD Study continued in an open‑label long‑term extension study. After 5&nbsp;years of adalimumab therapy, 74.0% (37/50) of the 50&nbsp;patients remaining in the study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical response per PCDAI.</p><p>&nbsp;</p><p><em>Paediatric ulcerative colitis</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of adalimumab was assessed in a multicenter, randomised, double-blind, trial in 93&nbsp;paediatric patients from 5 to 17&nbsp;years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their corticosteroid therapy after Week&nbsp;4.</p><p>&nbsp;</p><p>In the induction period of the study, 77&nbsp;patients were randomised 3:2 to receive double-blind treatment with adalimumab at an induction dose of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2; or an induction dose of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0, placebo at Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2. Both groups received 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) at Week&nbsp;4 and Week&nbsp;6. Following an amendment to the study design, the remaining 16&nbsp;patients who enrolled in the induction period received open-label treatment with adalimumab at the induction dose of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2.</p><p>&nbsp;</p><p>At Week&nbsp;8, 62&nbsp;patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as a decrease in PMS&nbsp;&ge;&nbsp;2 points and&nbsp;&ge;&nbsp;30% from Baseline) were randomised equally to receive double-blind maintenance treatment with adalimumab at a dose of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every week (ew), or a maintenance dose of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every other week (eow). Prior to an amendment to the study design, 12 additional patients who demonstrated clinical response per PMS were randomised to receive placebo but were not included in the confirmatory analysis of efficacy.</p><p>&nbsp;</p><p>Disease flare was defined as an increase in PMS of at least 3&nbsp;points (for patients with PMS of 0 to 2 at Week&nbsp;8), at least 2&nbsp;points (for patients with PMS of 3 to 4 at Week&nbsp;8), or at least 1&nbsp;point (for patients with PMS of 5 to 6 at Week&nbsp;8).</p><p>&nbsp;</p><p>Patients who met criteria for disease flare at or after Week&nbsp;12 were randomised to receive a re‑induction dose of 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) or a dose of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) and continued to receive their respective maintenance dose regimen afterwards.</p><p>&nbsp;</p><p><em><u>Efficacy results</u></em></p><p>&nbsp;</p><p>The co-primary endpoints of the study were clinical remission per PMS (defined as PMS&nbsp;&le;&nbsp;2 and no individual subscore&nbsp;&gt;&nbsp;1) at Week&nbsp;8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo Score&nbsp;&le;&nbsp;2 and no individual subscore&nbsp;&gt;&nbsp;1) at Week&nbsp;52 in patients who achieved clinical response per PMS at Week&nbsp;8.</p><p>&nbsp;</p><p>Clinical remission rates per PMS at Week&nbsp;8 for patients in each of the adalimumab double-blind induction groups are presented in Table&nbsp;31.</p><p><em>&nbsp;</em></p><p><strong>Table 31. Clinical remission per PMS at 8&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>a</sup></strong></p><p><strong>Maximum of 160 mg at Week&nbsp;0 / Placebo at Week 1</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>30</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>b,c</sup></strong></p><p><strong>Maximum of 160 mg at Week&nbsp;0 and Week 1</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>47</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td style="vertical-align:top"><p>13/30&nbsp;(43.3%)</p></td><td style="vertical-align:top"><p>28/47&nbsp;(59.6%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> &nbsp;&nbsp; Adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0, placebo at Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p><sup>b</sup> &nbsp;&nbsp; Adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p><sup>c</sup> &nbsp;&nbsp; Not including open-label Induction dose of adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p>Note 1: Both induction groups received 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) at Week&nbsp;4 and Week&nbsp;6</p><p>Note 2: Patients with missing values at Week&nbsp;8 were considered as not having met the endpoint</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>At Week&nbsp;52, clinical remission per FMS in Week&nbsp;8 responders, clinical response per FMS (defined as a decrease in Mayo Score &ge;&nbsp;3 points and &ge;&nbsp;30% from Baseline) in Week&nbsp;8 responders, mucosal healing (defined as Mayo endoscopy subscore &le;&nbsp;1) in Week&nbsp;8 responders, clinical remission per FMS in Week&nbsp;8 remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week&nbsp;8 responders were assessed in patients who received adalimumab at the double-blind maximum 40&nbsp;mg eow (0.6&nbsp;mg/kg) and maximum 40&nbsp;mg ew (0.6&nbsp;mg/kg) maintenance doses (Table&nbsp;32).</p><p>&nbsp;</p><p><strong>Table 32. Efficacy results at 52&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>a</sup></strong></p><p><strong>Maximum of 40</strong>&nbsp;<strong>mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>31</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>b</sup></strong></p><p><strong>Maximum of 40</strong>&nbsp;<strong>mg ew</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>31</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Clinical remission in Week&nbsp;8 PMS responders</p></td><td style="vertical-align:top"><p>9/31&nbsp;(29.0%)</p></td><td style="vertical-align:top"><p>14/31&nbsp;(45.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response in Week&nbsp;8 PMS responders</p></td><td style="vertical-align:top"><p>19/31 (61.3%)</p></td><td style="vertical-align:top"><p>21/31 (67.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal healing in Week&nbsp;8 PMS responders</p></td><td style="vertical-align:top"><p>12/31 (38.7%)</p></td><td style="vertical-align:top"><p>16/31 (51.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission in Week&nbsp;8 PMS remitters</p></td><td style="vertical-align:top"><p>9/21 (42.9%)</p></td><td style="vertical-align:top"><p>10/22 (45.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroid-free remission in Week&nbsp;8 PMS responders<sup>c</sup></p></td><td style="vertical-align:top"><p>4/13 (30.8%)</p></td><td style="vertical-align:top"><p>5/16 (31.3%)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Adalimumab 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every other week</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Adalimumab 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every week</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; In patients receiving concomitant corticosteroids at baseline</p><p>Note: Patients with missing values at Week&nbsp;52 or who were randomised to receive re-induction or maintenance treatment were considered non-responders for Week&nbsp;52 endpoints</p><p>&nbsp;</p><p>Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis Activity Index (PUCAI) (defined as a decrease in PUCAI &ge;&nbsp;20 points from Baseline) and clinical remission per PUCAI (defined as PUCAI &lt;&nbsp;10) at Week&nbsp;8 and Week&nbsp;52 (Table&nbsp;33).</p><p>&nbsp;</p><p><strong>Table 33. Exploratory endpoints results per PUCAI</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week</strong>&nbsp;<strong>8</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adalimumab<sup>a</sup></strong></p><p><strong>Maximum of 160</strong>&nbsp;<strong>mg at Week</strong>&nbsp;<strong>0 / Placebo at Week</strong>&nbsp;<strong>1</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>30</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>b,c</sup></strong></p><p><strong>Maximum of 160</strong>&nbsp;<strong>mg at Week</strong>&nbsp;<strong>0 and Week</strong>&nbsp;<strong>1</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>47</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Clinical remission per PUCAI</p></td><td style="vertical-align:top"><p>10/30 (33.3%)</p></td><td style="vertical-align:top"><p>22/47 (46.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response per PUCAI</p></td><td style="vertical-align:top"><p>15/30 (50.0%)</p></td><td style="vertical-align:top"><p>32/47 (68.1%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Week</strong>&nbsp;<strong>52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adalimumab<sup>d</sup></strong></p><p><strong>Maximum of 40</strong>&nbsp;<strong>mg eow</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>31</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab<sup>e</sup></strong></p><p><strong>Maximum of 40</strong>&nbsp;<strong>mg ew</strong></p><p><strong>N</strong>&nbsp;<strong>=</strong>&nbsp;<strong>31</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission per PUCAI in Week&nbsp;8 PMS responders</p></td><td style="vertical-align:top"><p>14/31 (45.2%)</p></td><td style="vertical-align:top"><p>18/31 (58.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response per PUCAI in Week&nbsp;8 PMS responders</p></td><td style="vertical-align:top"><p>18/31 (58.1%)</p></td><td style="vertical-align:top"><p>16/31 (51.6%)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0, placebo at Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; Not including open-label Induction dose of adalimumab 2.4&nbsp;mg/kg (maximum of 160&nbsp;mg) at Week&nbsp;0 and Week&nbsp;1, and 1.2&nbsp;mg/kg (maximum of 80&nbsp;mg) at Week&nbsp;2</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Adalimumab 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every other week</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp; Adalimumab 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every week</p><p>Note 1: Both induction groups received 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) at Week&nbsp;4 and Week&nbsp;6</p><p>Note 2: Patients with missing values at Week&nbsp;8 were considered as not having met the endpoints</p><p>Note 3: Patients with missing values at Week&nbsp;52 or who were randomised to receive re-induction or maintenance treatment were considered non-responders for Week&nbsp;52 endpoints</p><p>&nbsp;</p><p>Of the adalimumab-treated patients who received re-induction treatment during the maintenance period, 2/6 (33%) achieved clinical response per FMS at Week&nbsp;52.</p><p><em>&nbsp;</em></p><p><em>Quality of life</em></p><p>&nbsp;</p><p>Clinically meaningful improvements from Baseline were observed in IMPACT&nbsp;III and the caregiver Work Productivity and Activity Impairment (WPAI) scores for the groups treated with adalimumab.</p><p>&nbsp;</p><p>Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in Body Mass Index were observed for subjects on the high maintenance dose of maximum 40&nbsp;mg (0.6&nbsp;mg/kg) ew.</p><p>&nbsp;</p><p><em>Paediatric uveitis</em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in a randomised, double‑masked, controlled study of 90&nbsp;paediatric patients from 2 to &lt;&nbsp;18&nbsp;years of age with active JIA‑associated non‑infectious anterior uveitis who were refractory to at least 12&nbsp;weeks of methotrexate treatment. Patients received either placebo or 20&nbsp;mg adalimumab (if &lt;&nbsp;30&nbsp;kg) or 40&nbsp;mg adalimumab (if &ge;&nbsp;30&nbsp;kg) every other week in combination with their baseline dose of methotrexate.</p><p>&nbsp;</p><p>The primary endpoint was &lsquo;time to treatment failure&rsquo;. The criteria determining treatment failure were worsening or sustained non‑improvement in ocular inflammation, partial improvement with development of sustained ocular co‑morbidities or worsening of ocular co‑morbidities, non‑permitted use of concomitant medications, and suspension of treatment for an extended period of time.</p><p>&nbsp;</p><p><em><u>Clinical response</u></em></p><p>&nbsp;</p><p>Adalimumab significantly delayed the time to treatment failure, as compared to placebo (see Figure 3, P&nbsp;&lt;&nbsp;0.0001 from log rank test). The median time to treatment failure was 24.1&nbsp;weeks for subjects treated with placebo, whereas the median time to treatment failure was not estimable for subjects treated with adalimumab because less than one‑half of these subjects experienced treatment failure. Adalimumab significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard ratio (HR&nbsp;=&nbsp;0.25 [95% CI: 0.12, 0.49]).</p><p>&nbsp;</p><p><strong>Figure 3. Kaplan‑Meier curves summarizing time to treatment failure in the paediatric uveitis study</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:315.5pt;
 height:260.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="421" height="347" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.jpg" /></p><p>Note: P&nbsp;=&nbsp;Placebo (Number at Risk); H&nbsp;=&nbsp;Adalimumab (Number at Risk).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>After subcutaneous administration of a single 40&nbsp;mg dose, absorption and distribution of adalimumab was slow, with peak serum concentrations being reached about 5&nbsp;days after administration. The average absolute bioavailability of adalimumab estimated from three studies following a single 40&nbsp;mg subcutaneous dose was 64%. After single intravenous doses ranging from 0.25&nbsp;to 10&nbsp;mg/kg, concentrations were dose proportional. After doses of 0.5&nbsp;mg/kg (~40&nbsp;mg), clearances ranged from 11&nbsp;to 15&nbsp;ml/hour, the distribution volume (V<sub>ss</sub>) ranged from 5&nbsp;to 6&nbsp;litres and the mean terminal phase half‑life was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid arthritis patients ranged from 31‑96% of those in serum.</p><p>&nbsp;</p><p>Following subcutaneous administration of 40&nbsp;mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady‑state trough concentrations were approximately 5&nbsp;&micro;g/ml (without concomitant methotrexate) and 8&nbsp;to 9&nbsp;&micro;g/ml (with concomitant methotrexate), respectively. The serum adalimumab trough levels at steady‑state increased roughly proportionally with dose following 20, 40&nbsp;and 80&nbsp;mg subcutaneous dosing every other week and every week.</p><p>&nbsp;</p><p>Following the administration of 24&nbsp;mg/m<sup>2</sup>&nbsp;(maximum of 40&nbsp;mg) subcutaneously every other week to patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4&nbsp;to 17&nbsp;years the mean trough steady‑state (values measured from Week&nbsp;20&nbsp;to 48) serum adalimumab concentration was 5.6&nbsp;&plusmn;&nbsp;5.6&nbsp;&micro;g/ml (102% CV) for adalimumab without concomitant methotrexate and 10.9&nbsp;&plusmn; 5.2&nbsp;&micro;g/ml (47.7% CV) with concomitant methotrexate.</p><p>&nbsp;</p><p>In patients with polyarticular JIA who were 2&nbsp;to &lt;&nbsp;4&nbsp;years old or aged 4&nbsp;and above weighing &lt;&nbsp;15&nbsp;kg dosed with adalimumab 24&nbsp;mg/m<sup>2</sup>, the mean trough steady‑state serum adalimumab concentrations was 6.0&nbsp;&plusmn; 6.1&nbsp;&micro;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9&nbsp;&plusmn;&nbsp;5.6&nbsp;&micro;g/ml (71.2% CV) with concomitant methotrexate.</p><p>&nbsp;</p><p>Following the administration of 24&nbsp;mg/m<sup>2</sup>&nbsp;(maximum of 40&nbsp;mg) subcutaneously every other week to patients with enthesitis‑related arthritis who were 6&nbsp;to 17&nbsp;years, the mean trough steady‑state (values measured at Week&nbsp;24) serum adalimumab concentrations were 8.8&nbsp;&plusmn; 6.6&nbsp;&mu;g/ml for adalimumab without concomitant methotrexate and 11.8&nbsp;&plusmn; 4.3&nbsp;&mu;g/ml with concomitant methotrexate.</p><p>&nbsp;</p><p>Following subcutaneous administration of 40&nbsp;mg of adalimumab every other week in adult non‑radiographic axial spondyloarthritis patients, the mean (&plusmn;SD) trough steady‑state concentration at Week&nbsp;68 was 8.0&nbsp;&plusmn;&nbsp;4.6&nbsp;&micro;g/ml.</p><p>&nbsp;</p><p>In adult patients with psoriasis, the mean steady‑state trough concentration was 5&nbsp;&micro;g/ml during adalimumab 40&nbsp;mg every other week monotherapy treatment.</p><p>&nbsp;</p><p>Following the administration of 0.8&nbsp;mg/kg (maximum of 40&nbsp;mg) subcutaneously every other week to paediatric patients with chronic plaque psoriasis, the mean &plusmn; SD steady‑state adalimumab trough concentration was approximately 7.4&nbsp;&plusmn; 5.8&nbsp;&micro;g/ml (79% CV).</p><p>&nbsp;</p><p>In adult patients with hidradenitis suppurativa, a dose of 160&nbsp;mg adalimumab on Week&nbsp;0&nbsp;followed by 80&nbsp;mg on Week&nbsp;2&nbsp;achieved serum adalimumab trough concentrations of approximately 7&nbsp;to 8&nbsp;&mu;g/ml at Week&nbsp;2&nbsp;and Week&nbsp;4. The mean steady‑state trough concentration at Week&nbsp;12&nbsp;through Week&nbsp;36&nbsp;were approximately 8&nbsp;to 10&nbsp;&mu;g/ml during adalimumab 40&nbsp;mg every week treatment.</p><p>&nbsp;</p><p>Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic modelling and simulation based on cross‑indication pharmacokinetics in other paediatric patients (paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&rsquo;s disease, and enthesitis‑related arthritis). The recommended adolescent HS dosing schedule is 40&nbsp;mg every other week. Since exposure to adalimumab can be affected by body size, adolescents with higher body weight and inadequate response may benefit from receiving the recommended adult dose of 40&nbsp;mg every week.</p><p>&nbsp;</p><p>In patients with Crohn&rsquo;s disease, the loading dose of 80&nbsp;mg adalimumab on Week&nbsp;0&nbsp;followed by 40&nbsp;mg adalimumab on Week&nbsp;2&nbsp;achieves serum adalimumab trough concentrations of approximately 5.5&nbsp;&micro;g/ml during the induction period. A loading dose of 160&nbsp;mg adalimumab on Week&nbsp;0&nbsp;followed by 80&nbsp;mg adalimumab on Week&nbsp;2&nbsp;achieves serum adalimumab trough concentrations of approximately 12&nbsp;&micro;g/ml during the induction period. Mean steady‑state trough levels of approximately 7&nbsp;&micro;g/ml were observed in Crohn&rsquo;s disease patients who received a maintenance dose of 40&nbsp;mg adalimumab every other week.</p><p>&nbsp;</p><p>In paediatric patients with moderate to severe CD, the open‑label adalimumab induction dose was 160/80&nbsp;mg or 80/40&nbsp;mg at Weeks 0&nbsp;and 2, respectively, dependent on a body weight cut‑off of 40&nbsp;kg. At Week&nbsp;4, patients were randomised 1:1&nbsp;to either the Standard Dose (40/20&nbsp;mg eow) or Low Dose (20/10&nbsp;mg eow) maintenance treatment groups based on their body weight. The mean (&plusmn;SD) serum adalimumab trough concentrations achieved at Week&nbsp;4&nbsp;were 15.7&nbsp;&plusmn;&nbsp;6.6&nbsp;&micro;g/ml for patients &ge;&nbsp;40&nbsp;kg (160/80&nbsp;mg) and 10.6&nbsp;&plusmn;&nbsp;6.1&nbsp;&micro;g/ml for patients &lt;&nbsp;40&nbsp;kg (80/40&nbsp;mg).</p><p>&nbsp;</p><p>For patients who stayed on their randomised therapy, the mean (&plusmn;SD) adalimumab trough concentrations at Week&nbsp;52&nbsp;were 9.5&nbsp;&plusmn;&nbsp;5.6&nbsp;&micro;g/ml for the Standard Dose group and 3.5&nbsp;&plusmn;&nbsp;2.2&nbsp;&micro;g/ml for the Low Dose group. The mean trough concentrations were maintained in patients who continued to receive adalimumab treatment eow for 52&nbsp;weeks. For patients who dose escalated from eow to weekly regimen, the mean (&plusmn;SD) serum concentrations of adalimumab at Week&nbsp;52&nbsp;were 15.3&nbsp;&plusmn;&nbsp;11.4&nbsp;&mu;g/ml (40/20&nbsp;mg, weekly) and 6.7&nbsp;&plusmn;&nbsp;3.5&nbsp;&mu;g/ml (20/10&nbsp;mg, weekly).</p><p>&nbsp;</p><p>In patients with ulcerative colitis, a loading dose of 160&nbsp;mg adalimumab on Week&nbsp;0&nbsp;followed by 80&nbsp;mg adalimumab on Week&nbsp;2&nbsp;achieves serum adalimumab trough concentrations of approximately 12&nbsp;&micro;g/ml during the induction period. Mean steady‑state trough levels of approximately 8&nbsp;&micro;g/ml were observed in ulcerative colitis patients who received a maintenance dose of 40&nbsp;mg adalimumab every other week.</p><p>&nbsp;</p><p>Following the subcutaneous administration of body weight-based dosing of 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum adalimumab concentration was 5.01&nbsp;&plusmn;&nbsp;3.28&nbsp;&mu;g/ml at Week&nbsp;52. For patients who received 0.6&nbsp;mg/kg (maximum of 40&nbsp;mg) every week, the mean (&plusmn;SD) trough steady-state serum adalimumab concentration was 15.7&nbsp;&plusmn;&nbsp;5.60&nbsp;&mu;g/ml at Week&nbsp;52.</p><p>&nbsp;</p><p>In adult patients with uveitis, a loading dose of 80&nbsp;mg adalimumab on Week&nbsp;0&nbsp;followed by 40&nbsp;mg adalimumab every other week starting at Week&nbsp;1, resulted in mean steady‑state concentrations of approximately 8&nbsp;to 10&nbsp;&micro;g/ml.</p><p>&nbsp;</p><p>Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic modelling and simulation based on cross‑indication pharmacokinetics in other paediatric patients (paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&rsquo;s disease, and enthesitis‑related arthritis). No clinical exposure data are available on the use of a loading dose in children &lt;&nbsp;6&nbsp;years. The predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial increase in systemic exposure.</p><p>&nbsp;</p><p>Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted comparable adalimumab exposure and efficacy in patients treated with 80&nbsp;mg every other week when compared with 40&nbsp;mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with adolescent HS, and paediatric patients &ge; 40&nbsp;kg with CD and UC).</p><p>&nbsp;</p><p><u>Exposure‑response relationship in paediatric population</u></p><p>&nbsp;</p><p>On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure‑response relationship was established between plasma concentrations and PedACR 50 response. The apparent adalimumab plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was 3&nbsp;&mu;g/ml (95% CI: 1‑6 &mu;g/ml).</p><p>&nbsp;</p><p>Exposure‑response relationships between adalimumab concentration and efficacy in paediatric patients with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, both with a similar apparent EC50 of approximately 4.5&nbsp;&mu;g/ml (95% CI 0.4‑47.6 and 1.9‑10.5, respectively).</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Population pharmacokinetic analyses with data from over 1,300&nbsp;RA patients revealed a trend toward higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels of free adalimumab (not bound to anti‑adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA.</p><p>&nbsp;</p><p><u>Hepatic or renal impairment</u></p><p>&nbsp;</p><p>Adalimumab has not been studied in patients with hepatic or renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated dose toxicity, and genotoxicity.</p><p>&nbsp;</p><p>An embryo‑foetal developmental toxicity/perinatal developmental study has been performed in cynomolgus monkeys at 0, 30&nbsp;and 100&nbsp;mg/kg (9‑17&nbsp;monkeys/group) and has revealed no evidence of harm to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross‑reactivity to rodent TNF and to the development of neutralising antibodies in rodents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L‑Histidine</p><p>L‑Histidine hydrochloride monohydrate</p><p>Sucrose</p><p>Edetate Disodium Dihydrate</p><p>L‑Methionine</p><p>Polysorbate 80</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 

Do not use Abrilada after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze. Keep the pre‑filled syringe or pre‑filled pen in its outer carton in order to protect from light.</p><p>&nbsp;</p><p>A single ABRILADA pre‑filled syringe or pre‑filled pen may be stored at temperatures up to a maximum of 30&deg;C for a period of up to 30&nbsp;days. The syringe or pen must be protected from light and discarded if not used within the 30‑day period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>ABRILADA 40&nbsp;mg solution for injection in pre‑filled syringe</u></p><p>&nbsp;</p><p>ABRILADA 40&nbsp;mg solution for injection in single‑use pre‑filled syringe (type I glass) with a plunger stopper (chlorobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).</p><p>&nbsp;</p><p>Packs of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;pre‑filled syringes (0.8&nbsp;ml sterile solution) with 2 alcohol pads, each pre‑filled syringe is in a blister.</p><p>&nbsp;</p><p><u>ABRILADA 40&nbsp;mg solution for injection in pre‑filled pen</u></p><p>&nbsp;</p><p>ABRILADA 40&nbsp;mg solution for injection in single‑use pre‑filled pen for patient use containing a pre‑filled syringe. The syringe inside the pen is made from type 1&nbsp;glass with a plunger stopper (chlorobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).</p><p>&nbsp;</p><p>Packs of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;pre‑filled pens (0.8&nbsp;ml sterile solution) with 2 alcohol pads.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Pfizer AG, Switzerland

Manufactured by
Catalent Indiana, LLC
United States 

and

SHL Pharma LLC
United States


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>